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The Human Cell Atlas (HCA) will be made up of comprehensive reference maps of all human 
cells — the fundamental units of life — as a basis for understanding fundamental human 
biological processes and diagnosing, monitoring, and treating disease. It will help scientists 
understand how genetic variants impact disease risk, define drug toxicities, discover better 
therapies, and advance regenerative medicine. A resource of such ambition and scale should be 
built in stages, increasing in size, breadth, and resolution as technologies develop and 
understanding deepens. We will therefore pursue Phase 1 as a suite of flagship projects in key 
tissues, systems, and organs. We will bring together experts in biology, medicine, genomics, 
technology development and computation (including data analysis, software engineering, and 
visualization). We will also need standardized experimental and computational methods that will 
allow us to compare diverse cell and tissue types — and samples across human communities — 
in consistent ways, ensuring that the resulting resource is truly global.  
This document, the first version of the HCA White Paper, was written by experts in the field 
with feedback and suggestions from the HCA community, gathered during recent international 
meetings. The White Paper, released at the close of this yearlong planning process, will be a 
living document that evolves as the HCA community provides additional feedback, as 
technological and computational advances are made, and as lessons are learned during the 






1. OVERVIEW  
VISION 
For the past 150 years scientists have classified cells by their structures, functions, locations, and, 
more recently, molecular profiles, but the characterization of cell types and states has remained 
surprisingly limited. We do not yet comprehensively know our cells — how they are defined by 
their molecular products, how they vary across tissues, systems, and organs, and how they 
influence health and disease. This has limited our ability to study fundamental domains in 
biology – such as physiology, developmental biology, and anatomy – in health and disease, and 
to translate our knowledge to accelerate diagnosis and treatment of disease1. 
But an extraordinary opportunity is emerging because of transformative advances in 
experimental and computational methods (Figure 1; Section 3 and Section 4). Massively 
parallel single-cell genomics assays can now profile hundreds of thousands of cells. 
Technologies to profile DNA and proteins in single cells, as well as a combination of DNA, 
RNA, and proteins in the same cell, provide important additional layers of information. New 
spatial analysis techniques, including in situ assays, imaging approaches, spatial coding, and 
computational inference, allow high-resolution analysis of large tissues in two (2-D) or three (3-
D) dimensions. Computational algorithms have emerged to determine cell types, states, 
transitions, and locations from these new data, at increasing scale and resolution (Section 4).  
Together, these 
advances have 
catalyzed a growing 
sense in the scientific 
community that we 
are finally capable of 
realizing a long-
sought goal of 
identifying and 
understanding human 
cells and molecular 
states within tissues 
and systems in their 
full diversity and 
glory. Indeed, many 
researchers have 
already begun to 
apply these 
techniques to identify 
new cell types in 
tissues ranging from 
the blood to the brain 
— an unprecedented 
achievement.  
We have therefore 
launched the Human 
Figure 1. Advances in experimental technologies empower the HCA. 
(A) Technologies for single-cell genomics. (B) Timeline and scale of single-cell 
RNA-Seq (grey circles) and single-cell ATAC-Seq (black circles). (C) Timeline 
and scale of methods for highly multiplexed spatial analysis of intact tissue, 
including the measurement type (protein, RNA) and tissue area.  
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Cell Atlas (HCA) Consortium — an international, collaborative effort that aims to define all 
human cell types in terms of their distinctive patterns of gene expression, physiological states, 
developmental trajectories, and location. This consortium builds on the work of previous 
consortia to map the human genome, starting with the Human Genome Project, and leverages 
and engages with recent efforts to characterize and interpret functional genomic (ENCODE), 
epigenetic (IHEC, BLUPRINT), transcriptomic (GTEx), and proteomic (the Human Protein 
Atlas) elements. 
The HCA will be a foundation for biological research and medicine: a comprehensive reference 
map of the types and properties of all human cells and a basis for understanding and monitoring 
health and diagnosing and treating disease. The project will help propel translational discoveries 
and applications, ultimately laying a foundation for a new era of precision and regenerative 
medicine. 
The diverse, international consortium that builds the HCA will be open and collaborative, 
bringing together and aligning experts to form networks focused on biological topics. Some of 
these networks — such as the Immune Cell Atlas (ICA), the Developmental Cell Atlas (DCA), 
and the Skin Cell Atlas (SCA) — have already emerged and initiated pilot efforts with scientific 
leadership and committed participants, including relevant clinical and biological experts. 
Scientists from across the globe have enthusiastically joined the HCA, in meetings, through 
social media, and electronically — helping to design the effort and participating in it. Indeed, 
each meeting thus far, and the work that preceded and followed it, has helped formulate key 
aspects of this White Paper (Figure 2).  
The initiative will progress in phases to generate reference maps at increasing resolution. Google 
Maps serves as an analogy: instead of geographical features, such as continents, countries, cities, 
streets, and houses, the HCA’s maps of the human body will “zoom in” on molecular and 
organizational features of organs, tissues, and cells.  
The first draft of the HCA — a focus of this White Paper — will profile 30 million to 100 
million cells, both isolated and in their tissue context, from major tissues and systems from 
healthy research participants of both genders (Section 2; Table 1). It will combine single-cell 
profiling of dissociated cells and single-nucleus profiling of frozen samples with spatial analysis 
of cells in the context of tissues. It will also integrate data from other projects and consortia, as 
appropriate. In this first draft, a set of representative organs and systems will be analyzed in 
depth; a broader range will be analyzed to a more limited extent. While the first draft will be 
Figure 2. Timeline of HCA activities, October 2016 through January 2018. 
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assembled with geographic, age, disease, and ethnic diversity in mind, it will not yet aim to be 
comprehensive with respect to these features.  
This first draft and the lessons learned in building it will serve as the basis for a comprehensive 
atlas of at least 10 billion cells, covering all tissues, organs, and systems — the necessary 
reference for future comparison and biological insight across disease areas, genetic diversity, 
environments, and ages. The cells will come from both healthy research participants and small 
cohorts of patients with relevant diseases, as these are critical to reflect on cells’ diversity. The 
cells will be studied using a broad range of techniques to capture both breadth and depth and will 
fully represent the world’s diversity. 
As with previous genomic projects, bounds for the HCA must be defined. First is the desired 
resolution: the rarity of cell types and states to be detected, analogous to the bounds on human-
variant frequency in human genetic studies. Second is disease and diversity. The draft atlas will 
endeavor to characterize healthy samples that capture as much genetic, geographic, 
environmental, and age diversity as possible. In particular, the HCA is committed to genetic and 
geographic diversity and equity at every phase, even if mapping genetic variation from very 
large cohorts may not be feasible in the initial stages. Although disease will not be a focus of the 
first iteration of HCA, we expect some disease samples to be captured that may include, in 
addition to disease cells, additional cell types relevant for correctly referencing healthy cell 
types; for example immune cells from the tumor microenvironment. The HCA methods and 
framework, together with dedicated partnerships, will also empower disease-mapping efforts in 
individual tissues and across cancers. A third bound will be cellular function. The HCA will 
validate the existence of identified cells and enable their functional assessment, but the functional 
characterization itself is not included in its scope. By analogy, the functional characterization of 
the genes discovered in the Human Genome Project is still an ongoing endeavor, through 
numerous inspired studies by individual investigators as well as concerted efforts by 
international consortia.  
The HCA should help answer questions in all areas of human biology, from the taxonomy of 
cells and histological tissue structure, to developmental biology and cell fate and lineage, to 
physiology and homeostasis and their underlying molecular mechanisms. With corresponding 
atlases of model organisms that facilitate functional assessment, the HCA will allow us to better 
understand how faithful our models are to human physiology and pathology and to validate 
findings through perturbation.  
Because the HCA will be an open resource, it will dramatically accelerate discoveries by 
biological researchers, data scientists, and translational scientists and clinicians worldwide, 
inspiring insights in therapeutic discovery, drug development, and diagnosis. The HCA will 
provide crucial information about the cell types in which a given gene and its disease-associated 
variants are expressed; will empower us to develop better drugs and more readily predict their 
unintended toxicities; and can transform today’s standard diagnostic practices. 
In this White Paper, we detail a research and organizational strategy for the HCA as a 
comprehensive, open, global resource — one with the potential to transform our understanding 
of biology and ultimately allow us to fulfill the promise of precision medicine. 
VALUES 
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The HCA will be built on a set of guiding principles and values to ensure its success and 
maximize its utility to the research community and humanity at large. Some of these build on 
lessons from earlier consortia; others reflect the unique opportunities at this moment in time. 
These value include: 
 Transparency and open data sharing. Data will be released as soon as possible after it 
has been collected so it can be used immediately.  
 Quality. The HCA community will be committed to producing the highest-quality data 
and establishing rigorous standards, shared openly and broadly and updated regularly. 
 Flexibility. The HCA community will maintain intellectual and technical flexibility, so it 
can revise the design of the HCA as new insights, data, and technologies emerge. 
 Community. The HCA community will remain global, open, and collaborative, led by a 
scientific steering group. It will remain open to all interested participants who are 
committed to its values.  
 Diversity, inclusion, and equity. The selection of tissue samples will reflect geographic, 
gender, age, and ethnic diversity. Similar diversity will be reflected in the distribution of 
participating researchers, institutions, and countries. 
 Privacy. We are committed to ensuring privacy of research subjects, consistent with the 
consent of research participants. 
 Technology development. The HCA community will develop, adopt, and share new tools 
to empower others. 
 Computational excellence. The HCA community will develop new computational 
methods, leveraging and driving the latest algorithmic advances, and share these through 
scaled, open-source software. 
FRAMEWORK FOR A FIRST DRAFT ATLAS 
We currently envision a Draft Atlas v1.0 that contains data from 30 million to 100 million 
profiled cells and their matching tissues, though the scale and scope may grow as measurement 
methods increase in throughput, robustness, and affordability (Section 2). 
Building the first draft will require careful decisions about the organs, systems, and tissues to 
be analyzed; the level of resolution, such as the rarity of cells to be detected and spatial 
resolution; the sampling and measurement approaches applied to the selected samples; and the 
data analysis and a data platform needed to store, analyze, and visualize the data. 
Organs, systems, and tissues 
A complete Human Cell Atlas will map all tissues, systems, and organs. The first draft will 
incorporate a carefully chosen subset that is immediately useful and addresses key representative 
examples, from which general lessons can be learned for the next phase (Section 2).  
Choice of tissues: depth and breadth. The first draft will not cover every organ. Instead, it should 
incorporate data from several major tissues and systems (Table 1). Some tissues will be sampled 
deeply; for others, only a portion will be sampled. All studies will include adults; some will also 
incorporate pediatric samples. This will nonetheless yield global insights into the intersection of 
systems and tissues and into what is needed to handle different kinds of tissues.  
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Acquisition. The core activities of the HCA project will be the profiling of normal — ideally, 
freshly obtained — human tissues. Multiple tissues from the same donor should be processed 
using the same technology in the same place, then preserved and banked consistently in 
appropriate form for subsequent processing (e.g., Formalin-fixed, Paraffin-embedded [FFPE] or 
flash frozen in optimal cutting temperature [OCT]) for single nucleus RNA-Seq, spatial analysis, 
and additional possible future applications. To achieve this, we will need reliable sources of 
suitable tissues. Normal tissue samples can be challenging for individual labs to acquire, but 
concerted efforts — e.g., the Genotype-Tissue Expression (GTEx) Project and the Cambridge 
Biorepository for Translational Medicine (CBTM) — have demonstrated how to assemble and 
bank excellent sample collections for use by the community. It is essential to have the ability to 
procure all human organs and tissues from postmortem samples, as this is the only source from 
which an entire human body can be studied. At the same time, samples from live research 
participants or transplant organ donors are likely to be closer to normal physiology and, 
therefore, should be obtained, banked and analyzed whenever possible.  
Reproducibility and diversity. For each selected tissue, a minimum of 20 ethnically diverse 
samples will be collected and banked from at least three geographically distinct sites. The 
number of required samples is based on our community’s current experience and on the 
impressive reproducibility observed in healthy cells across individuals in a few studied tissues. 
Possibly, a larger number will be required or a smaller number will suffice. Adaptive power 
analyses will be conducted as part of the collection effort to revise these choices. 
Each site will collect and bank samples from individuals of both genders, all adults (with the 
exception of the human development atlas — see below), ranging from 20 to 55 years of age. 
Ethnic diversity will be ensured at each site to the maximal extent possible, given the number of 
individuals and that site’s location. 
Additional optional elements. For each tissue, it is expected that the relevant biological 
community will incorporate deeper investigation of at least one additional dimension, such as 
more extensive genetic diversity or disease state. For example, to properly sample normal 
immune cells, disease challenges must be included. Similar rationale would apply in many other 
tissues. 
Resolution 
A draft atlas must have predefined technical bounds, such that we can determine the completion 
of phase I within those bounds. This involves determining how tissues are sampled within 
organs, the rarity of cells to be recovered, the resolution of spatial coordinates, and the depth of 
molecular information.  
Cellular resolution. Each biological tissue or system will have a predefined cell-rarity threshold 
achievable within the proposed phased sampling procedure. We note the need to detect both 
discrete subsets of cells (stable cell types or states), often presented as dense regions in high-
dimensional space (where the dimensions are gene expression or other cellular features), as well 
as continuous processes (dynamic transitions) reflected as paths in the space. 
Spatial resolution. Each analyzed tissue will have a predefined scheme for spatial resolution. We 
anticipate the use of rapidly evolving technologies, such as MERFISH, Seq-FISH, FISSEQ, 
Spatial Transcriptomics, CODEX, MIBI, and targeted in situ RNA sequencing. In the first draft, 
we do not expect to generally analyze complete organs, but rather cells in their histological 
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context. The spatial scheme 
for a tissue will define the 
level of histological unit to 
be analyzed (macro 
resolution) and its internal 
partitioning.  
Molecular resolution. 
Currently, there is a trade-
off between the number of 
cells a technique measures 
and the depth (complexity 
of data) afforded per cell. 
Massively parallel 
techniques profile many 
cells, but show less of the 
molecular complexity of 
each cell, while more in-
depth technologies typically 
handle far fewer cells at a 
time. We will strike a 




An important role for the 
first draft is to learn key lessons on appropriate sampling, sample handling, and measurement of 
representative tissues. The experience of past consortia, such as the Human Protein Atlas and 
Figure 3. Framework for 
sampling and measurements for 
an initial draft. Any given tissue 
specimen will be analyzed 
through a two-pronged strategy 
combining [1] single-cell 
molecular profiling of dissociated 
cells or single-nucleus molecular 
profiling of nuclei from frozen 
tissue (cellular/nuclear branch, 
left) with [2] highly multiplexed 
spatial analysis of intact tissue 
(spatial branch, right). To relate 
the two, before tissue processing, 
physical specimens will be 
registered and imaged for their 
physical coordinates, and 
matching portions will be 




GTEx, may serve as a guide. Any given tissue specimen will be analyzed through a two-pronged 
strategy, combining single-cell molecular profiling of dissociated cells (cellular branch) and/or 
single-nucleus molecular profiling of nuclei from frozen tissue (nuclear branch) with highly 
multiplexed spatial analysis of intact tissue (spatial branch) (Figure 3). To relate the two, before 
tissue processing, physical specimens will be registered and imaged for their physical 
coordinates, and matching portions, such as adjacent sections, of the same specimen will be 
analyzed by cellular and spatial approaches. Within and across the branches, we expect to use 
multiple methods (each standardized with appropriate quality controls and benchmarks) to 
analyze the same type of tissue or actual specimens. We expect the HCA effort to catalyze 
further technology development and to adapt to such changes in an agile manner (Section 3). 
For the cellular branch, we will address the current trade-off between scale and molecular 
complexity, as well as aim to efficiently sample complex cell mixtures when different cell types 
or states may be represented at radically different proportions. To this end, we will follow a “Sky 
Dive” strategy, with initial uniform (“agnostic”) profiling by massively parallel approaches, 
followed by profiling of stratified samples (e.g., through sorting and/or enrichment or depletion 
of subpopulations). The number of cells to be profiled in each phase will be determined by 
statistical calculations with prespecified goals for detection sensitivity (cell rarity). These 
calculations will initially be informed by prior biological knowledge (“educated guess”) and then 
adaptively re-estimated as data are collected. Both the uniform and stratified phases may be 
repeated until a predefined stopping threshold is met. When possible, cells from multiple 
individuals will be mixed in a single assay, and then distinguished based on the genetic 
differences, reducing batch effects and costs, and streamlining the process. Specialized, but 
lower-throughput, techniques, which provide deeper and/or more diverse molecular profiles, will 
be applied to limited numbers of cells in the stratified groups. Auxiliary data (e.g., corresponding 
bulk molecular profiles of RNA, chromatin, or protein for annotation) will be generated within 
the HCA effort or in coordination with other consortia. We will engage with related communities 
(e.g., Tumor Cell Atlas Network, the BRAIN Initiative) to share best practices, collection 
strategies, and data platforms.  
For the spatial branch, we will address the current trade-off between the number of distinct 
molecules to be analyzed and spatial resolution. Ideally, each specimen will be analyzed by both 
genomic-profiling approaches with lower spatial resolution and by RNA- and protein signature–
based assays or in situ sequencing with high spatial resolution. Because some of the key 
techniques are not yet widely disseminated or fully scaled, we will aim to preserve and bank 
specimens in appropriate form for subsequent processing. Fortunately, most methods are 
compatible with common preservation strategies. 
The two branches are highly complementary and intimately connected. Currently, most profiling 
approaches do not preserve spatial information, whereas most spatial techniques either rely on 
predefined signatures of genes and proteins or do not have single-cell resolution. Thus, the 
cellular branch can help define signatures for spatial measurements or single-cell deconvolution; 
the spatial branch can validate cells defined by profiling approaches, position them in their tissue 
context, and help identify any compositional biases in the profiling branch introduced during 
tissue dissociation.  
The key results of the draft must be validated for their reproducibility, integrity, and predictive 
value. Reproducibility (stability) is defined by the ability to recover, through prospective 
isolation or repeated analysis, cells with the same profiles and features predicted by the initial 
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data and analysis. Integrity is defined by the ability to capture all cells in the tissue in the correct 
proportions and appropriate profiles. Predictive value is defined by the ability to determine that a 
subset characterized with one distinctive set of features (e.g., molecular profiles) either 
appropriately maps to a known, previously validated biological entity or predicts a new entity 
with distinctive features of a different nature (e.g., cell morphology or histological or anatomical 
context).   
Data analysis and a Data Coordination Platform (DCP) 
As soon as the first HCA data are generated, they should be of immediate use to the research 
community. For this reason, data will be openly released (Section 7) through a data platform 
(Section 5) as soon as possible after it has been collected. The Data Coordination Platform 
(DCP) will take on all relevant data types, from both the cellular and spatial branches. The 
platform will be open source and open data and can be fully cloned. 
Key analysis methods to address each of the central questions regarding a cell’s identity — 
types, states, transitions, developmental history, and tissue organization — will be built by 
grassroots efforts across the HCA community. The open source DCP, governed by HCA, will 
allow any method to connect to the platform through dedicated APIs. In addition, HCA will 
designate some of these as HCA official pipelines, an integral part of the open-source data 
platform. These official pipelines will be applied immediately to any new data and will be part of 
any streamed version and formal releases. Data processed through the pipelines will be accessed 
through portals and apps, with functionalities for both computational users (through APIs) and 
biologists (through GUIs). 
In addition to streaming, the HCA will have formal releases, where data has been processed, 
analyzed, and vetted. Such cohesive drafts should ensure that the project: 
 is able to integrate data from multiple organs, techniques, and researchers; 
 possesses a data infrastructure that synthesizes data in a way that maximizes the 
knowledge that the data provide; 
 is indeed a true atlas by revealing relationships between the cell types that are included; 
and 
 reflects on the lessons learned in the HCA effort up to that point to guide practices for the 
next phase of the project. 
SCIENTIFIC ORGANIZATION 
The HCA consortium will be built on four scientific pillars: Collaborative Biological Networks, 
the Technical Forum, the Data Coordination Platform, and the Analysis Garden.  
The Collaborative Biological Networks will bring together the scientific community’s domain 
experts in specific systems and organs, together with genomics, computational, and engineering 
experts to construct the atlas of each tissue, system, or organ.  
The Technical Forum will develop new technologies and run dedicated pilot projects to test, 
compare, and disseminate existing technologies.  
The Data Coordination Platform will be a centralized way to “bring researchers to the data” by 
creating software to perform data ingestion, storage, processing, analysis, visualization, and 
access controls. 
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The Analysis Garden will be a rich, diverse, open, and easily accessible ecosystem where 
computational methods and algorithms developed by any interested group can bloom and be 
shared across the community.  
The full and formal governance of the HCA and its membership is stated in Section 7 and 
Appendix I. Briefly, the HCA is governed by an Organizing Committee (OC), currently 
comprising 27 scientists from 10 countries with diverse areas of expertise. It is led by two co-
chairs, who are members of the OC, and has an Executive Committee (EC), which includes the 
two co-chairs and five additional OC members. The OC establishes Working Groups in specific 
key areas. It also governs the Data Coordination Platform (DCP). It establishes and appoints a 
DCP Governance Group (DCPGG), which reports to the OC, to oversee the implementation of 
its policies for the DCP. The HCA is coordinated by Executive Offices (EOs), currently in four 
locations (U.K., U.S., European Union, and Asia), which staff the OC in performance of its 
duties. The OC also convenes members of the community in meetings, workshops, and 
jamborees. The OC also convenes but does not monitor the Funders’ Forum, an opportunity for 
funders and potential funders of the HCA to discuss the project.  
Any individual may become an HCA Member by registering at the HCA Member Registry and 
agreeing to abide by the principles of the HCA (as stated in Section 7), especially its ethical 
standards. In addition, an HCA member who is a participant in an HCA project, or a member of 
an OC-designated HCA group, will be designated as an HCA Collaborating Member.  
Any scientific project related to systematic biological characterization at single-cell resolution 
may become an HCA Project by registering in the HCA Project Registry. Projects will fall into 
three categories: HCA Participating Project, HCA Network Project, and HCA Flagship Project. 
Each of the pillars and the overall organization will require dedicated engagement, support, and 
funding. Examples include: 
 Biological Networks: tissue acquisition, data generation, and HCA Flagship Projects 
(see below and Section 7) for each tissue, including development and testing of the 
Common Coordinates Framework; 
 Technical Forum: technology development, benchmarking, dissemination, and training; 
 Data Coordination Platform: software development, revision, and maintenance, plus 
support of data portals, data storage, and computational resources; 
 Analysis Garden: computational methods development, software dissemination 
(including through the DCP), method comparison, testing, and training; and 
 Overall Organization: workshop and jamboree planning, research progress tracking, 
connecting with and onboarding of community members, HCA meeting planning and 
convening, and engagement with the broader scientific community, the public, and the 
media. 
IMPACT 
The HCA will help answer fundamental questions in all aspects of biology as well as serve as a 
guide to unravel the secrets of human disease (Figure 4). The translational promise of the cell 
atlas ranges from basic biology of the human organism, to disease mechanism, diagnosis, 
prognosis, and treatment monitoring, to immunotherapy, drug development, and cell and organ 
replacement. General areas of medical impact include: 
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 Genes to drugs. The cell atlas will enable researchers to identify the cell types in which a 
given genetic variant acts, thus helping to pursue therapeutic targets identified by genetic 
studies of disease. For example, analyzing tens of thousands of neurons in the retina 
revealed new subtypes that eluded neuroscientists before, which can help us find in which 
cells the genes important in blindness actually act.  
 Regenerative medicine. An atlas of cell types that are lost in disease will enable efforts 
to generate such cells faithfully. Similarly, an atlas of healthy human tissues and the 
matching organoids or in vitro differentiated cells will help determine if the engineered 
samples faithfully represent normal tissue composition and identify ways to complete any 
missing components. For example, efforts are under way to produce dopamine neurons in 
vitro or, alternatively, to reprogram cells in vivo into dopamine-producing neurons to 
treat Parkinson’s disease; an atlas of cell types will pinpoint characteristics that must be 
programmed into these cells for them to succeed.  
 Disease mechanisms. Because the cell atlas will provide detailed maps of cells and their 
roles in tissues, researchers will be able to understand the mechanisms underlying any 
disorder at both the cell and the cellular-ecosystem level. For example, an atlas of the 
small intestine will help map the cell of action for genes associated with Crohn’s disease, 
food allergy, obesity, and colon cancer. 
 Drug discovery. The cell atlas will provide guidance as to which gene signatures to 
pursue in drug screens to represent desired cell phenotypes. For example, it can give us a 
molecular map of which genes and signatures drive cell development and how it goes 
awry in, say, cancer and provide targets for drug discovery.  
 Toxicity. It will be possible to determine where else in the body a particular gene is 
expressed, helping to identify 
potential off-target effects prior to 
drug trials. For example, a cell 
atlas will help CAR-T 
immunotherapy cell developers 
ensure that the cells do not 
inadvertently target healthy 
essential cells that express the 
same gene or that drugs will not 
have off-target effects in other 
tissues (for example, causing 
blindness by targeting genes 
expressed in the retina).  
 Drug efficacy and resistance. The 
atlas will provide the tools 
necessary to understand why drugs 
work — or don’t — at the level of 
cells and tissues, both prior to and 
after treatment. For example, a 
“cellular-ecosystem map” that 
identifies both target cell types and 
target molecules of immunotherapy 
Figure 4. The Human Cell Atlas will have profound 
impact on biology and medicine. 
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will help predict and monitor tumor response and provide new leads for immune 
modulation in resistant patients.  
 Diagnostics. Knowledge of all the cell types in the body and their role in disease will 
enable updated and much more powerful versions of common diagnostic tools, such as 
the Complete Blood Count (CBC) and next-generation biopsy. For example, the CBC, a 
census of a limited number of blood components that is used in a variety of diagnostic 
settings, could be supplemented by a “CBC 2.0” that would provide a high-resolution 
picture of the nucleated cells in, for example, blood disorders, infectious disease, 
autoimmune disease, and cancer. Tissue biopsies from patients could also be analyzed 
with unprecedented resolution. 
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2. A FRAMEWORK FOR CONSTRUCTING A PHASE I ATLAS: 
EARLY DRAFT 
While our overall goal is to build a comprehensive Human Cell Atlas, we think it is wise to set 
intermediate goals for draft atlases of increasing resolution, comprehensiveness, and depth. This 
phased approach will define milestones along the way, provide guidance for better planning of 
subsequent milestones, hold the project accountable, and provide immediate utility to the 
scientific community.  
In this section we provide a general framing for constructing Phase I of the HCA. We discuss the 
key design considerations and provide an overall approach to address them. Nevertheless, many 
details must be specified precisely for each data collection effort, and some will vary by tissues 
(Section 6). 
TISSUE ACQUISITION 
Accessing the tissues needed to meet the aims and objectives of the HCA will present significant 
biological, logistic, and regulatory challenges. For adult samples, we will primarily acquire 
healthy tissue from rapid autopsies and deceased organ donors (who have already donated any 
organs useful for medical purposes). In some instances (Section 6) these will be complemented 
with disease tissue. For samples of human development, we will acquire tissues from available 
repositories. Whenever possible, we will obtain resections, biopsies, and other sources from 
living healthy research participants, but we recognize that this will not be possible for some 
tissues and organs. Comparing tissues obtained from live healthy donors to their counterparts 
from post-mortem sources would help determine the validity of the latter for those cases when 
postmortem sources are the only ones available. 
Tissue sources 
Tissue sources used for the HCA must have the following essential features:  
 Access to normal live cells and tissues from male and female research participants or 
donors across a range of ages and ethnicities. 
 Ability to obtain adequate tissue mass from all organs and tissues of interest to enable 
multiple comprehensive analyses of the same samples. 
 Full regulatory approval and participant informed consent for comprehensive 
(including genetic) sample analysis as required by legal and ethical standards. 
 Unrestricted open access to the data generated.  
Additional features that could ideally be met, at least for some sources, include: 
 Ability to perform comprehensive sampling from multiple organs and multiple samples 
from the same donor. 
 Access to a range of developmental tissues. 
 Access to full donor demographic data, including relevant past medical, family, and 
social history. 
 Comprehensive infectious disease screening of the research participants and donors. 
 Access to live cells and tissues from disease cohorts of interest.  
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To satisfy these requirements, the HCA effort will use three major complementary tissue 
sources: (1) live individuals as research participants; (2) deceased transplant organ donors; and 
(3) rapid autopsies. Each presents a trade-off between the breadth of available tissue and the 
faithfulness of the source to normal living humans.  
 Live research participants. Access to healthy live tissue and cells is mostly limited to 
samples donated by living volunteers (e.g., blood, fat, or skin biopsies) or resected tissue 
collected as part of an invasive procedure (e.g., surgery or endoscopy) performed as part 
of screening or on patients with known or suspected pathologies. Viable tissues are 
naturally limited in quantity and range and may be challenging to obtain for some tissues 
without data-access restrictions. However, these tissues represent truly healthy 
individuals and can also be the starting material source for many organoids. 
 Deceased transplant organ donors. This source allows controlled and planned tissue 
acquisition in a very rapid manner after death. There is detailed anonymized medical and 
social history and screening data available for each donor, along with ethical approvals, 
and many (albeit not all) organs and tissues can be obtained from each deceased donor. 
Tissues can be perfused with cold organ preservation solution, ensuring cell and tissue 
viability for >24 hours after donation, or with newer ex vivo perfusion systems that keep 
organs warm and operational for hours after death. Tissue can also be acquired from 
donors with a range of pathologies that are not absolute contraindications to organ 
donation (e.g., diabetes, hypertension, ischemia-related heart disease, and autoimmunity 
— but not cancer). Similar strategies can be applied for developmental tissue.   
 Postmortem examinations can provide tissue from any organ, with appropriate consents 
for open-access data, and can be collected via rapid, or “warm,” autopsy. Many rapid 
autopsies are pre-consented, or individuals have predeclared their interest in donating 
organs to scientific research after death. Tissue can be acquired from deceased donors 
with relevant disease histories, including cancer, or can focus on pathologically 
uninvolved tissue.  
Feasibility case studies 
Two use cases highlight the potential and power of deceased transplant organ donors and rapid 
autopsies for systematic collection of organs and tissues for HCA. 
Feasibility Case Study 1: Cambridge Biorepository for Translational Medicine (CBTM)  
CBTM (www.CBTM.group.cam.ac.uk) was founded in Cambridge, U.K., in April 2015 to 
support translational research projects that require access to fresh or biochemically viable tissue. 
It currently supports 31 major research projects, led by 24 PIs in 14 departments and institutions, 
and has collected tissue from >50 deceased human donors with comprehensive ethical approval 
and informed consent. The research projects supported by CBTM cover diverse use cases, 
including genomics, transcriptomics, regenerative medicine, immunology, metabolism, 
physiology, and pathology. CBTM has successfully enabled projects, which, like HCA, required 
access to tissue as detailed below. 
 Normal live tissue that is very rarely available from living volunteers or through 
resections (e.g., dorsal root ganglia, heart, thymus, and spinal cord). 
 Normal tissue that is not available in sufficient quantities from individual patients or 
living volunteers (e.g., large volumes of peripheral blood). 
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 Multiple normal live tissue samples from the same organ (e.g., entire length of the 
gastrointestinal tract and its secondary lymphoid organs).  
 Multiple normal live samples from several organs and anatomical locations from the 
same donor. 
 Normal live tissue that must be processed very rapidly and within seconds of interruption 
of the blood supply (e.g., oxygenated myocardium).  
CBTM is already providing tissue for pilot projects to perform tissue dissociation and scRNA-
Seq and is planning a CBTM-HCA collaboration for up to 3,000 specimens per donor from 5 to 
10 deceased donors.  
Feasibility Case Study 2: The GTEx project collection network  
GTEx is a U.S. NIH Common Fund project initiated in 2010 to determine how genetic variation 
affects gene expression across 44 normal human tissues. To support this effort, it developed a 
tissue-collection platform, spanning multiple organ procurement sites, that meets the ethical, 
scientific, informatic, and operational challenges of large-scale, rapid, viable postmortem 
biospecimen collection. To date, GTEx has collected ~30,000 tissue specimens from 960 donors, 
across 53 distinct tissue sites (median of ~26 tissues per donor), from both transplant organ 
donors and rapid-autopsies. A small portion of the archived samples have been flash frozen and 
can be profiled by using single-nucleus RNA-Seq2-4. Unfortunately, most of the samples were 
not archived for such purposes, and the original project does not specify consent that data would 
be shared and released openly, so previously collected samples cannot be used for the open-
access HCA.  
Nevertheless, the GTEx collection network has demonstrated that it can fulfill all of the aims and 
objectives of the HCA for tissue acquisition from postmortem donors, including open access. 
 It conducted a successful pilot project to enroll four donors who consented to full open-
access sharing of research results (performed together with the ENCODE 4 consortium).  
 All of the protocols and standard operating procedures developed for the GTEx 
collection network have been made publicly available and remain in place.  
 All of the aims and objectives outlined above were met by the GTEx collections.  
Figure 5. Retrospective samples from GTEx can be successfully profiled using single-nucleus RNA-Seq. (A) 
Bulk gene expression profiles from all GTEx tissues. Hippocampus and frontal cortex sample clusters, from which 
samples in (B) are obtained, are circled. From Auget and Ardlie, Current Genetic Medicine Reports (2016); 4:163-
9. Reprinted with permission from Springer Nature. (B) Single nucleus RNA-Seq (by DroNc-Seq) of hippocampus 
and frontal cortex samples from the GTEx collection. tSNE plots are colored by k-NN graph clustering and labeled 
post hoc by cell type. (C) Each cluster is supported by multiple individuals (from relevant tissue). (B) and (C) from 
Habib et al., Science (2016) Aug 26;353(6302):925-8. Reprinted with permission from AAAS.  
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 Although GTEx tissues were not specifically collected for single-cell analysis, the organ-
procurement sites involved have considerable experience with the collection and 
stabilization of tissues for single-cell research. Indeed, it was recently demonstrated with 
retrospective samples, that rapidly collected, frozen samples from GTEx can be 
successfully used in snRNA-Seq (Figure 53).  
 The GTEx collection network also obtains an extensive collection of detailed histology 
images, enabling integrative computational analyses of molecular and spatial features.  
Challenges and related pilot studies 
There are three key challenges to create the necessary infrastructure and optimize and validate 
protocols for tissue acquisition for the HCA: (1) engage or establish tissue-acquisition networks 
beyond the U.K. and the U.S.; (2) determine the impact of ischemia time; and (3) perform tissue 
acquisition in the context of a Common Coordinate Framework for anatomical mapping. We 
discuss each in turn, along with pilot studies to address them. 
Deceased transplant organ donors for tissue acquisition beyond the U.K. and U.S. The CBTM 
and GTEx pipelines provide proof-of-principle for the suitability of deceased organ and rapid-
autopsy donors for HCA tissue acquisition. It is now necessary to identify a small number of 
transplant centers in these and other countries to maximize international access and geographical 
and ethnic diversity. Representatives from several European organ-procurement operations, who 
participated in two recent GTEx meetings, have begun exploring such involvement. A potential 
pilot study (of 3 to 6 months) could examine the feasibility of extending this model to one more 
European Transplant Unit. In parallel, for the HCA it will be advantageous to tap into other 
organ-collection efforts from ethnicities and geographic regions traditionally neglected by the 
research community — for example, by collaborating with scientists in Africa, Asia, and Latin 
America. 
Impact of ischemia time. Understanding molecular changes during warm and cold ischemia after 
circulatory arrest, in a tissue and organ-specific manner, is critical for setting acceptable limits 
for processing time after circulatory arrest and will have significant operational implications. 
Moreover, pathophysiological changes after brain-stem death and premorbid medical conditions 
can impact the donor’s cells and might require the development of criteria for inclusion in or 
exclusion from the HCA. To date, analyses of bulk samples in GTEx have suggested that the 
ischemic interval affects the transcriptome in a tissue-specific manner. A pilot study at the 
single-nucleus and spatial level could leverage the pre-existing Biospecimen Methods Study 
(BMS) in GTEx, in which samples from 30 donors and six tissues were collected at four 
sequential ischemic time intervals; alternatively, new collection can be performed to test this.  
Anatomical mapping in a Common Coordinate Framework. A Common Coordinate Framework 
(CCF) is essential for mapping the anatomical location of every sample from each organ in a 
comparable manner. A CCF must have higher granularity and precision beyond classical 
anatomical descriptions, be robust to natural variations in donor and organ size and shape, be 
bespoke for each organ, and should flexibly enable higher levels of precision sampling, such as 
spatial grids. This is a general challenge for HCA and will require proper standard operation 
procedures, encoding of current anatomical knowledge, and computational inference. Clearly, it 
has a direct impact on tissue acquisition. A pilot study, will aim to develop an initial CCF for 
one or two organs (e.g., kidney, liver, heart, or colon) that will include appropriate referencing to 
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constant anatomical landmarks, nomenclature, and the necessary data platform for linking to 
spatial coordinates within the organ. We discuss the CCF further below. 
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COMMON COORDINATE FRAMEWORK  
DATA COLLECTION 
We will collect data for the HCA using a two-pronged approach: a cellular branch for 
molecular profiling of dissociated cells or nuclei; and a spatial branch for analysis of cells in 
tissue (Figure 3).  
Cellular branch: a Sky Dive for single-cell or single-nucleus profiling  
Key operational challenges in building a cellular atlas include the absence of a priori ground 
truth on the number of cell types and states and their relative proportions and rates of transitions; 
the need to ensure that understudied cell populations — whose molecular markers or mere 
existence may be entirely unknown at the outset — are not ignored; and the possibility of 
technical biases in the recovery of different cells because of, for example, differential loss during 
sample handling. 
To address these challenges, the first cellular draft will be built using a Sky Dive: a step-wise, 
iterative, and adaptive design strategy. Akin to skydiving — in which the jumper sees a wide 
landscape upon leaping from the plane, then continually resolves finer and finer detail on the 
ground as she falls — this strategy starts with a broad uniform survey of cells in a specimen, 
followed by stratification into specific subsets for additional profiling guided by accrued 
knowledge. This iterative strategy ensures that rare cells can be discovered and adequately 
profiled. Similar strategies have been deployed for the cost- and time-efficient sampling of large 
human populations for census taking. To make the atlas most useful in the long-term, we expect 
to use multiple technologies to examine the same tissues, both at the same and/or at different 
levels of the Sky Dive. This strategy has already been used to profile the cells in the mouse 
retina, where first the whole retina was profiled5 and then a more focused effort to profile a 
specific cell type, bipolar cells, followed6. A similar approach was taken in colon organoids7 and 
the subsequent analysis of rare enteroendocrine cells8. Key to the success of this Sky Dive will 
be an “all negative” bin that will recover even those cells that could not yet be distinguished in 
the initial survey. Finally, to address the possibility of differential loss, both single cells and 
signal nuclei will be profiled in the cellular branch. The latter can be isolated from tissue without 
dissociation in a manner than appears to minimize compositional biases2-4,9. 
Initial uniform sampling will be performed to profile a defined number of cells, k, from a 
specimen with minimal, if any, additional stratification. The number of cells to be profiled must 
be determined based on a statistical model. An early example (Box 1) accounts for the number of 
cell types expected in the tissue, the proportion of the rarest type that we desire to detect, the 
minimal number of cells desired of the rarest type, and the desired confidence level to achieve 
this number. The key unknown parameter is the number of cell types; it is initialized by prior 
knowledge or an “educated guess.” This early model makes several simplifying assumptions and 
should be enhanced, for example, to address biases in sampling of cells (e.g., loss of specific cell 
types because of differential viability or capture efficiency) and to handle cases where the 
distinctions between cells may be subtler and require larger numbers of cells. (Similar models 
A workshop focused on developing, piloting, and deploying a CCF will be held in Washington, 
D.C., in December 2017, engaging anatomists, pathologists, clinicians, organ experts, technology 
experts, machine-learning experts, software engineers, and visualization experts. This section will 
be written after the workshop and will appear in a later version of the White Paper. 
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will be required for the case of continuous paths, such as cell differentiation.) The Analysis 
Working Group (AWG, Sections 4 and 7) is already working on improved approaches for 
experimental design and power calculations.  
The process may be iterated. Following initial profiling and analysis, the key parameter of the 
number of expected cell types may be revised, in which case a recalculation will be performed 
and additional cells may be profiled. Based on the composition of the tissue revealed in this 
phase, an additional power analysis and a cost-benefit analysis will determine the empirical rate 
of discovery and will determine when to move to a stratified analysis. Notably, in these iterations 
it may be possible to select — from the Whole Transcriptome Amplification (WTA), barcoded 
material — a subset of cells or nuclei barcodes of interest for deeper sequencing of such 
transcripts, without any a priori cell enrichment. This will not recover new cells, but could 
deepen the characterization of rare cells in the sample without the need to similarly sequence 
molecules from more prevalent cells. 
Stratified sampling requires that cells be first separated into “buckets” by sorting, enrichment, or 
depletion strategies. In addition to any affirmative buckets, a final “all negative bucket” is 
maintained to help discover additional, possibly rare subsets. The buckets aim to optimize 
collection when cell proportions vary substantially, but critically depend on the availability of 
reagents and experimental procedures. For example, we may not have many antibodies for less-
known cell types and can possibly use RNA probes on “fixed cells” for sorting; this would also 
simplify enrichment for nuclei. Within each bucket, the same power calculations are applied as 
in the initial uniform approach, along with the same procedure for iteration and the same 
stopping criteria. In each iteration, buckets may be further partitioned. Notably, the goal will be 
to determine composition up to the predefined rarity P, but, depending on tissue composition, 
rarer subsets may be detected.  
The first two phases of the Sky Dive — uniform and stratified sampling — will rely on 
massively parallel profiling. At the moment, two types of molecular profiles can be collected at 
such scale: RNA, using one of several strategies for scRNA-Seq or single nucleus snRNA-Seq, 
and chromatin, using a single cell Assay for Transposase Accessible Chromatin (scATAC-Seq). 
RNA and chromatin profiles are highly complementary, especially in the context of cell 
differentiation. For each of these methods, it may be possible to mix cells from multiple 
individuals prior to profiling, and using their genetic variation as natural genetic barcodes to 
distinguish them. This has both operational and analytic advantages, but is applicable only to 
Box 1: Statistical models to determine the number of cells to profile. A simple statistical 
framework can help answer the question: “Given a tissue with N discrete cell subsets, the rarest of 
which is present at proportion P, how many cells k need to be sampled such that at least n cells are 
recovered in each subset with confidence level C?” The model assumes the conservative (worst-case) 
scenario in which there is one dominant cell type and many equally rare cell types. It further assumes 
that the Central Limit Theorem (CLT) holds, and the samples are independent: that is, the set of cells 
sampled is far larger than the number of cells desired, a safe assumption in nearly any case but the 
smallest samples. While the sampling of each cell type is not actually independent it is not a serious 
violation if the number is large enough. Given these assumptions, the number of cells from each type, 
Ti, will distribute as E[Ti] = N*p, SD[Ti] = sqrt(N*p*(1 – p)), and we solve for N such that all (N – 1) 
subtypes to have at least n cells. The last (dominant) subtype easily clears this threshold since its 
proportion is much higher. This model is now available at http://satijalab.org/howmanycells. We 
expect further refinements, as well as a similar model to be developed for continuous transitions. 
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those samples that can be accrued (e.g., frozen) prior to processing. Whenever single-cell 
profiling methods are similarly scaled, they can be considered as potential additions to this 
process. An example approach recently scaled to achieve high throughput is lineaging through 
targeted tracking of selected DNA mutations10. Other approaches will be added as they scale and 
based on the extent of independent information that they provide. 
Deep analysis with specialized but lower-throughput methods. Massively parallel methods do not 
reflect all key aspects of the cell, do not currently integrate multiple profiles in the same cell, and 
may provide relatively lower depth (complexity). A host of sophisticated methods currently 
available only at lower throughput has emerged to measure DNA mutations (for lineaging), 
epigenomic profiles (e.g., histone modification, 5’ CAGE, DNA methylation, which may reflect 
cell types at longer time scales) and multiomics (e.g., RNA and DNA methylation, RNA and 
protein; chromatin accessibility and RNA; which provide mechanistic insights). Furthermore, 
sensitive methods are available for full-length scRNA-Seq and snRNA-Seq, but they are 
currently available only in lower throughput. These methods will provide a fuller profile of the 
molecules present, including splice variants and epigenetic states, thus providing a more 
comprehensive characterization of each cell type. 
As the Sky Dive reaches high resolution, with subset stratification, the massively parallel profiles 
will be complemented by these lower-throughput and/or more specialized and costly methods 
applicable with more modest cell numbers within predefined cellular subsets. 
Auxiliary bulk profiles for annotation and interpretation. Analysis of single-cell profiles, 
especially those from massively parallel methods, relies on auxiliary annotations. For example, 
massively parallel scRNA-Seq quantifies RNA levels relative to transcript annotations: if 3’ end 
and splice isoforms are not well-reflected in pre-existing annotations, as is likely to be the case 
for less frequent and less studied subsets of cells, important information may be lost. To address 
this challenge, “annotation grade” bulk RNA-Seq profiles (deep, long, paired-end reads) will be 
collected at each level of the Sky Dive — from the entire specimen to iteratively finer buckets — 
and used to generate high quality annotations. Other profiles — for example, of histone 
modifications and proteomics — should be similarly collected. This is a remarkable opportunity 
for partnership between the HCA consortium and other consortia, such as ENCODE and the 
Human Protein Atlas, to share the same, open-consented specimens. 
Spatial branch: Molecular microscopy into cells in their tissue context  
Direct- and virtual-imaging technologies can relate molecular measurement with cellular, 
subcellular, and structural features of tissues. Current techniques have a clear and continuous 
trade-off between speed, resolution, and molecular complexity (Figure 3): high-resolution 
methods mostly use predefined molecular signatures (e.g., sets of RNA, proteins), whereas 
profiling methods are mostly applied at lower spatial resolution. While technologies advance, 
this can be addressed by iteratively using the lower-resolution methods, including single-cell 
profiles, to define signatures and the higher-resolution methods to obtain exquisite spatial details. 
Ideally, portions of every specimen will be analyzed with methods in each of three increasing 
levels of resolution.  
 Anatomical tiles. At the coarsest level, tissue will be assayed with Anatomical Tiles 
(ATs), collected through serial 3-D sectioning that produces voxels of tissue for further 
processing, which are registered to imaging information. Ideally, each AT is further 
partitioned to provide samples both for single-cell profiles and for spatial analysis of the 
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same specimen. The length scales of tiles should reflect the anatomy and histology of the 
specific tissue. 
 Spatial barcoding. At the next level, molecules in tissue can be spatially barcoded, with 
techniques currently at the resolution of 100 µm (~2 to 50 cell diameters) and improving.  
 High resolution, in situ measurements. Multiplex hybridization, in situ sequencing, and 
protein-capture methods can measure RNA or protein signatures at the highest resolution, 
from cellular to single molecule, depending on the technique. This is also an opportunity 
to collaborate with the Human Protein Atlas and measure the spatial distribution of the 
human proteome at a subcellular level11,12. 
Iterative signature selection and spatial power analysis. The need to choose molecular 
signatures for high-resolution spatial profiling introduces questions about the power to detect 
different spatial patterns (“spatial power analysis”). We will address this iteratively: Initial 
signatures will be selected by a combination of prior knowledge (known landmarks) and from 
signatures defined from single-cell profiles or lower-resolution spatially barcoded profiles. Once 
a signature is measured, entire genomic profiles can be computationally projected through the 
landmarks9,13-15 to identify additional putative patterns and to define new spatial signatures for 
measurements. A key remaining concern exists if profiling methods suffer from systematic 
biases, but this can be addressed by performing multiple compositional measurements, each 
assessing the sum abundances of multiple molecules16, and use decoding strategies to determine 
an entire profile.  
Tissue preservation. Because some of the spatial techniques are not yet broadly disseminated and 
scaled, in some cases high-resolution spatial data may be collected only after substantial single-
cell profiles have been collected from the same specimen. Fortunately, most spatial methods are 
compatible with long-term tissue preservation, allowing for this staggered approach. Thus 
spatially and anatomically registered tissue specimens will be routinely preserved.  
Validation: reproducibility, integrity, and predictive value 
In assessing the validity of the generated draft, we should consider reproducibility or stability, 
defined by the ability to recover (through both planned replicates and follow-up prospective 
isolation) cells and cell subsets with the same profiles and features; integrity, defined by the 
ability to capture — using all techniques and data in aggregate — all cells (up to the defined 
rarity thresholds) in the tissue in the correct proportions and appropriate profiles, without 
disproportionate loss of specific subsets or change in molecular patterns; and predictive value, 
defined by the ability to determine that a subset defined by a distinctive set of features (e.g., 
molecular profiles) either appropriately maps to a known, previously validated biological entity 
(cell type, state, or transition) or predicts a new entity with distinctive features of another nature 
(e.g., histological).   
To assess reproducibility or stability, we will compare across multisite, multi-individual 
replication studies of both profiling and spatial analyses. In addition, the later phases of the Sky 
Dive will include prospective isolation, followed by single-cell and/or bulk profiling. In this 
context, Rosetta Stone samples will be collected early in the project, as an archived, large set of 
specimens, available for comparison of protocol application, at least when fresh cells are not 
required.  
To assess integrity, bulk RNA-Seq or proteomics measurement can help determine the 
probability of residual, unascertained types residing within samples, if those are not too rare and 
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are sufficiently distinctive. For cases with such residual signals unaccounted for in dissociated 
cells, additional cell profiles may need to be acquired, either randomly by comprehensive tissue 
dissociation or through stratification. Single-nucleus profiling should also help identify biases in 
cell composition or state introduced by dissociation. In the case of tissues analyzed in situ, this 
will require new panels of probes. It may be advisable to use multiple, randomly selected 
combinations of probes in such instances.  
Consistency between profiles of dissociated cells and spatial measurement of intact tissue will 
provide another estimate of integrity. Comparison to spatial transcriptomics of intact tissue can 
be applied in a similar way, for more sensitive analysis. Comparison to in situ measurements can 
help determine changes in single-cell profiles introduced during dissociation.  
To assess predictive value, cross-referencing between distinct molecular signatures, defined from 
profiles, and distinct spatial features (cell morphology, spatial localization, histological 
structures, cellular neighborhood) will be a primary tool. We note that functional assessment — 
such as studies of the physiological function of cells and their characteristic molecules — are 




3. TECHNOLOGY  
Building the HCA will require careful experimental design, including consideration of which 
technologies we should deploy to generate reproducible and high-quality data and which we will 
need to develop to enable new measurement capabilities or increased scale. Indeed, the HCA has 
been inspired by and will be facilitated by technological innovations that address a broad range 
of measurements and experimental challenges, including single-cell and single-nucleus “-omics” 
profiling (e.g., transcriptomics, genomics, epigenomics, proteomics, and multiomics); tissue 
dissociation; tissue and cell preservation; and spatial and temporal characterization. Some of 
these are currently more mature and broadly disseminated than others. As a result, it is 
reasonable to assume that, at any given moment, some data will be collected using established 
technologies (“production”), while next-generation, emerging methods progress through 
refinement and dissemination (“scaling”) to production. We also envision that, similar to the 
Human Genome Project and other consortia, the HCA will inspire the development of new 
approaches by helping provide a sense of community and mission-driven focus, as well as 
resources and drive that foster innovation.  
The Technical Forum  
To serve such an effort, the HCA’s Technical Forum (Forum) will have two goals:  
 bring together groups and centers to compare and disseminate existing methods; and 
 ensure that new techniques are developed and adopted through a combination of 
academic efforts and the activities of technology companies that are eager to help the 
HCA and to learn from its collective expertise and experiences. 
To compare, test, and scale methods, the Standards and Technology Working Group (STWG; 
Section 7) will initiate the Forum with groups spanning different countries and areas of 
expertise. These groups will carry out well-designed technical pilots in a handful of biological 
systems, in close partnership with computationally focused researchers. Pilots will be initiated 
among both the cellular and the spatial branches of the HCA and span the entire life cycle from 
invention to proof-of-concept and finally dissemination in optimized systematic pipelines at 
scale. 
Development of new technologies. To promote the development of new techniques, the STWG 
and the Forum will first identify key areas in which new technologies are greatly needed and 
promote work within them. Advancing new methodologies will require  
 dedicated support to individual labs that are inventing methods;  
 dissemination of nascent protocols into additional labs beyond those that developed the 
initial technique, including additional benchmarking;  
 generation of preliminary open data sets on which computational groups can hone 
different analytic techniques; and  
 providing ongoing, iterative feedback from computational experts to experimentalists that 
will expedite the improvement of techniques.  
To fulfill these latter needs, the analysis working group (AWG) will identify potential pitfalls, 
provide early and rapid feedback that helps pinpoint artifacts, speed optimization, and generally 
guide the technology development efforts. For example, jamborees co-organized by AWG and 
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STWG (Sections 4 and 7) can help rapidly develop initial analytics or quality-control measures 
for new technologies. 
Technology optimization and comparison. Techniques for sample preservation, tissue 
dissociation, “-omic” preparation, and spatial profiling should be evaluated, and benchmarking 
or validation data sets generated. Comparisons can be made between different protocols that 
have the same goal (e.g., different methods of scRNA-Seq or of multiplex fluorescence in situ 
hybridization [FISH]). They can also be made between laboratories using the same protocol to 
assess robustness and reproducibility. Finally, they can be made by using complementary 
methods (scRNA-Seq and spatial analysis) on the same kind of sample for a feasible subset of 
samples. The AWG will help facilitate this process by developing metrics and benchmarks for 
the comparison that are broadly agreed, including through community-wide efforts such as 
jamborees, co-organized with STWG. 
Technology dissemination. Early single-cell sequencing techniques required fairly ubiquitous 
skills and equipment, leading to wide and rapid adoption (for example, SMART-Seq required 
only 96-well plates, a method of isolating single cells, and limited infrastructure). By contrast, 
many spatial technologies require highly specialized tissue-handling protocols and sophisticated 
microscopes. Moreover, the handling and dissociating of human tissue specimens requires 
substantial domain know-how, which is often not broadly disseminated. We will need to ensure 
hands-on training and equipment to disseminate both of these techniques to a wider community, 
as well as system-specific and general benchmarks to ensure effective adoption. This will require 
investment in both infrastructure (e.g., equipment) and in training, including on-site hands-on 
guidance by Specialized Work Acquisition Teams (SWAT teams), which will convey expertise 
and know-how from one site to another.  
Below, we discuss these considerations more fully in the context of technologies underlying the 
two key strategies for the HCA: molecular profiling of dissociated single cells or nuclei (cellular 
branch) and highly multiplexed spatial analysis of intact tissue (spatial branch). In each case, we 
present the state of the art, key areas for development and optimization, approaches for 
evaluation and benchmarking, and strategies to disseminate, combine, and deploy techniques in 
building the HCA.  
SINGLE-CELL MOLECULAR PROFILING OF DISSOCIATED CELLS  
The revolution in single-cell genomics has enabled genome-wide quantification of mRNA in 
thousands of individual cells at once. Additionally, multiple techniques have been developed to 
study the genetic and epigenomic characteristics of single cells, including DNA mutations (and 
associated lineage information), cytosine modifications, higher-order chromosome conformation, 
histone modifications, and regions of accessible chromatin (Figure 1)17-19. Each of these 
methods will need to be further optimized and deployed to generate the HCA — some as the 
main workhorses and others as auxiliary methods, with agile reassessment of chosen techniques 
in a fast-evolving landscape.  
We have also begun to integrate and couple multiple “-omics” measurements on the same 
individual cell. Recently, the first methods for integrating genomic DNA and mRNA sequencing 
from the same cell20,21, single-cell methylome and transcriptome measurements22, and even 
chromatin accessibility, methylation, and transcriptomes23 from the same single cell were 
described23. Several methods have been developed that allow coupling of single-cell 
 28 
transcriptomics to protein measurements24-27. Collectively, these and newly developed single-cell 
multiomics methods would help integrate information on the genome, lineage, 
(hydroxy)methylome, genome accessibility and structure, transcriptome, and proteome, and 
would provide more comprehensive pictures of the properties of, and relationships between, each 
cell type in the atlas. 
Current technologies 
mRNA. Because of the close connection between a cell’s function and its transcriptional 
program, as well as the relative simplicity of amplifying and detecting nucleic acids, gene-
expression profiling at the single-cell level has become a major form of molecular phenotyping28. 
As the most mature to date, single-cell transcriptomic tools will form the initial foundation of a 
draft taxonomy of cell populations across whole tissues. 
Building on molecular techniques for amplifying minute quantities of mRNA, which first made it 
possible to analyze gene expression from single-cell lysates, rapid advances in single-cell 
handling — including flow cytometry-based sorting29,30 and microfluidic partitioning31,32 — 
enabled the study of entire transcriptomes in up to hundreds of cells. Most recently, innovations 
in DNA-based cellular barcoding using primer-coated microparticles have been combined with 
droplet microfluidics (Drop-Seq5, InDrop33) or nanowell arrays (Seq-Well34, CytoSeq35) to scale 
single-cell profiling to hundreds of thousands of cells at once. Commercialization and 
simplification of these techniques have enabled widespread adoption of high-throughput scRNA-
Seq across labs and research areas36,37. In situ tagging, propagated through split-pool processing 
cells and nuclei, also allows extensive scale37,38. 
DNA and epigenetics. Single-cell profiling of DNA sequence and epigenetic state — including 
cell type–specific differences in genetics, gross DNA folding, DNA methylation, chromatin 
accessibility, and histone modifications — have also seen marked technological improvement. 
Detection of DNA mutations in single cells allows precise cell lineage reconstruction39-43, 
whereas epigenetic measurements19 provide a unique lens on cellular state, can be more robust 
across time than the more dynamic transcriptome, and often convey more detailed mechanistic 
information.  
Some of these techniques already have combinatorial potential — for example, methods that use 
restriction enzymes to detect epigenetic marks generate unique overhangs, meaning that several 
can be used together to gain information about multiple epigenetic marks in the same cell18. 
Meanwhile, combinatorial indexing38,44,45 and microfluidics46,47 have significantly improved the 
throughput of several of these approaches, allowing, for example, for measurement of chromatin 
accessibility (scATAC-Seq) at a large scale4,48,49. Epigenetic and transcriptomes measurements 
may often be complementary, with one emphasizing more cellular features that are invariant on 
longer-term scales and the other able to capture more subtle, dynamic variations in cell state.  
Proteins. Since proteins most directly carry out the cell’s functions, their levels can provide more 
biologically meaningful information. (Their expression is also more buffered from intrinsic 
sources of noise than mRNA and, sometimes, may be more reproducible50.) While some progress 
has been made in single-cell proteome profiling51, it is not currently possible to profile entire 
proteomes at scale in single cells because of limitations in detection reagents and lack of direct 
amplification. Instead, antibodies to specific proteins can be multiplexed either by coupling to a 
suite of heavy metals52,53 or nucleic acid tags54,55, permitting the profiling of dozens of epitopes 
in individual cells by CyTOF. In addition, antibodies barcoded with DNA can be co-detected 
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with cellular nucleic acids through sequencing, enabling simultaneous high-throughput profiling 
of whole transcriptomes and targeted epitope panels56. The availability and consistency of 
antibodies and similar capture reagents is a substantial hurdle. This is an opportunity for 
partnership with the Human Protein Atlas efforts11,12. 
Key areas for development and optimization 
Incorporating lineage information in single-cell -omics measurements. Lineage information will 
help determine how cell states change with cell division and differentiation. The ability to add 
lineage information to single-cell measurements of accessibility, the (hydroxy)methylome, and 
the transcriptome should be within reach. Currently, this could be achieved in model organisms 
by methods that change the endogenous genome sequence by editing (e.g., with CRISPR/Cas9) 
or by integration of barcoded viruses. In humans, meanwhile, it is possible to infer lineage 
relationships between cells from the accrual of genetic mutations with each cell division39-43. 
Coupling single-cell genotyping across multiple loci with epigenomic and/or transcriptomic 
profiles — especially if performed at scale — could lead to promising noninvasive methods that 
could be highly attractive for human lineaging work within the HCA19.  
Simultaneously recording nucleosome accessibility, methylation, and the transcriptome. 
Methods are emerging to combine single-cell methylation profiling (by bisulfite sequencing) and 
transcriptomics or for coupling nucleosome or chromatin accessibility and transcriptomics23. 
Some are still in initial development, and none has been demonstrated yet at scale; the 
information trade-off between scale in one metric and collecting several orthogonal ones is being 
actively explored. Further incorporation of nuclear RNA into these measurements could provide 
a more direct understanding of the relationship between epigenetic marks and transcription 
initiation. 
Time-resolved multiomics. Single-cell states, particularly the epigenome and the transcriptome, 
are highly dynamic, but we currently lack time-resolved measurements, particularly in vivo but 
also in vitro because genomic protocols are destructive. Imaging approaches for readers of 
epigenetic and transcriptional state in live cells could add to these capabilities. 
Approaches for evaluation and benchmarking 
Variety of methods. Often, large-scale “-omics” projects adopt a single technology, with the aim 
of minimizing technical variability in sample processing and allowing cross-sample 
comparisons. By contrast, we imagine that a useful long-term atlas will instead foster new 
technologies and use multiple methods to examine the same tissues. At the same time, however, 
there is great value in systematically applying a smaller number of technologies with consistent 
standard protocols within each. Analyzing samples across different technology platforms will 
allow us to cross-validate data, while remaining nimble to adopt disruptive technologies and able 
to engage a wider community of scientists; applying consistent, standardized protocols within 
each technique would reduce batch effects, facilitate comparison, and streamline HCA 
operations. To gather scRNA-seq data in the cellular branch, for example, we will use a 
combination of techniques, since some methods (e.g., droplet and nanowell) generate “broad” 
information, while others (e.g., SMART-Seq, CEL-Seq) provide depth. Each method will be 
applied in a stringent, standardized way, and additional valuable methods will be incorporated as 
they become ready.  
Evaluating technologies. To assess the suitability of existing and emerging technologies to 
generate the HCA, we should focus not only on technical measures, such as yield, cost-
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effectiveness, robustness, reproducibility, and comparability, but also on how well each method 
identifies relevant data-driven biological structures in tissues compared with predefined 
biological benchmarks, whenever possible (Section 2). We caution that some technical metrics, 
such as per-cell/per-gene sensitivity, may have less final impact on data utility57.  
Benchmarking and Rosetta Stones. A multiplatform, multilab atlas must rest on extensive 
benchmarking tools and reagents — a set of vetted standards and protocols that can be used to 
calibrate new experimental and computational methods, as well as Rosetta Stone sample 
resources that allow comparisons. Benchmarks and Rosetta Stones are critical not only to enable 
data reconciliation between HCA labs working on similar tissues, but also as reagents for HCA 
end-users in the longer term. Possible benchmarking tools and reagents include barcoded mRNA 
capture beads, synthetic cells, spike-in reagents, a repository of frozen cells (primary or cultured) 
of demonstrated uniformity, and heavy-metal isotopes. 
Strategies to standardize, disseminate, combine, and deploy techniques in building the 
HCA  
Optimizing each method will require the coordinated efforts of the STWG and AWG. Once 
convergence has been achieved, members of the STWG will work in conjunction with a given 
method’s developers to generate publicly available standard operating procedures for performing 
the protocol and for quality-controlling all necessary reagents against validated, centrally 
coordinated benchmarks. Notably, all HCA Projects (Section 1 and Section 7) are required to 
openly release and share all protocols. We envision that initial testing of and iterative 
improvements to these standard operating procedures will be driven by SWAT teams, first in 
centralized, controlled facilities and then in remote locations. Dedicated resources will be 
required to actuate this vision. For both current and future technologies, the STWG and AWG 
will need to determine and then disseminate best practices for ensuring maximum consistency, 
ease of cross-comparison, and protocol optimization, carefully integrating in feedback from 
those actively engaged in the HCA.  
ScRNA-Seq, snRNA-Seq, and (increasingly) scATC-Seq can all be used on a massive scale and, 
therefore, will be employed as the main profiling methods in the top of the Sky Dive in Phase I 
of the cellular branch of the HCA (Section 2). As the HCA evolves, we will add other 
techniques. For example, if human-cell lineaging is possible at scale (e.g., by massively parallel 
sc(DNA+RNA)-Seq, with targeted DNA sequencing10), it could be an excellent candidate for 
similar deployment. Similarly, scBS-Seq at scale could be used to provide highly informative 
methylation profiles. As additional profiling approaches are introduced, especially at the top of 
the SkyDive, one should take into consideration the distinct information content about cell types 
or states provided by it compared to the information conveyed by other existing profiles. The 
STWG and AWG will partner on such guidelines, along with the Biological Networks.  
By commercializing single-cell sequencing and adapting it to multiple sample types—including 
fixed58 and frozen59 tissues, which are the default options for certain organs (Section 2) — the 
scientific community will gain widespread access to reproducible mRNA analyses, allowing 
independent research teams to generate atlases of each tissue, organ, and system. Those atlases 
will, ultimately, lead to the full HCA. This wide accessibility will allow scRNA-Seq data, as well 
as other single-cell “-omics” data, to serve as a common “information currency” that can be 
readily collected for every tissue under consideration.  
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We envision that, initially, transcriptomic maps could serve as a scaffold for multiplexed 
information. To achieve this, we could couple at lower levels of the Sky Dive (Section 2) 
specialized methods that provide depth but do not yet scale — for example, linking cellular 
transcriptional profiling with epigenetic or genetic measurements. These capabilities already 
exist in low throughput20-22 and may soon extend to more cells through combinatorial indexing or 
microfluidic approaches4. Ultimately, if and when such technologies mature, the HCA effort 
should support the deployment of multiomic assays at the top of the Sky Dive across many cells 
and tissues, while considering the sequencing needs of the entire effort and the distinctive 
information provided about cell type or states that each measurement provides. 
SPATIAL TECHNOLOGIES OF INTACT TISSUES  
A high-definition spatial representation of cell types, cell boundaries, neighbors or interacting 
cells, niches, and tissue contexts is necessary to generate a complete 3-D picture of the cells in 
the human body. We envision this data harnessed to a Common Coordinate Framework that 
other cellular data can be mapped onto. For instance, with the help of computational inference, 
multiplexed imaging of RNA signatures can give spatial placement for scRNA-Seq gene-
expression profiles. Meanwhile, proteinaceous components of tissues (such as the extracellular 
matrix, which makes up nearly half of brain tissue) could be mapped by staining and imaging of 
relevant protein targets. Together, merged 3-D protein and RNA gene-expression profiles would 
provide a common reference for normal and pathological tissue structure. 
Imaging technologies have long provided cellular, subcellular, and structural windows into 
tissues. Recently, several new technologies have been developed to facilitate the direct mapping 
of proteins and/or RNA into tissue slices at a highly multiplexed level. Other technologies for 
high-resolution tissue imaging, such as optical sectioning and aberration correction methods, 
super-resolution imaging, tissue expansion, and associated analyses, are all converging to enable 
near molecular-scale mapping of cellular states in tissues and to determine the key abstract 
relationships within and between tissues. 
Current technologies 
There are two broad classes of technology for highly multiplexed spatial analysis: approaches 
that measure known proteins or nucleic acids in a targeted manner — using antibodies or nucleic 
acid probes, respectively — at the cellular or subcellular level; and approaches that profile RNA 
using sequencing.  
Targeted approaches. Targeted approaches can be further partitioned to mass spectrometry or 
fluorescence-based measurements. In general, mass spectrometry can enable targeted 
multiplexing using from fifty to hundreds of mass labels, depending on the resolution. The 
fluorescence-labeling systems are deployed in a variety of approaches to reach high-throughput, 
spatially resolved detection of proteins (50 to 70 species) and RNAs (hundreds to thousands of 
species).  
Mass spectrometry-based imaging. “Conventional” mass spectrometers have long been used to 
detect metabolites, lipids, proteins, and other cellular material directly from tissues on slides. 
These approaches generally enable an unbiased measurement of all ionizable analytes of a tissue 
region within a defined mass range. However, they are currently limited to high-abundance 
analytes because of the physics of ionization and detection, and quantification of molecules is 
challenging60. 
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To overcome these limitations, two targeted imaging methods based on mass spectrometry61-63 
use cocktails of antibodies attached to metal isotopes of a defined atomic mass as reporters to 
label epitopes on a tissue of interest64. Given the absence of auto-fluorescence, these imaging 
approaches are particularly applicable to formalin-fixed, paraffin-embedded (FFPE) tissue, 
which is a mainstay of pathology sample handling and storage because of its superb maintenance 
of tissue integrity.  
One system, Imaging Mass Cytometry (IMC), uses a high-energy, high-resolution ultraviolet 
laser to systematically ablate a region of tissue, and the resulting tissue particles are analyzed by 
a inductively coupled plasma time-of-flight mass spectrometer, the mass cytometer, or 
CyTOF63,65. It currently allows routine measurement of 52 antibodies simultaneously at a 
resolution of 500 nm to 1,000 nm with comparable sensitivity to fluorescence microscopy (~50 
molecules per pixel63). The Z depth of the image can be controlled via the thickness of the 
analyzed tissue section. A square millimeter of tissue can be analyzed in ~30 minutes, and the 
method has already been applied to 3-D tumor models at single-cell resolution and used to 
simultaneously image transcripts, proteins, and protein modifications. 
The second system, Multiparameter Ion Beam Imaging (MIBI)61, employs secondary ion mass 
spectrometry (SIMS) to result in near-single antibody sensitivity. In this technique, beams of 
ions ranging in width from 50 nm to 4,000 nm ablate the tissue at a Z depth of 1 nm to 250 nm. 
The technique can be performed to establish 3-D maps. Although MIBI uses isotope-labeled 
antibodies as tags, it can also employ lighter elements to simultaneously read carbon, nitrogen, 
oxygen, etc., in the tissue, which is useful for metabolic labeling. The current speed of the 
instrument is 1 minute for a 1-mm square tissue at about 1,000 nm beam width (~500 nm 
resolution). It is also possible to do a rapid (15-second) survey scan at low resolution (2,000 nm) 
and then reimage at high resolution (200 nm to 500 nm).  
Fluorescence-based imaging. Two kinds of fluorescence-based targeted imaging approaches are 
relevant to building the HCA: multiplexed fluorescence in situ hybridization (FISH) for RNA 
imaging and iterative fluorescence imaging of protein epitopes.  
Among RNA imaging approaches, single-molecule fluorescence in situ hybridization (smFISH) 
is the gold-standard method to determine the copy numbers and localizations of RNA molecules 
in individual cells66,67. Various multiplexed versions of this method exist, allowing simultaneous 
imaging of 10 to 1,000 RNA species in individual cells68-72. For example, multiplexed error-
robust FISH (MERFISH) allows imaging and profiling for RNA species at the transcriptome 
scale, with high detection efficiency, by error-robust barcoding, combinatorial labeling, and 
sequential imaging; simultaneous imaging of 1,000 RNA species in single cells has been 
demonstrated with MERFISH69. MERFISH can create cell atlases of sizable tissues and has 
demonstrated the ability to measure several tens of thousands of cells, or several tens of square 
millimeters of brain tissue, in a single-day experiment73,74. A different highly multiplex FISH 
method is seqFISH, which uses color-based barcodes and sequential imaging72. SeqFISH has 
also recently demonstrated the ability to image a few hundred RNA species in single cells in 
brain tissues75. These methods can be combined with other technologies, such as recent advances 
in tissue clearing73,76 or expansion77,78, to improve the detection accuracy and the density of RNA 
that can be probed. 
Serial fluorescence imaging approaches also allow multiplex analysis, especially of proteins79,80. 
CODEX (CO Detection of EXpression) is a recently developed rapid multiplexing method for 
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imaging cytometry, which cheaply and easily allows the imaging of 50 to 100 cellular 
components with nearly any fluorescence microscope. Antibody cocktails are used to stain 
tissues, and DNA tags on the antibodies are revealed iteratively, to successively image 2 to 5 
fluorophores at a time, based on the oligonucleotide sequence conjugated to the antibody. This 
approach has already been used to create initial maps of human immune organs at 400 nm 
resolution—the limit of light, with comparable sensitivity to standard fluorescence. With a 
regular microscope 30 hours are required to image 40 components in a 1-cm2 region of a tissue 
with 12 Z stacks at 400 nm resolution, or 18 minutes for 1 mm2. This is reduced to ~2 minutes 
with a confocal microscope (or for 1 Z plane). 
Untargeted profiling approaches. Strategies that rely on genomic profiling in tissue are 
emerging, either using in situ sequencing or by spatial barcoding. 
In situ sequencing. Transcriptome-scale RNA imaging of single cells has also been achieved 
with fluorescence in situ sequencing methods81,82. In these methods, cellular RNAs are converted 
into cross-linked cDNA amplicons and then sequenced in situ by imaging. This can be done in a 
multiplex, targeted assay81, or without targeting as demonstrated in FISSEQ82. The detection 
efficiency of fluorescence in situ sequencing is currently lower than multiplexed FISH, making 
the quantification of low-abundance RNAs more difficult. However, unlike multiplexed FISH, 
fluorescence in situ sequencing does not require preselection of genes, thus allowing untargeted 
transcriptome measurements in single cells. 
Spatial barcoding methods allow visualization and quantitative analysis of the transcriptome 
with spatial resolution in 2-D tissue sections. In one approach, Spatial Transcriptomics (ST)83, 
histological sections are placed on glass slides with arrayed oligonucleotides containing 
positional barcodes to impart the spatial barcodes prior to RNA-Seq. Although ST does not 
generate single-cell data, it captures tissue transcriptomes comprehensively within each tissue 
voxel, thereby providing a sensitive standard for tissue composition that is complementary to 
tissue dissociation methods. We expect additional methods to emerge in this area. 
Key areas for development and optimization 
Mass spectrometry-based imaging can improve in sensitivity, speed, resolution, and in the 
number of molecular species that can be assayed in multiplex. Sensitivity can improve through 
higher detection of ions to the range that will enable single-molecule detection. Speed should 
improve for both laser and ion beam ablation to reduce the analysis time. The extent of multiplex 
can improve by adapting metal nanoparticles to greatly increase the number of simultaneously 
measurable mass channels, up to 100 or so. Resolution should improve for both methods through 
more sensitive instrumentation and nanoparticle reagents (IMC) and smaller tip size and 
antivibration systems (MIBI). With such improvements, methods like MIBI can be deployed at 
the scale and speed required for the HCA. Additional advances may allow detailed mapping of 
multicomponent structures and RNA in 3-D using ion-tagged oligonucleotide probes instead of 
fluorophore methods.  
Fluorescence-based imaging. Pending improvements to multiplexed FISH methods make it 
conceivable to simultaneously measure several thousand or more RNA species in single cells. In 
addition, measurement throughput — the number of cells measured per day per instrument — 
will likely be increased by orders of magnitude, which would be of particular use to the imaging 
of very large tissue volumes for the HCA. Meanwhile, the detection efficiency of fluorescence in 
situ sequencing methods is also being improved. Notably, measuring more RNA species at high-
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detection efficiency will require the resolution of RNA molecules that are in close proximity to 
each other — in some cases, beyond the diffraction limit. We envision that it will be beneficial to 
combine these RNA profiling methods with super-resolution imaging methods, either by optical 
approaches or by tissue expansion77,78. Finally, highly multiplexed RNA and protein imaging of 
the same samples would provide simultaneous information on these complementary aspects; the 
compatibility between RNA imaging and immunofluorescence-based protein imaging suggests 
that such combination should be feasible.  
Approaches for evaluation and benchmarking 
Several key aspects require evaluation and benchmarking in the context of spatial approaches: 
validation of reagents; comparison to gold-standard methods; comparison between related 
techniques; and relation to analyses on dissociated cells.  
Reagents. Spatial approaches that currently rely on probes require validated reagents. In 
particular, antibody reagents must be validated for their performance in relevant specimens. For 
example, more than 150 antibodies and reagents to determine absolute copy numbers of a given 
epitope have been validated for FFPE, and IMC has generated reference samples for 50 
markers84,85. Such efforts will remain ongoing and should lead to an HCA-wide resource. This is 
also an opportunity to collaborate with the Human Protein Atlas, an effort to measure the spatial 
distribution of the human proteome at a subcellular level (http://www.proteinatlas.org/). 
Benchmarking to gold standards. It is important to validate the quantitative measurements made 
by multiplex or genomic spatial methods relative to well-accepted gold standards, such as 
staining for individual proteins or smFISH. Not every measurement requires validation, but new 
methods, new reagents, and their application in new tissue should be validated. 
Comparison between related techniques. As is the case for single-cell genomics, the HCA 
consortium does not expect to converge on a single method for all spatial analysis, but rather to 
have the same tissues analyzed by multiple methods, with each method having established 
standard operating procedures and protocols. However, this approach relies on careful 
benchmarking of multiple techniques on matching samples — for example, consecutive sections 
of the same specimen. The compared techniques could be of the same class (e.g., multiplex in 
situ hybridization) or of different classes (e.g., MERFISH, FISSEQ, and Spatial 
Transcriptomics). The ability to preserve tissue prior to analysis will facilitate benchmarking as 
technologies evolve through the prospective banking of Rosetta Stone samples; maintaining such 
specimen collections should be an important goal of the consortium. Because these technologies 
are less mature than many sequencing techniques, additional steps will need to be taken to fine 
tune them. 
Comparison to measurements of dissociated cells. Tissue dissociation often introduces biases in 
both cellular composition (as fragile cells are disproportionately lost) and intrinsic cell states 
(through the stress of dissociation and even RNA degradation). Conversely, targeted in situ 
measurements are limited by the set of probes they recover, and spatial genomics to date either 
does not have single-cell resolution or is limited in the number of recovered transcripts. 
Comparing the same specimens between the two strategies will help assess their respective 
strengths and limitations, help optimize each, and inform how the data they generate can be 
integrated between the cellular and spatial branches of the atlas. This effort would be assisted by 
computational integration, in collaboration with the AWG. 
Strategies to disseminate, combine, and deploy techniques in building the HCA  
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Today, most spatial technologies are performed only by a specific lab or a small number of labs, 
chiefly because most require specialized tissue-processing procedures and some require 
specialized equipment. For methods that require complex and expensive instruments, we should 
consider setting up a few instruments in centralized locations for centralized data collection and 
for training HCA community members in their use. For other methods that are considerably 
easier to use and do not require sophisticated equipment, a SWAT team from the labs that 
invented and/or developed the technologies could travel and disseminate them across multiple 
HCA sites to ensure broad adoption. Conducting hands-on workshops could also aid in widening 
use of these methods, as would robust software for data preprocessing. Finally, most of these 
techniques are not deployable at genomic scale yet. Therefore, the developer labs could optimize 
and scale them to make them available as systematic pipelines. 
Well-chosen pilots will help drive this effort. Absent vast increases in resources or technical 
development, the initial focus of the HCA should be a select number of target tissues important 
not only for their biology and clinical relevance but also for representing distinct tissue 
architectures and properties and thus posing diverse technical challenges. Such tissues could 
include kidney, pancreas, colon, liver, immune tissues (spleen, tonsil, lymph nodes), breast, 
prostate, and the brain.  
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4. DATA ANALYSIS 
Computational methods and analysis will form the backbone of the HCA. They will be required 
for design of data collection, for low-level data processing and normalization, for data 
organization and for data interpretation, all of which will require the design of novel algorithms, 
statistical models, and intuitive visualization strategies. Consequently, a wide range of 
innovative, rigorous, and appropriately tested computational methodology will be critical to 
make the HCA a success.  
Computational methods are needed to integrate data generated using a wide variety of (noisy) 
technologies to create a comprehensive reference catalogue of all human cells. This reference 
catalogue will not only define individual cell types and their spatial architecture but also map by 
inference their lineage relations, regulatory circuitry, and the interactions between them. 
Consequently, key tasks for the HCA’s computational pillar will be to generate strategies for 
ascertaining the best existing methods, identify and prioritize problems that lack solutions, and 
develop new methods as appropriate. Additionally, each emerging technology and each 
biological question will likely require distinct computational solutions, from guidance through 
initial quality control, benchmarking, and optimization of new technologies to methods that yield 
new biological insights.  
We distinguish three key layers of computational methods. 
Basic data processing and normalization of the raw output of the different technologies. For 
example, it will be necessary to convert reads generated from single-cell sequencing 
technologies into normalized cell-by-molecules count matrices. In addition, experiments should 
be designed to allow proper modeling of batch effects. When considering data collected using 
multiplex imaging technologies, it will be necessary to establish quality-control metrics and to 
register and segment the raw files.  
Data organization in the atlas. This includes discovery and taxonomy of the different cell types 
and their relationships, including formally addressing the fundamental question “What is a cell 
type?”  The Atlas will be organized using multiple complementary maps and coordinate systems: 
spatial and molecular systems followed by functional, physiological, and lineage-derived maps. 
A key challenge will be to generate these maps and to understand how they relate to one another. 
To do so, we will need to develop methods to link different layers (including data generated 
using very different technologies) and understand common features. This will shed light on the 
relationship between phenotype and function.  
Queries, visualization, and analysis methods for exploiting the atlas. These include both simple 
queries and visualizations and more complex computational analyses. First, simple queries and 
data visualization will be required to make the data accessible to the biological community as 
quickly as possible. This will facilitate identification of markers that can be used to isolate 
selected cell types for further study, as well as allow interrogation of cell type-specific and 
spatially localized patterns of gene expression, similar to a BLAST query for cell phenotypes. 
Finally, there will need to be a suite of sophisticated methods that utilize the Atlas for more 
complex computational analyses. For example, single-cell data allow circuits and regulatory 
networks to be inferred at the cellular and tissue level. Additionally, analysis methods built upon 
approaches honed in Genome Wide Association Studies (GWAS) will reveal how genetic 
variants alter cell-type composition and spatial location. Ultimately, methods that harness the 
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HCA to elucidate mechanisms of disease by projecting cells from new cohorts of disease 
samples onto the reference atlas will also be vital. 
ANALYSIS WORKING GROUP (AWG) 
To achieve these goals, we are building a vibrant community of computational biologists, who 
will interact with one another at regular meetings, to stimulate the development and critical 
evaluation of appropriate methods. To provide structure, the Analysis Working Group (AWG) 
has been convened as a small steering committee by the HCA Organizing Committee (Section 
7). The AWG organizes working groups, data-analysis teams, meetings, jamborees, and 
recommends experimental designs, analysis frameworks, and best practices for different aspects 
and needs of the HCA, from data collection to the Data Coordination Platform (DCP).  
Guidance to the DCP. A key goal of the AWG is to formulate computational challenges and to 
establish “benchmark data sets” and metrics that facilitate comprehensive comparison of a wide 
variety of strategies. The AWG organizes activities to help guide the DCP and the DCP 
Governance Group (DCP GG) and publishes best practices in data processing and analysis. In 
some cases, such as quality control and basic data processing (e.g., from sequencing reads to a 
gene count matrix or from raw image to cell segmented), the AWG will decide on a single best 
protocol to be implemented in the analysis pipelines of the DCP, while in others, such as 
trajectory detection and network analysis, the AWG will foster a wide range of methods that are 
designed for different goals.  
Guidance to and participation in biological networks. An important role of the AWG is to 
provide advice and guidelines for experimental design. This will ensure cost-effective and 
consistent collection of data that can be both integrated into the atlas and used to address key 
biological questions. To make this process as seamless as possible, we envision that a 
computational biologist who is part of the data-analysis team be part of the relevant working 
group for each organ or technology. This representative will disseminate the relevant 
computational methods to the group and liaise with those who best understand the specific 
biological challenges and questions faced by each community. Then, they will bring these 
questions back to the working group and help to define the computational methods that need to 
be developed. Finally, the representative will participate in the planning of data collection, thus 
ensuring that the experimental design is well suited for computational analysis and statistically 
powered to address the project goals.  
Building, engaging, and training the HCA computational community. To facilitate the 
participation of a large group of computational scientists and establish a vibrant analysis 
community, the AWG will hold regular scientific meetings, which will allow members of the 
community to present updates on new methods through talks or scientific posters and to 
formulate and pose new computational challenges in breakout sessions and informal discussions. 
Analysis jamborees are focused on a specific question (e.g., the best method for removing 
doublets from scRNA-Seq data), with the goal of collectively reaching a conclusion by the end 
of the meeting. Best practices — and transparent reporting on how these were derived — will not 
only be disseminated to the entire HCA community but also made public and readily available to 
the global scientific community. Gold-standard open-source data sets and code will be provided 
as well. Jamborees also serve to train young scientists and foster a collaborative community 
across labs.  
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The first AWG jamboree was held in August 2017 at the European Bioinformatics Institute 
(EMBL-EBI) in the U.K., and involved 48 young scientists from 19 computational biology labs, 
who worked together intensively in multi-lab teams to solve open challenges facing the HCA. 
These challenges, along with problem definitions, unique benchmark data sets, and necessary 
infrastructure, were prepared by 10 lead PIs, nine of whom attended the event. Three additional 
software engineers provided computational support for the event. Enabled by the collaborative 
nature of the event, participants tackled six problems:  
 identifying ambient RNA and cell events 
 removing cell doublets in scRNA-Seq data 
 identifying dead and damaged cells 
 normalization (and batch effect correction) between samples 
 comparing clustering strategies; and  
 defining experimental design strategies.  
Substantial progress has been made on most tasks, whereas some (normalization and clustering 
comparisons) were more challenging and will be further addressed in future jamborees. These 
advances will likely result in publications. The postdocs and graduate students found the 
jamboree valuable to their training and reported a high degree of satisfaction with the event in a 
post-jamboree survey. Additionally, the jamboree helped foster further interactions among labs. 
Future jamborees will tackle both other algorithmic tasks and “live data analysis,” focused on a 
specific organ or biological question.  
SELECT KEY CHALLENGES 
The computational challenges faced by the HCA are numerous, rapidly evolving, and encompass 
a diverse range of areas. We outline a few immediate challenges, but note that there are many 
other areas where methods development will be vital. Through the lifespan of the project, new 
challenges will continue to emerge as new technologies and biological questions arise. The 
AWG will help convene and guide the community to identify and articulate these challenges, 
formulate the problems into a more mathematical framework, define benchmark datasets and 
engage the wider computational community to address them.  
Processing and normalization of scRNA-Seq. Data collected from massively parallel scRNA-
Seq are rapidly accumulating. However, like most experimental techniques, these powerful and 
cost-effective recent technologies also include noise, batch effects, and other biases. It is critical 
to help select the best experimental approaches and best processing pipelines to increase signal 
and reduce noise in the resulting data so that the wider community can best exploit it.  
A key challenge to address in this context is to establish a “best-practices computational 
pipeline” that can support initial processing, quality assessment, standards, and normalization for 
the technologies selected for the HCA, as well as provide rigorous quality metrics to guide the 
selection of these technologies. The pipeline will need to include quality control, removal of 
erroneous and low-quality reads, and the removal of barcodes that represent debris, dead cells, 
doublets, and ambient RNA. Establishing the most appropriate strategy will require rigorous 
metrics and computational comparisons, exploiting both real and simulated data. Of critical 
importance will be the creation of benchmark data sets that can form the basis of comparison. 
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The primary output of this pipeline will be a matrix of cell-by-gene expression values that can be 
leveraged for downstream analyses. We envisage the existence of one cell-by-gene (or transcript) 
count matrix that represents actual observed transcripts, corrected for any errors in the raw data. 
Following this step, different data- normalization procedures will serve subsequent downstream 
analysis tasks. Normalization will be a major challenge when integrating data collected across 
different tissues, technologies, and labs or centers. To support data-driven experimental design, 
power analysis methods should be developed and incorporated for assessing coverage and 
completeness of cell states and/or types that have been sampled.  
Defining a cell type and organization of the atlas. A primary goal in creating the HCA is to 
define cell types and to characterize their biological roles. A data-driven approach to this 
challenge takes single-cell measurements and provides a grouping of cells into distinct 
subpopulations (i.e., clusters). Specifically, each cell is represented as a point in high-
dimensional space (molecular phenotype), where clustering is tantamount to finding dense 
regions of similar cells in this space. Numerous computational methods exist for this task, but 
their relative merits have not been fully assessed. As spatial data accumulate, methods should be 
developed that integrate spatial and molecular data toward more accurate cataloging of cell 
types.   
Cell type definition. Before an optimal clustering algorithm can be selected, the notion of a cell 
type must be formally defined. Currently, a cell type implies significant phenotypic and 
functional stability over time, achieved perhaps through epigenetic regulation. While a cell type 
suggests a discrete entity, recent data sets are highlighting that many presumed cell types 
actually form part of a continuum. For example, a T cell can exist in different states (mitotic, 
activated) while maintaining its identity as a T cell, and T cell activation is considered as a 
continuum, rather than as two discrete modes. Stable cell types encompass many states and, 
therefore, exist in a diverse but restricted set of the high-dimensional phenotype space. 
Epigenetic data modalities such as ATAC-Seq will help distinguish cell types from cell states 
(Section 2 and Section 3). 
Similarity metrics. A key computational challenge when identifying cell types is determining 
appropriate similarity metrics between cells. When are two cells “the same”?  How do you 
determine a similarity metric that best serves biological questions, such as similarity in function 
or lineage? Feature selection will play an important role in any similarity metric and will likely 
depend on the envisioned tool, such as clustering, a BLAST-like query and search tool for cells, 
or comparing healthy tissues to diseased tissues. Benchmark data sets that include morphology 
and spatial context from imaging data from the spatial branch will be pivotal in guiding the 
development of good similarity metrics based on molecular profiles from the cellular branch.  
Taxonomies. Consequently, clustering algorithms need to find salient features of more stable cell 
types and distinguish cell-type variations from those associated with physiological states (such as 
cell cycle), as well as to model continuous trajectories where these exist. Thus, new 
computational methods will be required both to discover types and to better classify cells. As 
these develop, they will ultimately refine the very concepts of cell type and state. Additionally, 
understanding the relationship between cell types and establishing new cell-type taxonomies will 
be critical. To achieve this, the AWG will coordinate with HCA subgroups to establish a series 
of benchmark data sets that can be used to determine effective similarity metrics and assess the 
performance of different methods.  
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Curation. Although these tools are useful in refining our understanding of cell types, a 
computational definition alone does not automatically convey biological meaning. However, 
given the vast amount of data that will be generated for the HCA, manual curation of cell-type 
identity may become extremely challenging. To this end, the AWG will work with relevant HCA 
subgroups to generate an automated way of assigning putative biological identity to groups of 
cells, first by using literature text mining approaches based on the genes expressed in each cell 
type, and later based on new technologies for functional interrogation of cells. This will facilitate 
comparison of cell types across tissues and enable assembly of a meaningful taxonomy of cell 
types. 
Spatial dimension: Imaging tissues and modeling spatial architecture. Multiplex spatial 
technologies, such as MIBI and MERFISH (Section 3), are advancing at a rapid pace, enabling 
spatial mapping of fine-grained cell-population structure at unprecedented resolution. With new 
technologies, however, come new computational challenges, both at the level of preprocessing 
(e.g., faithfully calling detection of a specific protein or RNA at a specific location, based on the 
raw signal specific to each technology), image processing (e.g., cell segmentation), alignment of 
images on a Common Coordinate Framework (CCF), and analysis (e.g., identifying cell-cell 
interactions and other meaningful expression patterns in tissue architecture).   
Several challenges must be tackled, including selecting the optimal set of spatial technologies 
that will contribute to the atlas; developing preprocessing pipelines for each; defining a CCF on 
which each image can be aligned and meaningful comparisons across samples from different 
individuals can be made; segmenting cells within each image; determining for each cell its 
appropriate cell type based on observed marker expression; and imputing unobserved genes and 
proteins based on integration with genome-wide data sets, especially from the cellular branch.  
Methods must be developed to select the most informative markers (genes or proteins) that can 
best resolve cell types and their architecture and derive a reliable mapping when combining the 
spatial branch with the cellular branch (e.g., scRNA-Seq, snRNA-Seq and scATAC-Seq). This 
integration would allow the genome-wide exploration of spatial architecture of molecules in their 
histological context, refine the characterization of cell identity by context or neighborhood, and 
help characterize interactions within and between cell types. Moreover, with a map of cells, their 
expressed molecules, and spatial boundaries, network-learning approaches can be developed to 
detect signaling networks within and across cell boundaries. 
Because of the enormity of this challenge and the relative lack of existing methods for spatial 
analysis, the AWG will work to accelerate the development of the necessary formalisms and 
data-analysis algorithms through publication of benchmark data sets, collaborative workshops, 
jamborees, and other forms of community engagement.  
Temporal dimension: cell-state transitions, pseudo-time, and lineage tracing. In addition to a 
spatial map, the atlas should describe how cell types are derived developmentally and outline 
possible transitions between cell types. We aspire to obtain for humans what John Sulston and 
colleagues developed for C. elegans — a complete and detailed map of all cell types in the body 
and the developmental relationships between them. This includes both cell-lineage relations 
(how extant cells are related through cell divisions) and cell-fate maps (describing the types of 
cells from which an extant cell is derived and its potential to yield other types). 
Single-cell data has highlighted the continuous nature of cellular phenotypes. Consequently, 
there has been a proliferation of algorithms that attempt to order cells collected in a single 
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snapshot in so-called pseudo-time. However, these methods are still in their infancy, and 
substantial work remains to improve these approaches and understand when they correctly 
represent temporal dynamics. Success would enable the mapping of developmental processes at 
high resolution, thereby helping to infer the molecular logic underlying cellular decision-making.  
Each cell phenotype has some probability of transitioning to another state. Because trajectories 
should provide dynamic information to elucidate cell fate decision-making, we need to work 
within a probabilistic framework, with the goal of inferring probabilities and possible paths of 
transition and intermediate states among all cell types. To assess the performance of these 
inference algorithms, it is important to develop benchmark data sets that enable the comparison 
and evaluation of different computational approaches.   
One strategy for generating such benchmark data sets is to use emerging genome editing 
approaches for large-scale lineage tracing (e.g., MEMOIR86 or GESTALT87) in either organoids 
or mammalian model organisms (e.g., mouse).  Because of the current limitations of these 
techniques, new algorithms are required to correctly interpret the output. In humans, we could 
also use endogenous lineage information, such as somatic mutations in DNA, SNVs, and 
methylation epialleles for lineage tracing, although these may be challenging when mutation 
rates are very high. Combining lineage-tracing (in organoids, model organisms, or 
endogenously), together with validated pseudo-time trajectory algorithms in primary human 
tissue, would ultimately derive a temporal cell lineage and cell-fate map for humans.  
Making the HCA accessible: portals for visualization and queries. The atlas is only as good as 
it is generally usable by a broad group of biomedical researchers. Therefore, it is essential to 
design early portals for querying and visualizing the data that are intuitive for the 
noncomputational user and update them frequently. Queries and search tools must be developed 
for cell types and tissue architectures, analogous to the way in which BLAST enabled queries of 
databases to find similar sequences. In addition to highlighting similarities, methods are needed 
that highlight differences (between cells from different healthy individuals and between cells 
from healthy and disease individuals). Because of the high dimensionality and complexity of the 
data, it is important to choose dimensionality-reduction and feature-selection techniques that 
capture the most salient aspects of the data. These techniques are likely to differ between 
biological domains and questions. Finally, since visualization is key, new methods must be 
developed to interactively explore the many layers and dimensions of the atlas in a way that 
facilitates interpretation and biomedical discovery. 
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5. DATA COORDINATION PLATFORM (DCP) 
The Human Cell Atlas will contain petabytes of data on billions of cells and tissue sections 
across multiple modalities used by hundreds of labs around the world. A project of this scale and 
complexity demands an open, modular, and extensible approach to coordinating, standardizing, 
and sharing data.  
A suitable data coordination platform will need to 
 provide as many researchers as possible with simple, open, and immediate access to all of 
the data and some standardized, derived results;  
 be built out of modular, open-source components that interact via standards and 
protocols, rather than monolithic systems, allowing different components to evolve 
independently and to be reused by other projects; and  
 be extensible to integrate and support a diversity of analyses, visualizations, and other 
components developed by the scientific community.  
Together, these three properties will maximize the opportunity for downstream innovation in 
how the data is analyzed and used.  
Over the past year, a team of engineers has worked to formulate an architecture for HCA that 
aims to satisfy these three properties and could support the scientific objectives of the project.  
Software engineers and computational biologists, working at several research institutes, 
including the European Bioinformatics Institute (EMBL-EBI), the Broad Institute, the University 
of California Santa Cruz (UCSC), and the Chan Zuckerberg Initiative, have now started to 
implement it. (We stress that this is just one potential solution that satisfies the principles 
described above.) The following summary of this plan is derived from a more detailed document 
(Appendix II).  
Figure 6. The Data Coordination Platform. A proposed open-source Data Coordination Platform, 
including (1) a data ingestion service (purple), (2) a synchronized data store replicated across multiple 
clouds (blue), (3) a collection of secondary analysis pipelines for basic data processing (green), and (4) 
a collection of tertiary portals for analyses, visualizations, and forms of data access (red). 
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The proposed architecture has four key components, each acting as a well-defined module 
interacting with the other modules through APIs (Figure 6). We refer to the four components as 
(1) the ingestion service, (2) the synchronized data store, (3) the secondary analysis pipelines, 
and (4) the tertiary portals. The proposed sequence of data flow through the system begins with 
ingestion of raw data and metadata by a broker into the ingestion service, followed by primary 
quality assurance, including basic file integrity and metadata syntax and schemas. Data and 
metadata are then deposited into the data store and replicated across multiple clouds. Data are 
processed via the secondary analysis pipelines to generate intermediate derived results and 
quality-control scores, which are then submitted back into the ingestion service and deposited 
into the data store. Basic access to both raw data and derived results are provided by the data 
store consumer API, on top of which a diversity of tertiary portals can be built. 
Consistent with the values of the HCA, the platform will be open-source and the data will be 
open-access, with the ability for any third party to provide tertiary portals through APIs and to 
readily clone the software and data platforms for use.  
Here are details about the four components.  
Ingestion service. The primary role of the ingestion service is to form a single point of entry for 
all HCA data, including both raw assay data and metadata for projects, experiments, and samples 
(e.g., sequencing reads, microscopy images), as well as standardized analyses and quality-control 
metrics, which result from running vetted analysis pipelines, and appropriate provenance 
describing those analyses. The ingestion service will both ingest data and perform basic quality-
assurance checks, including file integrity, metadata syntax and schemas, and consistency with 
ontologies and controlled languages. Metadata and user interaction will be developed, vetted, 
and agreed upon by the HCA community, with guidance from the HCA MDWG, as represented 
by a governance structure from the DCP GG under the HCA Organizing Committee (Section 7). 
Researchers will submit data through one of several “data brokers” that act as links between labs 
and a single ingestion service API. Brokers could include user-facing Websites or other Web or 
programmatic services and may target geographical regions or provide domain-specific data 
handling.  
Synchronous data store. After ingestion and quality assurance, data will be deposited into the 
synchronized data store. This multisite, replicated storage system will contain all raw data, 
metadata, and derived results from agreed-upon standardized analyses, materialized and stored as 
flat files. It will ensure simple and direct data access for downstream consumers and allow both 
download of all the data and computing on the data directly in the cloud. Replicating the data 
across multiple cloud-storage solutions allows researchers to use different cloud platforms to 
analyze the data. It will be wrapped as a producer API (to put data into the store) and a consumer 
API (to consume data from the store). It will include protocols for synchronizing data across 
providers and a system for notifying users of content changes. 
Secondary analysis pipelines. Although researchers will have access to all raw data in multiple 
cloud platforms, the majority of researchers will want to work with intermediate derived results 
that require at least some initial preprocessing, such as alignment and de-multiplexing of 
sequencing data to generate a gene-cell table; or spot detection, cell segmentation, and barcode 
decoding of imaging data to generate a spatial map of gene expression. The platform will include 
a secondary service that can automatically execute high-throughput analysis pipelines, using 
best-in-class algorithms for each data type, as developed, vetted, and agreed upon by the 
computational community, with guidance from the AWG, as represented by a governance 
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structure from the DCP GG under the Organizing Committee (Section 7). It is critical that these 
analysis workflows are portable and reproducible, built out of open-source components, and 
publicly available so that the execution service can automatically run them across multiple cloud 
environments while researchers can also run the same analyses locally on their own data. The 
notification systems provided by the data store will allow the execution service to automatically 
rerun as new data arrive. The results of the secondary analyses, including derived analysis 
outputs and quality scores, are ingested and deposited back into the data store so consumers can 
access them alongside the raw data and metadata. This portion of the system in particular will 
depend on algorithms contributed by the computational community and rely on HCA governance 
to ensure that all selected algorithms satisfy best practices and standards. 
Tertiary portals. To ensure good separation of concerns, the data store will provide only simple 
forms of data access through its consumer API. But the biological and computational 
communities will surely require a wide and ever-growing variety of forms of access, including 
rich indexing, slicing, and searching based on metadata, a diverse set of algorithms and methods 
for analysis, interactive data analysis and visualization, and ways to query a new sample against 
the complete data set. These will be provided through a collection of tertiary portals, each of 
which provides different functionality, analyses, and visualizations. To make sure creativity and 
innovation are fostered and encourage as diverse a collection of methods and portals as possible, 
the tertiary portals will not be generally assigned a governance committee, although HCA, 
through its governance structure, may choose to “bless” a particular tertiary portal for its official 
data release or for the community of a specific sub-atlas. Results from the portal community are 
expected to be less standardized because they will address differing community needs and 
approaches, so they will not be deposited back to the DCP. They will, however, be accessible 
directly from portals. The concept of portals also permits a wide variety of services, ranging 
from simple (a set of links to download slices of the data) to complex (an interactive visual Web-
based browsing experience).  
Together, these four components form a complete functioning data coordination platform. At the 
same time, they are sufficiently independent to allow parallel development and to allow each 
component on its own, or in combination, to be reused in other projects.  
Governance. The Organizing Committee governs the Data Coordination Platform (DCP), 
including making all policy decisions concerning the DCP, approving the overall plan for the 
DCP, and ensuring the plan’s successful execution by the major developers of the DCP. The OC 
will establish and appoint a DCP Governance Group (DCPGG), which will report to the OC, 
to oversee the implementation of these policies, by providing guidance and making decisions 
concerning certain key topics, including definition of data manifest; official analysis pipelines; 
required metadata to reflect data collection standards; common coordinates framework; and any 
formal “release portal.” The DCPGG will be led by two OC members; will include at least one 
member from each of the AWG, MDWG and CCFWG; and will include at least three additional 
experts from the community. 
The OC will convene, on a quarterly basis, a DCP Coordination Meeting (involving the DCPGG, 
the major developers of the DCP, and others, as appropriate) to review progress and assist the 
OC in developing policy. 
This is part of the governance for the HCA, as stated in Section 7 and available in Appendix I.  
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6. BIOLOGICAL SYSTEMS 
The HCA will be composed of atlases of individual biological tissues, systems, and organs, 
constructed by teams that include experts in each tissue or system.  
The human body comprises the following systems (Table 1): central nervous, peripheral 
nervous, lymphoreticular, immune, urinary, respiratory, reproductive (male and female), 
hepatopancreatico-biliary, gastrointestinal, endocrine, skin, musculoskeletal, cardiovascular, and 
breast.  
Sub-atlases. We will pursue individual tissues, organs and systems as sub-atlases, following the 
prioritized ranking in Table 1. In each sub-atlas, to ensure rapid early progress toward the first 
draft, we will first initiate Pilot Networks, each representing one tissue or system of interest. 
The networks aim to demonstrate the feasibility of profiling human tissues, while also generating 
useful data to explore the biology of those tissues. They will test and help to optimize all aspects 
of the HCA pipeline, from tissue acquisition through data processing and interpretation, and will 
grow into HCA Flagship Projects.  
There is an overlap between sub-atlases, because of the natural intersection between systems, 
tissues, and organs. For example, immune cells in the skin will be profiled in both the Immune 
Cell Atlas and the Skin Cell Atlas. 
This is a remarkable opportunity for 
data validation and replication and will 
strengthen the overall quality and 
utility of the atlas.  
The efforts will also inform each other 
technically: For instance, when 
multiple tissues can be taken from the 
same donor, the sub-atlases ideally 
will coordinate to ensure that the 
tissues are processed with the same 
technology in the same place. This will 
address inter-individual and technical 
batch effects and provide a framework 
to integrate across atlases.  
While each sub-atlas focuses on a 
different tissue or system, they all 
share key principles:  
 Adherence to general HCA 
principles and to the overall 
scheme for the draft atlas (Figure 
3; Section 2). 
 Sharing of experimental protocols 
for tissue procurement and 
processing for the sub-atlas. 
 Collaborative, multicenter analysis 
Table 1. Organs of the Human Cell Atlas.  
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of all data collected in a sub-atlas.  
 Engagement of computational biologists in all stages, from inception and design to analysis 
Nevertheless, each sub-atlas may require modification of the overall shared scheme, with 
specific choices of parameters for age, gender, diversity, sites of collection, or tissue sampling 
from large organs as appropriate for its biological context. For example, in one setting a smaller 
number of individuals is analyzed across a large number of regions in one organ, whereas 
another system requires more individuals, each studied at lesser depth.  
Below, we provide more detail on several representative biological areas and their efforts. 
Additional biological networks are working to provide similar synopses for their organs, 
systems, and tissues in the living White Paper.  
NERVOUS SYSTEM 
The brain is the most structurally complex organ in the body. In particular, the human brain is 
distinguished by its expanded neocortex88,89, prolonged developmental plasticity90, and the 
unusually complex mental functions it serves. We still have much to learn about the brain’s 
fundamental structure and function, but we are hampered by its size and complexity. Despite 
this, a comprehensive understanding of the cellular composition of the brain is within reach. The 
recent advent of transformative technology and analytical methods will make this possible — but 
we will be significantly challenged by the brain’s unparalleled diversity of cell types, spread over 
hundreds of discrete anatomical regions.  
Why a nervous system atlas? 
Understanding how the brain works requires knowing its parts, and surprisingly little cellular-
resolution information is available for the human brain. There is, therefore, enormous potential to 
dramatically accelerate basic and translational research through an atlas that systematically 
characterizes, classifies, and models neuronal and non-neuronal brain cell types and makes these 
data and tools available as catalytic open-access community resources. These cell types could 
then be mapped onto a 3-D Common Coordinates Framework (Section 2) of each brain region, 
creating a standardized nomenclature for neuroscience and building a bridge to functional 
imaging studies.  
Prior efforts to create human and model organism whole-brain transcriptional atlases using 
microdissected brain regions91-93 provide a good template for experimental strategies. For 
example, the Allen Human Brain Atlas (AHBA) profiled six neurotypical adult human brains 
using DNA microarray analysis of macro- to laser-microdissected regions spanning the entire 
brain and mapping the sample locations to MNI coordinate space91. More recently, the BRAIN 
Initiative Cell Census Network (BICCN) pilot has shown the promise of single-cell profiling for 
neural-cell classification94. Indeed, existing initiatives, such as the BICCN, are committed to a 
cell atlas of the mouse and human brain, and key members of the initiative are participants in the 
HCA. 
What are key considerations for a nervous system atlas?  
An ultimate atlas of the brain should include diverse molecular profiles (transcriptomic, 
epigenetic, and proteomic), anatomical properties (morphology, cell ultrastructure), connectivity 
(local, long-range), and functional properties (electrophysiology).  
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Several key design principles are essential for the success of the atlas and need to be carefully 
established in the pilot phase. 
Anatomical sampling. Because the brain is divided into functionally distinct regions, each with 
its own unique cellular variations, fine spatial dissections are essential to capture cellular 
diversity. Thus, it will be critical to agree on a sampling strategy that will both reflect previously 
determined distinctions and be able to uncover novel ones. Within each brain region, we will 
rank regions by the extent of cellular diversity and selectively enrich rare cell types. We will 
combine uniform sampling, with existing knowledge on cell type proportions to guide a 
sampling strategy that optimizes the cost/benefit ratio for each region, and rely on stratified 
analysis to isolate specific cell types routinely and robustly. This would enable an iterative 
approach of broad, shallow sampling followed by enrichment of under-sampled subsets based on 
computationally identified markers to determine when the majority of cell types have been 
sampled (Figure 7). 
Analysis of nuclei and cells. The cellular branch will aim to deliver a molecular classification of 
brain cell types, ideally in the form of a hierarchical taxonomy of cell types that mirrors 
biological principles such as developmental origin. To generate this atlas, some specimens will 
require distinct preparations. Adult brain tissue cannot typically be dissociated to single cells, 
requiring analysis of single nuclei. In the adult, spinal cord and peripheral nervous system 
require unique handling. Conversely, in prenatal 
specimens, live cells can be dissociated, offering an 
opportunity to use the same samples for both single-cell 
and single-nucleus analysis, as a Rosetta Stone for 
comparison. 
Spatial analysis. The second key deliverable is a spatial 
census of molecular cell types based on their 
morphology and relative and absolute position. This will 
rely primarily on highly multiplexed analysis of RNA in 
situ, for example with single-molecule fluorescent in 
situ hybridization (smFISH). Applied systematically to 
tissue sections, this approach will quantitatively map 
spatial distributions, proportions, and organizational 
features such as topography. To determine the 
signatures for in situ analysis, we will rely on markers 
reflecting both prior knowledge, the cellular branch, and 
possibly random composite approaches16 (Section 2). 
Sample and cell type mapping to a Common 
Coordinate Framework (CCF). To make the brain atlas 
as useful as possible, source tissue samples from many 
laboratories should be mapped to a CCF. Such a 
framework enables data integration and the discovery of 
associations between brain regions, cell types, and cell 
function. Existing efforts along these lines, such as the 
whole brain Allen Human Reference Atlas95 and Big 
Brain Atlas96, provide a 2-D (and coarse 3-D) CCF with 
a comprehensive hierarchical structure-level ontology. 
Figure 7. The human brain. The brain 
likely consists of more than a thousand 
distinct cell types, including a large 
variety of neurons, glia (astrocytes, 
oligodendrocytes, ependymal cells), 
vascular (endothelial, pericytes) and 
immune cells. These are arranged in an 
intricate three-dimensional organization 
that is essential for brain function. Brain 
regions vary enormously in cellular 
composition and organization across 
spatial domains, thus requiring sampling 
from a large number of defined regions. 
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Alternative approaches could learn some of this mapping from collected spatial data and images. 
In principle these structure-level atlases can be extended to the level of substructural cellular 
spatial positions and cell type nomenclatures, although a great deal of work remains to be done 
in this area. By integrating molecular cell type classifications with spatial mapping data in a 
CCF, we can also exploit computational approaches to assign cell types to detailed anatomical 
structures (e.g., relative to vessels, surfaces, ventricles), and to discover cell type communities 
that are organized in local niches (e.g., stem cell niches in the subventricular zone).  
Ideally, the human atlas would be generated in parallel with similar mouse and non-human 
primate atlases, both to understand what is unique about the human brain and to understand 
which features are well modeled in genetically and experimentally tractable model organisms. 
Draft Atlas v1.0 
The principal goal of the first draft atlas should be to capture as much of the cellular diversity 
within and between brain, spinal cord, and peripheral nervous system compartments as possible. 
Because the brain is divided into functionally distinct regions of cells, each with its own unique 
variations, and because brain regions have shown a high degree of stereotypy across individuals, 
we propose that the draft atlas focus on a very small number (2 to 6) of high-quality 
individual specimens, where we analyze about 100 pre-defined regions of interest covering the 
brain, spinal cord, and peripheral nervous system. Future efforts can explore systematic variation 
by gender, ethnicity, and other variables. These high-quality brain specimens should be obtained 
through rapid autopsies from neurotypical individuals, with consent from next-of-kin through 
medical examiners or brain-banking operations. Because gene expression also varies 
significantly as a function of developmental age, we propose to focus on the stable adult period 
(18 to 65 years), but to include pilot projects focusing on brain development.  
Each specimen will be analyzed in three ways: for the cellular branch by single cell/nucleus 
RNA-Seq at scale across a set of predefined brain regions; for the spatial branch by generating a 
spatial census of types in those regions using smFISH or similar multiplex profiling methods for 
RNA (and protein if possible); and integrating them by mapping specimen locations to a 2-D, 3-
D, and ontological CCF, following approaches developed with the CCFWG. 
IMMUNE SYSTEM 
The immune system consists of several cell lineages with distinct and synergistic functions that 
aim to eliminate environmental threats and damaged cells. Many immune cells circulate in the 
blood, awaiting injury signals that prompt them to home to the site of damage and eradicate 
potential threats. Other immune cells reside in healthy organs to survey for injuries, while also 
contributing to maintaining organ homeostasis (Figure 8). Immune cells thus form a complex 
network of cells — with distinct origin, life cycle, and function — which is only fully revealed in 
response to challenges. 
Why an immune cell atlas? 
Immunologists have worked for decades to discover, classify, and study the cells of the immune 
system and their specific functions. They have created a taxonomy of cell types based on 
molecular markers, cellular functions, developmental origins, and differentiation potential. 
However, because the human immune system is highly complex — consisting of dozens of cell 
subtypes whose activation states are highly dependent on tissue location, environmental triggers, 
and individual genetics — it has not been feasible to measure these states with existing methods. 
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And since most immune cell types take 
part in the cascade of events that define an 
immune response, there is a great need for 
methods that more comprehensively 
monitor immune cell types over time. 
Finally, there is a paucity of information 
about how immune cells function 
differently across the many tissues and 
organs of the human body. 
Pioneering efforts by the Immunological 
Genome Project (ImmGen, 
https://www.immgen.org/) generated 
extensive and widely used gene expression 
profiles of mouse immune cells from 
diverse tissues at baseline and in response 
to challenges97. However, to date, such a 
coordinated and concentered effort has not 
been carried out for the human immune 
system. The Immune Cell Atlas (ICA) is a 
community-wide effort that aims to 
identify the molecular and phenotypic 
signatures and the spatial organization of 
all immune cell types that populate human 
lymphoid and non-lymphoid tissues at 
baseline or after many different 
challenges. The ICA will generate the 
largest unified, standardized database of 
the human immune cell network and make it available to the community through public data 
portals. Combined data on this scale should help shape the future of immunology and 
immunopathology knowledge and foster the development of novel immunotherapies for the 
treatment of human diseases including infections, autoimmunity, asthma, allergy, and cancer.  
What are key considerations for an immune cell atlas?  
The ICA will reveal the distribution and composition of the immune cellular network that resides 
in the different organs of the human body. It should illuminate the molecular wiring and the 
specific phenotype of each immune cell type, the spatial distribution and interactions between 
distinct immune cell types and with other cell types (e.g., epithelial cells, endothelial cells, 
fibroblasts) of each tissue compartment. Because immune cell function is revealed mainly in 
response to tissue threats, the atlas must also include immune cell populations and immune cell 
states that accumulate in injured tissues.  
Key principles for an optimal ICA include:  
Diversity of immune cell types. A comprehensive ICA will lead to an unprecedented global view 
of the immune cell populations that reside in human tissues, as was recently shown in the 
blood98.  
Figure 8. An Immune Cell Atlas. An Immune Cell Atlas 
will profile immune cells from primary and secondary 
lymphoid organs, and peripheral non-lymphoid tissues and 
organs, allowing for identification and characterization of 
all immune cells in any tissue. Example representative 
tissues are shown for illustrative purposes. Permission to 
re-use granted for skin (© Kellie Holoski); liver (© Joanna 
Culley); muscle cells (© John Wiley & Sons, Inc.); and 
bone marrow (HealthTap). 
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Local impact of tissues on immune cell functions. Immune cells of the same lineage often serve 
different functions depending on the tissue environment in which they reside99. To discover the 
range of immune cell functions, we must profile immune cells from different tissue sites.   
Patient-to-patient variation. Infectious and immune diseases vary with geography and 
population. Therefore, to gain snapshots into the immune profiles of patients at frontline 
infectious-disease outbreaks, we will sample patients across gender, age, ethnicity, and 
geography — and this information will be anonymously linked to the profiling data according to 
HIPAA standards. Phase I will encompass some human diversity, though not at the full scale 
expected for the complete HCA. 
Spectra of cell activation states in challenged conditions. In contrast to most cell types, immune 
cell fates, functions, and frequencies are determined dynamically in response to challenges such 
as pathogenic infection. An individual macrophage may serve a role in tissue repair or 
homeostasis in the steady state, but become an inflammatory, aggressive, antibacterial immune 
defender under challenge99. Thus, in addition to healthy tissue, we will profile immune cells 
from tissues in various states of challenges and disease, including cancers and infections, 
although individual diseases will not be the primary focus of the atlas.  
Transcriptional and protein profiles in cells and space. With these considerations in mind, we 
will profile all immune cell populations in blood and tissues (e.g., lung, skin, gut, lymph nodes, 
kidney, spleen, fat, muscle) from healthy individuals and from disease states. We will harvest 
tissues, dissociate cells from tissues, and establish the transcriptional program of dissociated, 
tissue-resident immune cells via scRNA-Seq and bulk profiling, as shown recently98,100-103. We 
will extend this work by validating transcriptionally defined cell markers at the protein level, 
using flow/mass cytometry, and by establishing the spatial distribution of cells in tissues, using 
both RNA- and protein-based in situ profiling methods.  
The pilot stage will be dedicated to optimizing standard operating procedures for tissue 
collection, tissue digestion, cell encapsulation, shipping, sequencing, and analysis among 
different collection sites. To gain information about spatial organization, we will also perform 
high-dimensional imaging in tissues61,104. We will start with pilot analyses of barrier tissues and 
lymphoid organs (as they are the most enriched in immune cells) from healthy research 
participants. Following the steps of ImmGen, we will develop strict quality-control guidelines to 
standardize sample quality and normalize analysis of tissue to minimize batch-dependent 
variation. 
Draft Atlas v1.0 
The first draft atlas aims to capture the cellular make-up of the immune system by profiling all 
immune cells that reside in most tissues of the human body (Figure 8) under baseline or 
challenged conditions. Each tissue will be analyzed by single-cell and tissue profiling to capture 
the transcriptional and phenotypic programs of each immune cell type, as well as their spatial 
distribution in the different tissue sties. 
In the first draft atlas, we will profile “healthy” tissue specimens from 20 research participants 
and sample each tissue in at least three geographically distinct sites. Tissue will be collected 
from 20- to 55-year-old men and women from different ethnic backgrounds. In addition, we will 
collect “challenged” or “disease” specimens (such as cancer and inflammatory lesions) from ~20 
research participants for each “challenged tissue.” Each specimen will be analyzed by the HCA 
Sky Dive approach (Section 2; Figure 3), at first for scRNA-Seq. The transcriptional signatures 
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will be used to develop protein markers that define immune cell populations and enable 
prospective cell isolation by FACS, for deeper RNA profiling and other molecular profiling (e.g., 
ATAC-Seq), as well as for in situ spatial characterization (at RNA and protein level). 
URINARY: KIDNEY 
The beauty — and difficulty — of the human kidney lies in its complex structure and the diverse 
interactions among its cells during homeostasis and in pathological states105. Progressive chronic 
kidney diseases affect more than 500 million people worldwide, and yet therapies to halt or 
prevent these diseases remain scarce. Most individuals have two kidneys that lie at the back of 
the abdominal cavity and perform a number of life-maintaining functions, such as filtering and 
excreting waste and acid, maintaining electrolyte and water balance, and producing the hormone 
erythropoietin, which stimulates the production of red blood cells to prevent anemia, and the 
active form of vitamin D, which preserves calcium and phosphate levels and bone health. 
Anatomically, each kidney comprises an outer cortex containing the glomeruli, through which 
blood is filtered, and the medulla, where urine is concentrated. Urine flows within tubules that 
coalesce in the renal pelvis, draining into the ureter and on to the bladder105. In addition to 
epithelial, mesangial, and endothelial cells, the kidneys also contain a network of immune cells 
that contributes to organ defense and injury repair.  
Why a kidney cell atlas? 
Understanding how the kidney works in health and disease is critically important for the 
development of future therapies. However, information on human kidney cell diversity has been 
hampered by limited tissue accessibility. The kidney is difficult to sample, and percutaneous 
biopsies contain mostly cortical tissue, and no comprehensive map of intercellular networks in 
the human kidney exists. The extreme anatomical variation in tissue environment can profoundly 
influence local epithelial and immune cell function106, and, as a highly vascular organ, the kidney 
is in constant contact with the blood and cells in the circulation. Finally, as human genetics is 
informing our understanding of kidney pathophysiology107, a detailed map of gene expression 
and disease circuits in the kidney will be instrumental in developing precision therapies. 
The Human Kidney Cell Atlas will aim to reveal with an unprecedented granularity the cell 
populations within the kidney. It will become the largest unified, standardized database 
characterizing human kidney cells, reveal previously unknown cellular diversity, and increase 
the resolution at which we comprehend cell function and phenotype in all anatomical regions of 
the human kidney. Since many diseases of the kidney are often cited as a fast recapitulation of 
normal aging mechanisms, these analyses will provide unprecedented insight into kidney 
diseases and enable further analysis and cross-validation in kidney tissue from individuals with 
specific kidney diseases (lupus nephritis, nephrotic syndrome, immune complex 
glomerulonephritis, diabetic kidney disease, acute kidney injury, etc.) or from kidney transplants 
with rejection or declining function to define the specific cell populations and kidney segments 
primarily affected in each case. Thus, the Human Kidney Cell Atlas will transform our 
knowledge of regional cell identity and function, providing an invaluable platform on which to 
base efforts to understand and treat kidney diseases (Figure 9). 
What are key considerations for a kidney cell atlas? 
To capture the data necessary to classify kidney cells, we will first focus on gene expression 
profiling by scRNA-Seq profiling to determine the combination of markers that allow the 
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identification and distinction 
of major cell types in the 
kidney. These will be 
followed by validation at the 
protein level, using flow and 
mass cytometry, and 
establishing the spatial 
distribution of cells in tissues, 
using both RNA- and protein-
based methods. Two 
completed feasibility studies 
have demonstrated that both 
kidney cells and kidney 
immune cells (CD45+) can be 
profiled from mechanically 
and enzymatically dissociated 
cells from nephrectomy 
specimens. 
In a pilot study, key 
technical remain to be 
addressed. 
Sample source. Discarded 
transplant kidneys and 
nephrectomy specimens can 
be obtained, allowing 
analysis of fresh tissue. The 
minimum amount of tissue 
that can be used to isolate all 
cell types must be assessed. It 
may also be important to 
explore how donor’s co-
morbidities (hypertension, 
diabetes, hyperlipidemia), 
age, sex, and ethnicity impact 
sample quality. Although this 
exploration may be limited in 
the pilot, it should be possible to collect relevant clinical data and begin addressing these 
questions, which play a key role in understanding disease. 
Sample handling. While freezing facilitates tissue collection, and transplanted organs are 
currently transported on ice, these factors, as well as delayed processing, may impact cell 
viability, transcriptomes, and proteomes. To this end, fresh, cold-stored, and frozen tissues 
should be compared.  
Single cells and nuclei. Feasibility studies to date suggest that different protocols will be 
required to obtain different cell types; for example, kidney epithelial cells are more easily 
damaged by disaggregation protocols than kidney immune cells. Both different dissociation 
Figure 9. Kidney atlas workflow. In the pilot phase, samples will be 
obtained from n=30 discarded kidney transplants and nephrectomy 
specimens, allowing the transcriptional profile of cells from different 
anatomical areas of the kidney to be assessed, including cortex, medulla, 
pelvis and ureter. We will establish the optimal processing protocols to 
allow good quality scRNA-Seq data to be generated for all major cell 
types in the kidney, including tubular epithelial cells, endothelial cells 
and immune cells. The kidney is comprised of ~1 million subunits called 
nephrons. The tubular epithelial cells in different regions of the nephron 
have different functional characteristics, and the scRN-Seq data 
generated will allow us to compare transcriptional profiles obtained from 
cells in the proximal convoluted tubule (PCT), loop of Henle (LH), distal 
convoluted tubule (DCT) and collecting duct (CD). In the draft atlas, we 
will extend our sampling to include kidney biopsies and fixed samples 
from patients with a variety of kidney diseases. We will also use flow 
sorting and microdissection to enrich for rare cell subsets and cells from 
specific subanatomical areas, such as the glomerulus. This structure 
forms the filtering unit of the kidney, plays a critical role in homeostasis, 
and abnormalities in its cellular constituents (podocytes, glomerular 
capillaries (GC), and mesangial cells) contribute to disease. Spatial 
transcriptional and proteomic data will be generated to support and 
validate scRN-Seq data obtained from homogenized samples. 
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protocols from fresh tissue and nuclei prep from snap-frozen specimens must be tested. 
Spatial analysis. In parallel, intact, nondisaggregated samples of all kidneys studied will be 
stored for future spatial analysis using both RNA and protein-detection techniques. This will 
include snap-frozen and formaldehyde-fixed specimens. 
Standard operating procedures. Strict quality-control guidelines will be developed to 
standardize sample collection and analysis to minimize batch-dependent variation. All optimized 
protocols will be shared online.  
By the end of the pilot, we will have generated a standard operating procedure for processing 
kidney epithelial, endothelial, and immune cells and ascertained the impact of cold storage and 
freezing on kidney cell viability. The generated data will also be a basic atlas of common cell 
types in different anatomical regions of the kidney. 
Draft Atlas v1.0 
The draft atlas will chart the kidney cortex, medulla, pelvis, and ureter in tissue samples obtained 
from discarded transplant organs, nephrectomy specimens, and kidney biopsies, as well as a 
moderate number of samples from diseased kidneys. Kidney tissue will be micro-dissected to 
anatomical areas of interest (e.g., glomerulus).  
For the first draft, 3 to 4 participating geographical sites will collect and process human tissue 
samples locally using strict standard operating procedures. We will sample kidneys from 20 
individuals from each site (20 to 55 years of age; diverse ethnic backgrounds, including African 
Americans, Asians, and Caucasians). In addition, we will sample 10 additional individuals, ages 
55 to 80, at each site, given the high frequency of 
chronic kidney disease in the elderly.  
Each specimen will be analyzed for both the cellular 
level (with uniform approaches and with 
stratification for rarer cell subsets using protein 
markers identified from the uniform analysis), 
measuring both RNA profiles and protein panels108, 
and the spatial level (with fresh, frozen, and fixed 
sections).  
RESPIRATORY: LUNG  
The human respiratory system is critical for gas 
exchange. Lung anatomy enables this through two 
main structures: the airways that lead the air to and 
from the respiratory unit and provide mucociliary 
clearance of inhaled particles and pathogens; and 
the alveoli, distal saccular structures where gas 
exchange occurs. The airways, beginning in the 
nasal cavity and connecting to the trachea, 
iteratively bifurcate into the branching bronchial 
tree, ending in terminal bronchioles, which branch 
into the respiratory unit encompassing the 
respiratory bronchioles, the alveolar duct, and the 
Figure 10. Lower airway structure of the 
lung. The structure of the lower airways is 
defined by the cartilaginous trachea and main 
bronchi, branching into progressively smaller 
bronchioles. Small airways are defined as the 
conductive airways with a diameter of less than 
2 mm, and end with the terminal bronchioles, 
which connect to the respiratory unit.  Adapted 
from eLife 2017;6:e30194 DOI: 
10.7554/eLife.30194, licensed under CC BY 
4.0. 
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alveolar sac109 (Figure 10). The entire respiratory tract is also an important part of the mucosal 
immune system. Consequently, a large diversity of cell types contained within a tailored 
extracellular matrix is required to maintain homeostasis of the lung. The recent discovery that the 
lung is a site of platelet biogenesis and a reservoir for hematopoietic progenitors110 highlights the 
fact that the full cellular diversity of this organ is not yet known.  
Why a lung cell atlas? 
The lung is a highly complex organ with at least 40 discrete cell types known to date, but there is 
limited knowledge about the functional relationships of these cells in disease. Lung disease is a 
leading cause of mortality in the U.S. and worldwide, with more than 7 million deaths attributed 
to lung disease annually. The Lung Cell Atlas will reveal novel insights about the identities, 
activities, and lineage relationships of all cells in the healthy human lung. This baseline will then 
serve as a starting point for profiling cohorts of chronic lung disease patients, inspiring 
translational research into the therapeutic strategies of the future, as well as potentially 
uncovering new diagnostic opportunities for lung disease. Thus, a Lung Cell Atlas is of 
paramount biological and clinical relevance.  
What are key considerations for a lung cell atlas? 
To build a Lung Cell Atlas, we will need to establish standardized procedures for 
comprehensively sampling the lung along the proximal-distal axis of the airways, aiming to 
develop a coordinate framework based on the 16 generations of the conductive airways in the 
bronchial tree up until the respiratory unit and their relative location within the five lung lobes 
(Figure 10).  
In a pilot phase, we will establish key procedures for this process. 
Samples. Lung and airway tissue can be obtained in several ways: direct sampling of fresh lung 
airway wall tissue through bronchoscopy; central or parenchymal tissue from transplant lungs; 
and lung parenchymal tissue from uninvolved resection material adjacent to primary or 
metastatic tumors. Single cell RNA-Seq data sets from freshly obtained bronchoscopy biopsies 
are under way and can be used as a reference for those from resection material or transplant 
lungs. The abundance of lung parenchymal tissue from tumor resection programs will also allow 
efficient optimization and standardization across centers.  
Anatomical sampling. It is critical to standardize a coordinate framework to define location 
within the lung, based on the proximal-distal axis along the generations of the conducting 
airways up to the terminal bronchioles and the respiratory unit, and their relative position within 
each of the lobes. This will include harmonizing dissection protocols for larger airways and 
peripheral lung tissue. 
Cell and nucleus profiles. The cellular branch of the Lung Cell Atlas (LCA) will initially be 
based on scRNA-Seq data, but aims to include proteomic and epigenetic profiles as single-cell 
methodologies evolve. Early studies have established scRNA-Seq profiles identifying the major 
cell types in freshly obtained airway wall biopsies and brushed airway epithelial cells, as well as 
in central and peripheral lung tissue from resection material and transplant donors111. More 
generally, single-cell profiling will rely on tissue disaggregation into suspensions of viable single 
cells, from specimens collected from multiple representative anatomical/histological sites. In 
addition, snRNA-Seq will be tested on cryopreserved tissue, which would allow profiling of cells 
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across the full spatial coordinate framework of several representative whole donor lungs and 
avoid possible biases introduced by tissue dissociation. 
Spatial profiles. Large-scale characterization of cellular heterogeneity from cell suspension or 
isolated nuclei should be integrated with corresponding in situ data for multiple sites along these 
standardized geographical coordinates. IHC and highly multiplexed FISH analyses on matched 
lung-tissue specimens will be used to validate the initial results from scRNA-Seq and snRNA-
Seq data sets from both freshly obtained biopsies and resection materials and to allow spatial 
mapping (by inference9,13-15 of entire transcriptomes). In addition, the recently developed 
nondestructive cryo-micro-CT approach112, which allows imaging of small airway structure up to 
the respiratory unit, can be combined with FISH analyses to identify novel cell types and activity 
states onto in a tissue context. These spatially resolving methods will dramatically advance our 
understanding of lung tissue architecture and generate new hypothesis on functional relationships 
between cell types. 
Draft Atlas v1.0 
A first draft of the Lung Cell Atlas will sample tissues from the nasal cavity, trachea, primary 
and tertiary bronchi, small airways (diameter <2 mM) and the respiratory unit (including 
transitional bronchioles and alveoli). For each defined position along the respiratory tract, the 
“healthy” atlas will be based on 20 to 30 healthy, nonsmoking individuals aged 25 to 55 years 
from each of at least three geographically distinct sites, both genders, and at least two ethnicities. 
For every specific location along the airways, the bronchial tree and respiratory unit, we will 
profile at least 50,000 to 100,000 cells or nuclei and perform spatial analysis of cell type specific 
mRNA signatures as well as protein signatures. We will then correlate tissue architecture with 
spatial organization of the identified cell types together with their extracellular matrix to define 
distinct cellular niches along the airway tree. To derive a deeper mechanistic understanding of 
lung development and disease, we will additionally include airway- and lung-tissue samples of 
small cohorts of clinically well-phenotyped patients with specific conducting airway diseases — 
COPD and asthma — and interstitial lung diseases, such as idiopathic pulmonary fibrosis (IPF). 
We anticipate integration of our data on the respiratory mucosa with the Immune Cell Atlas in 
the respiratory mucosa, with data sets of the lung microbiome and proteome in our sampled 
tissue specimens, and with those data sets and platforms currently available in the wider lung-
research community113,114. 
HEPATOPANCREATIC-BILIARY: LIVER 
The human liver is the central coordinator of the body’s metabolism and performs a wide range 
of functions critical for body health and maintenance115. Unlike almost every other human organ, 
the liver also has an incredible regenerative capacity: it can regrow even after 80% has been 
removed. However, once the liver fails, the only treatment is organ transplantation. Development 
of alternative treatments is currently limited by our lack of understanding of the cellular 
landscape of the human liver. Because liver diseases — resulting from obesity, alcohol abuse, 
drug toxicity, and chronic infections — are a major and increasing burden worldwide, novel 
investigations are urgently needed to better understand how liver cells grow and work together. 
Why a liver atlas? 
A human liver cell atlas will serve as a foundation for studies of normal and diseased liver 
function, and will support the development of novel therapies, such as methods to reduce 
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transplant-rejection rates and 
regenerative-medicine 
approaches to repair damaged 
tissue. First, the cellular 
complexity of the liver has 
been greatly underestimated, 
and much remains to be 
discovered about how the 
cells in the liver ecosystem 
fulfill hundreds of liver 
functions, possibly through 
sub-specialization of cell 
types, such as hepatocytes 
(Figure 11). Second, while 
we know liver diseases are 
highly localized, and their 
progression is likely 
associated with specific cell 
subtypes, we do not know 
what these cell types are. A 
liver atlas of the healthy 
baseline will serve as a 
reference to compare with 
disease samples. Third, the 
liver is a regenerative organ, and better understanding of liver regeneration will help the design 
of liver tissue repair technologies, including stem cell therapies. The human liver cell atlas will 
help define the molecular characteristics of cells that should be replaced.  
What are key considerations for a liver cell atlas? 
An ideal hepatic cell atlas will involve analyzing a large number of cells, both parenchymal [PC] 
and nonparenchymal [NPC], and their spatial organization, from all anatomic liver regions: two 
major lobes, subdivided in eight segments reflecting the major divisions of the portal vein and 
the bile duct, and for each segment, each of the three metabolic zones of the lobules (the 
segments’ functional units); the gallbladder; and the common bile duct of the extra-hepatic 
biliary system. 
However, collecting 20 samples per liver (8 segments  (PC + NPCs) + (gallbladder + common 
bile duct) could be challenging considering the difficulty to access entire and healthy organs and 
the wide variability in liver composition and activity between individuals.  
Key principles for an optimal liver cell atlas include: 
Characterization of liver cells at many levels. The liver is structurally and functionally 
heterogeneous115. Thus, a liver atlas should include a range of molecular profiles (e.g., 
transcriptome to identify cell type signatures, proteome to characterize the many liver protein 
products, metabolome because the liver is a metabolic tissue) from the different anatomical 
regions, as they differ in cellular composition.  
Figure 11. Liver. The main “building block” of the liver is the hepatic 
lobule, which includes a portal triad, hepatocytes arranged in linear cords 
between a capillary network, and a central vein. The functional unit of 
the liver is the sinusoid. Found within the sinusoid are parenchymal cells 
(hepatocytes and cholangiocytes) and non-parenchymal cells (endothelial 
cells, Kupffer cells, hepatic stellate cells and liver infiltrating 
lymphocytes- including B cells, T cells and NK cells).  
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A diversity of liver functions, human populations and environments. Important liver metabolic 
activities vary tremendously among individuals and depend on age, gender and other factors. For 
instance, some liver diseases are so common that they should be sampled as part of the atlas. The 
global prevalence of non-alcoholic fatty liver disease [NAFLD] is 25%116 and more than 70 
million people are chronically infected with hepatitis C, with some geographical areas affected 
more than others and some human populations more prone to disease progression than others. 
Also, liver varies greatly over the circadian clock cycle117. Thus, samples must be derived from a 
broad number of genetically diverse individuals in different environments; information about 
sleep and wake cycle should be captured if available. 
Disease susceptibility and progression is related to liver immune cell function. The liver cell 
atlas intersects with the Immune Cell Atlas, and comparing them will help characterize liver-
immune cells for their similarity to and distinction from peripheral counterparts and how they are 
affected by an individual’s environment. 
Spatial analysis. The function of hepatocyte and accessory cells, including immune cells, is 
affected by their anatomical position in the liver. For example, macrophages function differently 
based on where they are in the sinusoid, and hepatic immune cell activity may be influenced by 
metabolic zonation. However, how these cells’ phenotype, frequency, and functional diversity 
are impacted by anatomical location and histological neighborhoods remain to be fully detailed. 
Spatial analysis of liver cell 3-D distribution in multiple anatomical regions will help determine 
how location affects cell function.  
Development. We must understand liver cell development better to comprehend disease and liver 
regeneration. This provides a natural connection point with the human Developmental Cell Atlas, 
to monitor both cell development and regeneration. 
In a pilot study, key technical questions remain to be addressed. 
Optimizing sample preparation. Single-cell isolation from liver samples is notoriously 
challenging. Liver cells such as hepatocytes and cholangiocytes are delicate and frequently don’t 
survive standard tissue extraction. Furthermore, many liver cell types are influenced by tissue-
level metabolic gradients, which may change rapidly during tissue acquisition. Standard and 
optimal single-cell sample preparation protocols, compatible with processing of delicate liver 
cells, should be developed, as well as single-nucleus methods applied on snap-frozen samples2-
4,9,118. Fresh and frozen samples should be profiled to evaluate the impact of each preparation, as 
well as comparing scRNA-Seq to snRNA-Seq, including differences in cell composition. 
Sample source. Healthy human liver tissue can be collected from several sources: organ 
transplants (liver segments or wedge biopsies from deceased donor prior to transplantation or 
whole organs that are declined for transplantation); resections from healthy regions of liver 
cancer; and biopsies from standard liver diagnosis. These sources will also be valuable for 
collecting liver tissue affected by a variety of diseases. We should define the best source of cells 
(or nuclei) to perform single-cell profiling (biopsy versus organ donor versus resection); spatial 
methods can likely accommodate all these sources. Each source has distinct advantages and 
drawbacks, with respect to blood supply (ischemia), cell contamination, or anatomical region 
diversity. Protocols to isolate high-quality cells from all studied fractions must also be developed 
and validated, since most existing protocols are specialized for one particular cell type while 
discarding the others. Single-nucleus RNA-Seq and spatial profiling can help assess 
compositional biases in single-cell analysis of fresh tissue. 
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Data analysis. State-of-the-art single-cell genomics data-analysis workflows will be applied in 
collaboration with the broader HCA effort and should be modified as needed to address liver-
specific challenges, such as analysis of metabolomes, or studying zonation patterns that affect 
liver-cell function15.  
Draft Atlas v1.0 
A first draft will collect samples from eight anatomic segments of the liver for at least 20 
individuals collected from each of four geographically (and ideally ethnically) distinct sites (e.g., 
Cambridge, U.K.; Toronto, Canada; Boston, U.S.; Beijing, China); individuals from both 
genders; all adults 20 to 65 years of age. Three different tissue sources will be used whenever 
possible (biopsy, whole donated liver, and normal adjacent tissue from cancer resection) and PC, 
NPC, gallbladder, and common bile duct will be isolated (at least from cadaveric donors). Each 
collection center will use a different tissue sampling approach. Larger numbers of individuals 
will be necessary to encompass individual variability while larger numbers of cells for the top of 
the Sky Dive may be collected only with samples from some of the individuals.  All samples will 
include preservation of matching sections for spatial analysis. A subset of the samples will be 
analysed by spatial profiling of RNA and proteins.  
HEPATOPANCREATIC-BILIARY: PANCREAS 
The pancreas is a vital organ that is composed of cells with either exocrine or endocrine 
functions. It is the locus of key pathologies, including diabetes and pancreatic cancer (Figure 
12).  
The exocrine pancreas is comprised of acinar cells, which produce zymogens (an inactive 
precursor of enzymes) that hydrolyze macromolecules to aid digestion; and ductal cells that form 
branched tubules, whose principal products include bicarbonate, which helps neutralize gastric 
acid, thereby allowing effective enzymatic action. The full diversity of cell types in these two 
categories is still unknown. The endocrine pancreas is comprised of hormone-secreting 
epithelial cells organized in structures called Islets of Langerhans. Each endocrine cell type 
synthesizes and secretes a hallmark hormone product: -cells make glucagon, -cells produce 
insulin, and -cells produce somatostatin. The functions of islets, ducts and acinar cells are 
coordinated by important autonomic, paracrine, and endocrine inputs orchestrated by neuronal 
and specialized vascular structures119.  
Rodent studies over the past two decades have identified cellular, genetic, signaling and 
molecular pathways that lead to formation of the pancreatic exocrine and endocrine cells. In 
addition, recent progress has been made in identifying the transcriptomes and epigenetic features, 
including histone modifications, in human pancreatic cells120-125. However, much remains to be 
discovered about the cellular composition of the pancreas and the mechanisms regulating the 
developmental process in humans119,126,127. 
Why a pancreas atlas?  
Human pancreatic diseases, including type 1 and type 2 diabetes mellitus (T1D, T2D), 
pancreatitis, cystic fibrosis and adenocarcinoma, affect over 10 percent of the world’s 
population128-130. Thus, there is a clear need to understand the mechanisms governing the 
function and the development of these cells and how they work together in healthy and diseased 
organs.  
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In addition, diseases such as 
pancreatitis and 
adenocarcinoma involve 
interactions of pancreatic 
cells with “stromal” elements 
— (including fibroblasts, 
stellate cells, vascular 
endothelial and smooth 
muscle cells — as well as 
immune cells — including 
those localized to pancreatic 
lymph nodes. It has been 
widely speculated that the 
interaction between the 
stroma, immune cells, and 
tumor cells give rise to 
resistance to treatment of 
pancreatic cancer, which has 
been a major challenge in 
tackling this devastating 
disease. More detailed studies 
of these cell subsets are 
needed to understand their 
roles and function in 
physiological and 
pathological settings.  
What are key 
considerations for a 
pancreas atlas? 
There are good prospects for 
developing a detailed map of 
common pancreatic exocrine 
and endocrine tissue. All would require close collaborations with physicians, whether in general 
surgery, oncology, gastroenterology pathology, or transplantation surgery. Major challenges in 
leveraging these resources are methodological, especially standardization of tissue isolation, cell 
purification, and molecular studies. In particular, the high enzymatic activity within the pancreas 
renders extraction of high quality RNA from fresh material particularly challenging. 
In a pilot study, key technical questions remain to be addressed. 
Sample source. For endocrine tissue, cellular and molecular mapping studies of human pancreas 
in adults are currently feasible131, thanks to a variety of extant robust organ procurement efforts, 
such as the NIH-supported Integrated Islet Procurement Program in the U.S. (IIDP)132 and 
related efforts in other countries124,133.  Similarly, there are good prospects for exocrine diseases 
like pancreatitis or adenocarcinoma134-136, with specimens obtained from surgical extraction.  
Tissue handling. Practical challenges, like rapid autolysis of cadaveric human pancreas within 
minutes to hours after extraction, altered gene regulation and function of cells after in vitro 
Figure 12. Morphology of the healthy pancreas and sampling 
strategy. (A) Overview of the pancreas depicting the three regions: head 
(with the special subsites Processus uncinatus and ampullary region), 
body, and tail. From the head, four sample regions are selected 
representing the periphery of the head (2X), the central ampulla and the 
Processus (periphery). From the latter two anatomical subsites (body, 
tail), three sample regions each will be selected, with one central location 
(including the main pancreatic duct) and the periphery (2X). 
(B) Principle tissue composition of ampullary and central pancreatic duct 
regions. (C) Principle tissue composition of peripheral pancreatic tissue.  
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culture for even short periods120, and a need for large numbers of primary cells in prior 
investigations of chromatin and histone modifications, have limited donor sampling and use of 
single-cell resolution methods137-140.  
A human pancreas atlas requires coordinated focused efforts to procure human cadaveric organs 
in reliable, efficient, ethical and cost-effective ways. This could involve multicenter teams (e.g., 
Arda et al.120) organized within interdisciplinary consortia, like the NIH-funded Human Islet 
Resource Network (HIRN; https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-
1-diabetes-special-statutory-funding-program/Consortia-Networks-Centers/human-islet-research-
network/Pages/default.aspx), Human Pancreas and Analysis Program (HPAP; 
https://hirnetwork.org/consortium/hpap) and Chronic Pancreatitis, Diabetes and Pancreatic 
Cancer (CPDPC; http://cpdpc.mdanderson.org) consortia, or the privately-funded efforts like the 
JDRF Network for Pancreatic Organ Donors with Diabetes (nPOD; https://www.jdrfnpod.org). 
Cryogenic banking of specific cell types or structures like islets has been reported to maintain 
viability and function for years133 and may provide a useful adjunct. Likewise, coordinated 
collection of relevant non-pancreatic cell types, such as circulating or pancreas-infiltrating 
inflammatory cells) — a focus of nPOD and the T1D-focused TrialNet — would ideally be 
coordinated with pancreas procurement.  
Comparison of cellular, nuclear and spatial measurements. Because of the particular challenge 
of obtaining high-quality profiles in a rapidly lysing tissue, a pilot effort should compare single-
cell, single-nucleus and spatial methods. Single-nucleus and spatial methods can be applied to 
quickly preserved specimens, such as frozen (nuclei) or fixed (spatial) tissue. These can then be 
compared to determine the viability of each strategy in this challenging organ. 
Draft Atlas v1.0 
The principal goal of the first draft atlas should be to capture as much of the cellular diversity in 
the pancreas and understand the cells’ histological organization. Although the pancreas has a 
challenging lack of stereotypical tissue architecture, powerful approaches like the tissue 
transparency method CLARITY141 have begun to elucidate and quantify dynamic and previously 
undetected cell–cell interactions, like islet innervation, in the human pancreas142. A combination 
of cellular and spatial approaches will be able to tackle this challenge.  
The draft atlas will include a sampling of at least 10 regions of the pancreas, covering both 
endocrine and exocrine tissue from known macro-anatomical pancreatic regions including head, 
body, tail, processus uncinatus, and ampullary. However, on the microstructure level, many more 
regions might exist that are not yet recognized by morphology. In a draft atlas, we will collect 20 
samples for each of these regions from each of at least three geographically (and ideally 
ethnically) distinct sites; individuals from both genders; 20 to 55 years of age. To characterize 
cell types, we will apply both single-cell and single-nucleus RNA sequencing — the latter 
performed on snap-frozen tissue — and spatial techniques, including 3-D reconstruction, to 
identify the cell types present and understand how they are located and communicate with each 
other. 
GASTROINTESTINAL: SMALL INTESTINE AND COLON 
The colon and small intestine serve as a critical barrier separating ingested materials and 
microbes from the rest of the body. Both organs are critical for absorption, with nutrient uptake 
occurring in the small intestine and absorption of salts and water in the colon controlling 
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electrolyte levels throughout the body. Simultaneously, the colon excludes dietary waste and 
microbes from systemic exposure. To maintain these selective barriers, the epithelial lining of 
the small intestine is renewed every three to five days and that of the colon every 72 hours. This 
remarkable rate of self-renewal occurs in microanatomic structures — crypts — where intestinal 
stem cells divide and mature into more than a dozen specialized intestinal epithelial cell types143. 
The intestinal epithelium surface is primarily composed of epithelial cells of which there are 
three major types of cell types: absorptive columnar cells; mucus-secreting goblet cells; and 
hormone-producing enteroendocrine cells. These epithelial cells are continuously replaced by 
cells that are produced from stem cells that reside in the base of the crypt. The interaction of 
these cells with gut-resident immune cells, stroma, and enteric neurons is critical for maintaining 
the gut’s barrier function. The gut immune system — particularly T cells, B cells, and more than 
a dozen types of innate immune cells — is influenced by the presence of the gut microbiome, 
which is responsible for “educating” the immune system. These microbes are now increasingly 
appreciated to affect many aspects of human health, including metabolic disease, inflammatory 
disease, autoimmune disease, allergic disease, asthma, anxiety and depression, and even 
predisposition to neurodegenerative diseases like Parkinson’s144.  
Why a gut cell atlas?  
There are more than 40 cell types identified to date in the colon and small intestine (hereafter, 
“the gut”), including rare cell types such as enteroendocrine cells, mast cells, innate lymphoid 
cells, and gut “pacemaker” cells143,145 (Figure 13). 
A complete atlas of the cells in the gut would provide a critical resource to not only reveal the 
basic biology of this essential organ but also provide the information necessary to improve 
clinical care and diagnostics for a wide range of diseases. These include diseases such as 
inflammatory bowel disease — ulcerative colitis and Crohn’s disease — microscopic and 
collagenous colitis, colon cancer, food allergy, and neurodevelopmental or neurodegenerative 
conditions. 
While genetic risk factors are known for many of these diseases, the initiating cells and processes 
that trigger disease remain unknown. Providing a baseline for the normal composition of cells 
across age, sex, ethnicity, and exposure to antibiotics and other drugs will serve as a foundation 
for more detailed atlases of disease progression, such as the 
evolution of colon polyps into full-blown cancer. In addition, 
a full catalog of cell types in the gut will advance our 
understanding of therapeutics, such as immune checkpoint 
blockade (e.g., anti-PD1) for cancer, in which tumor 
regression is often accompanied by a toxicity condition 
known as checkpoint colitis 146,147. 
What are key considerations for a gut cell atlas? 
A pilot phase will determine the approaches for each key 
aspect necessary for a first draft.  
Sample sources. The colon (but less so the small intestine) is 
also an easily accessible tissue, since patients receive 
colonoscopies at all ages and regular screening from age 50. 
This means that there are opportunities to collect some 
biopsies from healthy volunteers, although entire organs 
Figure 13. Normal small 
intestine. e-cadherin, an epithelial 
marker (green); RELMbeta, an 
anti-parasitic agent (red); DAPI 
stains the nucleus. 
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require transplant organ donors (Section 2). Additional sources are resection and biopsy 
specimens for colon pathology, which often include healthy adjacent colon tissue. In particular, 
full thickness tissue will be essential to capture all non-epithelial elements. These cannot be 
obtained by biopsy, but will rely on the availability of surgical specimens. 
Cell sampling. To comprehensively profile the human colon and small intestine, where many 
cells are present in radically different frequencies, we will need to develop appropriate protocols 
for tissue dissociation to capture even rare or fragile cell types from the biopsy, such as stroma 
and submucosal neurons. In particular, neurons may only be efficiently recovered by single-
nucleus analysis, and very rare cell types may require either very large cell numbers at the top of 
the Sky Dive or enrichment thereafter.  
Spatial organization. An early cell census of the mouse small intestine not only captured all 
known epithelial cell types and several previously unknown subsets, but also highlighted that cell 
proportions and subsets vary between fine structures and between anatomical regions. A 
sampling of both aspects, with both cellular and spatial methods, would help determine the 
appropriate mapping strategy across this large organ. In particular, the small intestine and colon 
are massive in size. From proximal to distal, the gastrointestinal tract is divided into specialized 
regions within the small intestine (duodenum, jejunum, ileum) and colon (right, transverse, left 
colon, and rectum). At the histological level, the small intestine and colon have stereotypical 
repeating structures. In the small intestine, villi — finger-like projections of the internal 
intestinal surface  — are covered by a layer of epithelial cells. Of note, the surface of the colon 
carries no villi, yet its architecture is otherwise comparable. The crypt structures supporting the 
epithelial stem cell niche reside at the base of adjoining villi. Beneath the epithelial layer, is the 
lamina propria, which is comprised of connective tissue and stromal cells that are penetrated by 
blood vessels, lymphatic vessels, and nerves. Beneath the lamina propria, is a layer of innervated 
smooth muscle that is critical for digestive motility. Importantly, cells of the immune system can 
traffic to and reside in any region of the intestinal substructure. For example, intraepithelial 
lymphocytes reside between epithelial cells at the mucosal surface, and many additional immune 
cell types populate the lamina propria. The mucosa of the intestine also accommodates organized 
lymphoid structures such as Peyer’s patches (small intestine) and isolated lymphoid follicles 
(colon) where immune responses are mobilized and tailored to different infectious agents. In 
addition, specialized cells in the follicle associated epithelia (FAE) residing above the Peyer’s 
patches (small intestine) and lymphoid follicles (colon) facilitate antigen entry and processing by 
these adjacent immune residents. Thus, an atlas should include sampling from each macro-
anatomical region, as well as partition the distinct micro-anatomical structures in each.  
Organoids. The recent revolution in organoid biology has built on the pioneering work148,149 with 
intestinal organoids. Because of the ease of production and the close resemblance to human 
organs in health and disease, organoids hold great appeal for translational research and invite an 
almost immediate application into the clinic. The current versions of organoids should still be 
considered an abstraction of their in vivo counterpart: nerves, blood vessels, supporting tissue, 
and immune cells are absent, and as a consequence, disease processes are only partially 
recapitulated. Thus, a pilot would assess the composition of matching organoids to test the extent 
to which it mirrors that of in vivo tissue. This will be in partnership with the Human Organoid 
Atlas. 
Draft Atlas 1.0 
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A first draft atlas will expand the pilot to comprehensively characterize gut cellular subsets7,8,150 
and integrate these spatially into a comprehensive picture of the human gut as a reference for 
understanding and treating gut disease.  
A principal goal of the first draft atlas should be to capture as much of the cellular diversity in 
the gut as possible. In a draft colon atlas, we will sample four sites: the right colon, transverse 
colon, left colon, and the rectum. For the small intestine, mostly the ileum will be sampled from 
healthy living research participants (the limit of which routine colonoscopy can reach), whereas 
all three regions of the small intestine (duodenum, jejunum, and ileum) will be studied from 
resections or organ donors. Twenty samples for each of these regions will be collected from each 
of at least three geographically (and ideally ethnically) distinct sites; individuals from both 
genders; all adults representing a variety of ages (between 20 and 70). Each of these tissue sites 
will be represented by two punch biopsies, 3 to 5 mm in diameter, from neighboring sites. To 
characterize cell types, we will apply both single-cell and single-nucleus RNA sequencing and 
spatial techniques, including 3-D reconstruction, to identify the cell types present and understand 
how they are located and communicate with each other. 
SKIN 
The skin, our most visible tissue, is intimately tied to our identity, forms the outer covering of the 
body, and serves as a protective interface with the environment 151. It is not only a physical 
barrier but also a defensive one, providing the first immunological protection against pathogen 
and external challenge. 
Why a skin cell atlas? 
There are several reasons to pursue a pilot-scale atlas of the skin. First, the wealth of knowledge 
gleaned from such an atlas will be of broad scientific, clinical, and commercial benefit. Second, 
the tissue’s unique accessibility can help it serve as a prototype for organ-based HCA programs 
and inform how to sample a tissue that is distributed across the entire body. Encouragingly, 
initial scRNA-Seq studies of the skin of mouse models and cultured human keratinocytes, similar 
to those that might be involved in constructing the atlas, have already been published152,153, and 
more are underway. 
What are key considerations for a skin cell atlas? 
A pilot phase will determine the approaches for each 
key aspect necessary for a first draft. 
Anatomical locations. The skin is distributed across the 
body, and prior studies have shown that at least some 
component cells are substantially impacted by 
location154, as are features such as the skin 
microbiome155. Early efforts will pilot the systematic 
analysis of single-cell transcriptomes and spatial 
profiling of skin from two anatomical sites: abdomen 
and breast, which are readily available from cosmetic 
surgery operations.  
Tissue disaggregation. Skin is a challenging tissue to 
handle and disaggregate, while recovering all cell types 
faithfully (Figure 14). The pilot will seek to address 
Figure 14. Skin. En face view of human 
dermis showing lymphatic vessels (blue), 
dendritic cells (green), T cells (red) and 
macrophages (blue).  X10 magnification.  
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several technical questions, including: (1) What is the minimum size of biopsy that can be used 
to isolate all cells? (2) Should tissues be separated into different components prior to single-cell 
analysis (for example, separating epidermis from dermis), or should all cells be isolated 
simultaneously? (3) What is the impact of the donor’s health status, age, sex, ethnicity, and sun 
exposure on sample quality? (4) Which protocols, including single-cell and single-nucleus 
methods are most suitable to obtain good cellular representation? When the answers to these 
questions are determined, optimized protocols for cell disaggregation will be shared online. 
Already, three feasibility studies have been completed: an unbiased droplet-based single-cell 
transcriptome of enzymatically dissociated whole skin; plate-based adaptive sampling of skin 
mononuclear phagocytes; and spatial transcriptomic analysis of frozen OCT-embedded skin, 
which also helps serve as a control for biases in disaggregation methods. 
Optimizing additional methods and archiving samples. To assay protein levels in cells, the 
single-cell profiling data of the pilot will be combined with legacy knowledge of human skin to 
devise mass cytometry or flow analysis panels for protein-level information. Other auxiliary 
collections will include the surface microbiome of skin samples156 and blood archiving for 
subsequent correlation with the skin’s immune cell populations157.  
Spatial methods. We will optimize the methodology for visualizing all cell types within intact 
skin, including, for example, rendering the tissue transparent and performing flat-mount 
labelling158,159. 
Assessing relevance of additional data. The pilot data will be related to all existing scRNA-Seq 
datasets in skin, including from mouse152 and cultured human epidermis160, previous bulk data of 
skin components161, and other types of single-cell and population-based data, such as ATAC-Seq 
and proteomics, to assess the distinct contribution of each. 
Draft Atlas v1.0 
Once the pilot has developed the necessary methodology, a draft atlas will broaden its scope by 
collecting samples of different body sites (including from the same individual) and hair-follicle 
types. For each of the anatomical collection sites, at least 20 samples will be collected from age, 
site, ethnicity, and sex-matched individuals from each of three geographical sites. Detailed 
analysis of 10 to 20 research participants should capture all of the different cell types and states 
in adult skin, capturing diversity in terms of sex, ethnicity, and body site with the remaining 
samples. The cellular branch, will rely on both single-cell and single-nucleus profiling, the latter 
being important given the challenge of dissociating skin tissue. Some cell types require specific 
collection efforts: for example, capturing hair-follicle cell types would require a specific focus on 
hair follicles with at least three major ethnicities and five types represented, because these cells 
are difficult to disaggregate and will not be well represented in scRNA-Seq of abdominal waste 
skin. For the spatial branch, we will also perform spatial analysis on a subset of samples. Finally, 
some disease indications may be included, either within the draft or as a follow-up. Priorities 
include: atopic dermatitis, melanoma, basal- and squamous-cell carcinoma, scleroderma, and rare 
genetic skin diseases caused by known mutations but lacking a deeper mechanistic 
understanding. 
CARDIOVASCULAR: HEART 
The heart is the earliest organ to form during embryogenesis, and its continued function is 
essential for sustaining a person’s life, until the last heartbeat. Heart disease is the number one 
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killer in the Western world, surpassing all cancers combined; the burden on society in terms of 
mortality and morbidity and the costs of health care are astronomical and rising162. Moreover, 
congenital heart defects affect one of every 100 live births and are collectively the most frequent 
noninfectious cause of death in the first year of life163,164. The heart and its supporting blood 
vessels have been studied for centuries, since the anatomical drawing of Leonardo de Vinci, and 
discoveries relating to its physiology in the 20th century led to the development of several drugs 
that have helped combat heart attack and heart failure. Despite a deep knowledge of cardiac 
cellular and organ physiology, we currently lack the detailed molecular information that would 
fully capture the breadth of cell types found in the complex, densely populated cardiac tissue. 
Why a heart atlas? 
Defining the cell types that comprise the heart and the coronary arteries — its supporting blood 
vessels — and their developmental origins will be critical to refine our understanding of heart 
function in health and in disease. While we understand the broad anatomical compartments that 
comprise the heart — left and right atrium, left and right ventricles, outflow tract, 
interventricular septum — these are further subdivided into sub-compartments with distinct 
functional and cellular characteristics. For example, the right atrium has a set of specialized cells, 
the sinoatrial node, which is the main pacemaker of the heart. The ventricular walls have at least 
three types of cardiac myocytes that promote gradients of electrical properties based on 
differential expression of ion channels. Furthermore, heart tissue contains, in addition to 
myocytes, a multitude of cell types essential for the structure and function of the heart — for 
example, fibroblasts, endothelial cells, cardiac nerves, macrophages, and many other cell types. 
The developmental biology of the heart has been well studied in model organisms165,166, but 
despite current advances, a large-scale cellular atlas is lacking. A Heart Cell Atlas will be a rich 
resource to better define the cellular composition of the heart, which will lead to a greatly 
improved understanding of physiology and disease (Figure 15). Inclusion of iPS cell-derived 
cardiovascular cell types will enhance the heart atlas by helping devise both more accurate 
models of disease and more precise strategies for cardiac regeneration, thus facilitating rational 
development of regenerative strategies. 
What are key considerations for a heart cell atlas? 
A Heart Cell Atlas should include a broad diversity of 
anatomical sampling locations across a diverse 
population of healthy adults, supplemented with similar 
sampling from various disease types. A heart atlas should 
also include human developmental samples. An 
additional consideration for current efforts in disease 
modeling would be to include in an atlas a 
comprehensive set of cells obtained by in vitro directed 
differentiation of human induced pluripotent stem (iPS) 
cells. These hold much promise for in vitro modeling of 
human disease and for high-throughput screens aimed at 
finding new therapies, but it is not known if the identity 
of the cells obtained from iPS cells reflect the cell types 
found in the human heart. 
The following considerations should be carefully 
weighed in a pilot study, ahead of a comprehensive draft 
Figure 15. Anatomical drawing of the 






Heart Cell Atlas. 
Anatomical sampling. Cardiac anatomy is well defined, and its complexities and associated 
physiology are well understood. This makes it possible to sample discrete anatomical 
compartments with precision. Ideally, this sampling should be coordinated with cardiac 
anatomists and the Common Coordinate Framework Working Group, who could develop a 
consistent and broad sampling strategy.  
The key challenge is that it is uncommon to have access to healthy, intact hearts for rapid 
processing, and it will require considerable coordination between clinicians, anatomists, and 
HCA scientists to achieve this. A simpler approach would be to define a minimal set of regions 
that can be consistently and rapidly sampled either as live biopsies or as easily obtained post-
mortem samples with limited scope. In addition, human developmental samples would ideally be 
collected from diverse anatomical locations based initially on known developmental landmark 
structures, but aiming for eventually diverse and comprehensive sampling. 
Sample preparation. An important challenge in developing a pilot heart atlas is the ease of 
dissociation of adult heart tissue into single cells. The dense fibrous nature of the adult heart is a 
particular challenge that will need determined effort to overcome. One solution is to usesingle-
nucleus RNA-Seq, which does not require dissociation and will allow profiling of archived 
material. Dissociation is less challenging for human development tissue. 
Cardiac cells derived from iPS cells. A handful of effective approaches have made it possible to 
derive enriched populations of human cardiac and vascular cells from iPS cell lines, including 
recent refinements to produce cells that have characteristics of relatively specialized cell types, 
such as atrial versus ventricular myocytes, pacemaker cells, and endothelial and smooth muscle 
cells. However, the definition of these cell types is based on limited examination of functional 
and molecular parameters. For example, it is not clear if ventricular-like cells represent left 
ventricle, right ventricle, epicardial or endocardial myocardium, or a “hybrid” cell type that does 
not correspond to any endogenous cell type. Mapping of in vitro–derived cell types to a cell atlas 
reference will be invaluable. To this end, a pilot effort should include a limited number of well-
characterized iPS cell lines with robust existing differentiation protocols used to derive broadly 
defined cardiac myocytes, endothelial cells, and smooth muscle cells for study and comparison. 
Draft Atlas v1.0 
In the first draft of the atlas, it should be sufficient to collect a relatively simple diversity of 
anatomical samples (similar regions of each atrium, each ventricle, and a coronary artery) across 
20 individuals from each of at least three geographically (and ideally ethnically) distinct sites; 
individuals from both genders, and ideally of defined and varied stages in human development. 
A rich data set can be provided by scRNA-Seq, snRNA-Seq and scATAC-Seq, and if possible, 
samples suitable for spatial visualization of gene expression should be obtained. Spatial 
visualization will be accomplished using multiplexed fluorescent in situ hybridization on 
histological sections. Human developmental samples would initially be limited to developmental 
stages largely determined by availability. Knowledge of cellular diversity and identity from this 
pilot atlas will guide the development of strategies to more comprehensively map the heart and 
to include more variety of anatomical sampling sites as well as more diverse populations, 
including patients with defined diseases.  
DEVELOPMENTAL BIOLOGY AND STEM CELLS 
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Cells can only arise from other cells. It is therefore critical to trace where cells come from, and to 
identify their more immature predecessors, to fully understand their nature. Furthermore, the 
lineage and fate relations of cells provide a key aspect of their identity, helping in the elusive 
definition and validation of cell types and transitions. Developmental biology and stem-cell 
biology concern themselves with these questions—how a fertilized egg develops into all the 
various cell types that make up the fully formed organism, and how tissue-specific stem cells 
ensure the maintenance and repair of adult tissues.  
Cell fate decisions during development and stem-cell differentiation are executed at the level of 
individual cells and impacted by signals from their microenvironment to the organismal level. 
Conventional, population-average gene expression measurement techniques therefore have only 
limited utility to identify the underlying molecular processes, and they cannot identify 
continuous trajectories that are found in such data sets. As a consequence, the developmental 
biology and stem-cell research communities have rapidly developed and adopted new single-cell 
profiling techniques167-170. These have the power to help create an atlas of progenitor cells that 
will be transformative for the developmental biology and stem-cell research communities. 
Why a stem-cell/developmental biology atlas? 
A comprehensive human single-cell gene expression atlas, complemented with corresponding 
mouse data, will serve as an important reference point for developmental biology and stem-cell 
research. These two research communities are uniquely placed to connect single-cell molecular 
profiles with single-cell biological function. This, in turn, will transform a broad spectrum of 
biomedical research with direct implications for human health, including tissue repair and 
regenerative medicine, developmental syndromes mostly affecting children, aging, degenerative 
diseases, and cancer. In particular, adult tissue stem cells, and the subversion of their function, 
play critical roles in major human pathologies ranging from aging to degenerative disease and 
cancer. Linking tissue stem-cell biologists with organ-specific pathologists will therefore also 
have significant long-term benefits when comparing healthy and diseased tissues. 
What are key considerations for a stem cell/developmental biology atlas? 
A unique aspect in a developmental atlas is the temporal aspect. This promises to transform static 
single-cell measurements into an appreciation of a cell’s current state, past history, and likely 
future, with wide-ranging impacts for both basic and translational research.  
Tissues and stem cells. The atlas should encompass both adult stem-cell processes in tissues 
such as brain, heart, liver, kidney, and pancreas (in partnership with the effort around the 
relevant tissue), in vitro systems, and developmental time courses (including the placenta). For 
example, a pilot project studying mouse gastrulation using scRNA-Seq is already producing 
exciting results171. This key stage of mammalian development provides an excellent test case for 
new single-cell technologies, since all major cell types are being formed and the whole embryo 
(up to 50,000 cells) can be profiled at single-cell resolution. Application of emerging 
technologies for spatial single-cell profiling, lineage reconstruction, and real-time analysis 
should therefore all be applied to this system. Adult human tissues with adult stem cells, such as 
the skin or mammary gland, are readily accessible and/or have powerful clonal stem-cell assays 
and, therefore, also represent ideal test cases, to be done in partnership with the effort around the 
relevant tissue. In particular, stem-cell biologists should become fully engaged in any planned 
organ-specific HCA pilots to ensure that cell-sampling strategies capture adult stem cells, which 
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can be exceedingly rare. Finally, placental samples from diverse patients should be collected for 
study. 
Spatiotemporal analysis. The ability to perform complex single-cell analysis in 3-D could also 
be applied to in vitro–cultured developmental samples, organ slices, or cells grown on tissue-
engineered scaffolds. This, in turn, could be exploited to perform time-course analysis of 
developmental or stem-cell differentiation processes at single-cell resolution (4D analysis). It 
could also provide novel avenues to investigate disease phenotypes from patient tissue or 
investigate the potential therapeutic effects of small molecules at both the molecular and cellular 
level.  
Draft Atlas v1.0 
Analysis of samples taken along developmental time courses will be important to reveal insights 
into human development in addition to those generated from adult tissues. Only some time points 
of human development can be obtained. Therefore, analysis in model organisms would be 
particularly complementary and could be potentially pursued. An initial Developmental Cell 
Atlas HCA project will focus on later stages of development and specific tissues (e.g., liver, 
kidney, and skin during human development are in a current pilot) and will  process 20 samples 
for each of these tissues across two geographical sites, with scRNA-Seq or snRNA-Seq, as well 
as spatially resolved methods. It can also include a Placental Cell Atlas of samples from research 
participants of diverse genetic backgrounds, ages, and disease states.  
PEDIATRIC 
It is important to include pediatric tissues in the HCA as one-quarter of the world’s population is 
14 years of age or younger. Physiologically, children are not just small adults: their developing 
bodies behave differently in both health and disease. As they grow and develop, their bodies 
change at the cellular level in ways that are poorly understood. For the children unfortunately 
suffering from disease, these changes impact not only how the disease manifests but also the 
efficacy of treatment. A better understanding of the bodies of children at the cellular level and 
the changes they undergo will be critical to developing better diagnostics and treatments for the 
diseases of childhood, which afflict the 2% of school-age children in the U.S. in fair or poor 
health.  
To support this vital area, a Pediatric Cell Atlas (PCA) will generate an age- and cell-based 
cellular-level atlas of pediatric tissues. The PCA will create comprehensive reference maps of 
cells from all pediatric tissues and systems, sourced across several childhood ages ranging from 
birth through adolescence. These references will provide the basis for both understanding the 
cellular basis of child health and development and for future studies in diagnosing, monitoring, 
and treating pediatric disease. While a full Pediatric Cell Atlas will have to mirror the effort of 
the entire HCA, a carefully planned draft can be generated to maximize early impact, leveraging 
the work in the main branch of HCA and partnering in each system.  
Why a Pediatric Cell Atlas? 
Disease and medical interventions manifest differently at the molecular level in children and 
adults. There are well-known age-related differences in response to anesthesia and various 
medications, and similar pediatric diseases differ when compared by developmental age. 
However, the physiological basis of many of these age-related differences is not well understood. 
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Any high-resolution study of pediatric disease would require comparison with similar studies of 
age-matched normal pediatric tissue — a resource that does not currently exist. 
There is currently little to no understanding of normal cellular function within pediatric tissues, 
how these associated cellular processes relate to the course of normal child development and 
maturation, or how the cellular composition, state, and function in pediatric tissue compares with 
that in adults. Contrasting children’s cells and tissues across ages through to adulthood will 
provide a lens into pediatric treatments and diseases. 
Thus, a PCA will provide a normal reference for studies on the origins of diseases affecting 
children; reveal physiological differences in tissues between adults and children; provide insight 
into growth and development of human tissues across ages that may also provide a perspective 
into organ regeneration; and provide insight into the basic biology of growth, development and 
maturation. 
What are key considerations for a Pediatric Cell Atlas? 
Sample procurement. The scale of the PCA endeavor will require contributions from large teams 
spanning clinical and basic research across multiple institutions and across a range of ages in all 
pediatric tissue systems. This can also be enhanced through partnerships with the organ-specific 
teams working on adult tissues. Most tissue will be sourced as incidental from surgeries. 
Although acquiring tissue from live donor sources is preferred, it is also possible to rapidly 
harvest samples at the time of organ donation and at autopsy from appropriate donors with the 
generosity of consenting families. It is reasonable to expect several dozen donors a year across 
the current PCA network.  
Systems. In principle, the PCA, mirroring the general HCA, would study all pediatric tissues, 
systems, and organs. However, that scope is excessive for an initial draft, and it does not 
leverage the knowledge and technical effort of the HCA in the corresponding adult tissue. Thus, 
a PCA pilot, followed by a first draft, will focus on four key areas: brain, skin, the immune 
system, and the colon. 
Draft atlas v1.0  
The first draft of the Pediatric Cell Atlas would focus on four key systems or tissues. In each 
system, 20 samples from each of at least three geographically (and ideally ethnically) distinct 
sites will be obtained; individuals from both genders; all pediatric — from birth to 18 years of 
age. For each sample, both scRNA-Seq and/or snRNA-Seq profiling will be performed, as well 
as spatial analysis for a subset of samples and auxiliary profiling as needed. 
A Pediatric Brain Cell Atlas will map variability in brain cells from unaffected brain tissue 
directly after the resection from 100 resective surgeries.  
A Pediatric Immune Cell Atlas will study children of different ethnic backgrounds, aged ~1 
through 18 years, as well as newborns and preterm infants, covering primary (bone marrow, 
thymus) and secondary lymphoid tissues (lymphatic fluid, blood), as well as other immune 
relevant tissues (lung, liver, intestine, skin). 
A Pediatric Epithelial Colon Cell Atlas will focus on colon mucosal biopsies as well as 
surgically resected tissue from normal and disease patients (e.g., IBD, Hirschsprung’s disease, 
immunodeficiency).  
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A Pediatric Skin Cell Atlas will study skin variability 
from surgical samples sourced from diverse pediatric 
patients aged 0 to 18. A series of skin disorders will 
also be available for profiling from surgical resections, 
including congenital melanocytic lesions, spitz nevi, 
epidermal nevi, vascular tumors, vascular 
malformations, hair follicles and scalp, and lipomas. 
ORGANOIDS 
Recent advances in 3-D culture technology allow 
pluripotent — ES cells, iPS cells — and adult human 
stem cells to exhibit their remarkable self-organizing 
properties172. When sequentially exposed to defined 
signaling molecules, both types of stem cells can be 
converted into organoids: small structures that reflect 
key properties of organs such as kidney, lung, gut, 
brain, or retina172 (Figure 16). Both healthy and 
disease tissues can be converted into organoids, and 
thus organoid technology can be applied to model 
human organ development, physiology and various 
human pathologies “in a dish,” including cancer 
“tumoroids” that complement animal experimentation 
as an increasingly faithful human model.  
Why an Organoid Cell Atlas? 
Organoids provide a useful tool for unraveling aspects of biology that have been difficult to 
pursue in model organisms or in living humans. For example, human brain organoids have 
recently been applied to document how Zika virus causes brain-development abnormalities173. In 
addition, organoids may hold the key to precision medicine: patient-derived organoids can be 
used as “avatars” to predict drug response in a personalized fashion — and are already being 
used for this purpose in cystic fibrosis174,175. The technology also holds great promise for 
regenerative medicine as an alternative to whole-organ transplantation.  
However, the current versions of organoids are still an abstraction of their in vivo counterparts. 
Thus, it is important to have a detailed knowledge of the composition of both the original tissue 
and the organoid to determine whether core cell types are missing or whether variations in 
organoid tissue across patients result because of biological or technical factors. In addition, 
accessory cells such as nerves, blood vessels, fibroblasts, and immune cells are absent in the 
organoid, and as a consequence, disease processes are only partially recapitulated. Similarly, the 
process of derivation may not be optimal because some of the factors secreted by the niche are 
missing. Yet it is anticipated that the potent self-organizing properties of organoids may extend 
beyond their current boundaries and allow the proper incorporation of additional cellular (or 
microbial) elements — which can be determined by developing organoid and matching-tissue 
atlases.  
An open-access Organoid Cell Atlas will be a road map for researchers taking on new organoid 
challenges, allow us to assessing the changes that occur in disease and use them for better 
disease modeling and drug screening. Because of the ease of production of organoids, and their 
Figure 16. The inside surface of an 
airway organoid. Airway organoids can 
be grown from biopsies but also from 
airway lavages of individuals of any age. 
They contain the  various cell types of the 
original tissue: ciliated cells (cilia are 
stained in green), basal cells, club cells etc. 
Blue: nuclei (DAPI). Red: actin. Image: 
Norman Sachs. 
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close resemblance to human organs in health and disease, an Organoids Cell Atlas holds great 
appeal for translational research and invites an almost immediate application into the clinic. 
What are key considerations for an organoid cell atlas? 
An Organoid Cell Atlas, collected in conjunction with the originating endogenous tissue, aims to 
yield an unprecedented understanding of the human body, provide faithful models of exceptional 
utility for research, and transform precision and regenerative medicine. In particular, it should 
allow us to definitively assess how faithful and reproducible current organoid technology is and 
to improve organoid-generating techniques iteratively in an informed, data- and model-driven, 
way — through better representation of the true human tissue composition and organization in 
the dish.  
Organoids and matching tissue. To create a Rosetta Stone of the cellular composition of a key 
set of organoids, along with matching originating tissue, orgnaoids will be generated from tissue 
collected in coordination with the relevant HCA effort in that tissue. Each initiating human tissue 
specimen will be partitioned in two, and one portion will be analyzed immediately, using both 
single-cell and spatial genomics methods to determine its full endogenous composition. In 
parallel, the other portion will be used to generate matching organoids, and those organoids will 
be subsequently analyzed with the same techniques.   
Comparison. Computational algorithms will be used to compare the source tissue to its organoid 
model, for cellular composition, cell states, and spatial organization, thus determining in a 
precise and comprehensive way the extent to which the model faithfully recapitulates the human. 
(In cases initiated from iPS cells, such as brain organoids, the comparison will be to the closest 
possible specimen source.)  
Optimization. Through the comparison, opportunities for optimization will be identified: the 
process will then be iterated, to generate better organoids with more comprehensive composition 
of cell populations (e.g., sub-types of epithelial cell in the gut; sub-types of neurons in brain), the 
effective co-culture of accessory cell type (e.g., addition of immune cells), or the introduction of 
new secreted niche factors for more efficient and reproducible organoid generation (e.g., based 
on secreted factors expressed by stromal cells in the endogenous tissue). 
Draft Atlas v1.0 
A draft atlas should sample each of the currently used experimental organoids and their 
corresponding tissues (which should be coordinated with the appropriate organ cell atlas). These 
include central nervous system, stomach, lung and thyroid, small intestine, liver, and kidney 
organoids grown from pluripotent stem cells, as well as small intestine and colon, stomach, liver, 
pancreas, and prostate organoids from adult stem cells. A key focus will be on organoid 
variability — across starting specimens, across replicates from the same starting specimens, and 
across varying protocols for derivation. For each organoid category, 20 healthy specimens for 
deriving organoids should be sampled for each tissue from each of at least three geographically 
(and ideally ethnically) distinct sites; individuals from both genders; all adults (20 to 55 years of 
age under baseline), and each should be derived into organoids at least in triplicate. Both single-
cell profiling and spatial methods will be applied to verify that these organoid-generating 
protocols create organoids that are similar in cellular and spatial composition to each other and to 










This section will be added in a later draft. First, however, a workshop is being 
convened to discuss the goals and best approaches for building atlases of model 
organisms. 
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7. THE HCA CONSORTIUM  
The HCA builds on a historical legacy of large-scale scientific projects involving many 
international participants, and consequently can draw inspiration and knowledge from these 
projects while developing an organizational and governance model unique to its challenge (Box 
2). In particular, the consortium must engage a broad range of experts across its four pillars — 
the collaborative Biological Networks, Technology Forum, Data Coordination Platform, and 
Analysis Garden — and each pillar must engage in deeply collaborative, hands-on work to build 
the atlas. The consortium is also responsible for governance of the Data Coordination Platform 
and for key decisions and policies, including those related to the data-collection scheme, 
common coordinate framework (CCF), and data release; for convening the community in 
meetings and other forums; and for representation and negotiation around the atlas effort. To 
enable these activities, we have established a robust organizational and governance structure, led 
by an Organizing Committee, that constitutes Working Groups and delegates organization, 





Box 2: Key features of past transformative projects to generate biological resources. 
 
Upon reflection on past projects to generate biological resources that have proven 
transformative in biology in the test of time, the following features emerged: 
  A comprehensive approach to a fundamental biological unit that can propel progress in thousands 
of laboratories on diverse problems 
 An audacious, but potentially tractable, scale 
 A technology landscape with rapidly decreasing costs and rapidly advancing capabilities 
 Intellectual flexibility in the community that allows goals to evolve 
 Commitment to quality control, with rigorous focus on quality and full transparency 
 International collaboration 
 A strong leadership group that is chosen and led by scientists 
 Both larger centers and smaller groups contribute according to strengths and capacity 
 Development of a data-sharing infrastructure  
 Regular scientific meetings to bring the community together 
 Strong commitment to data sharing, with associated technical solutions 
 Clear, inspiring communications for scientists, funders, and the public 
 Attention to ethical issues, such as global equity and privacy 
 Supportive funders  
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GOVERNANCE AND ORGANIZATION 
HCA GOVERNANCE1 
Organizing Committee 
The HCA is steered and governed by an Organizing Committee (OC), which is the decision-
making body of the HCA.  
OC responsibilities. The responsibilities of the OC include convening the community through 
regular meetings, workshops and jamborees; coordinating and authoring key documents; 
defining scientific values and ethical principles; defining and upholding processes including QC 
standards and analytic standards; governing the Data Coordination Platform (DCP) and Common 
Coordinate Framework (CCF); coordinating HCA work products; communicating on behalf of 
HCA; representing and negotiating on behalf of the HCA with other entities and organizations; 
and polling the HCA community at regular intervals for input on issues, including performance 
of the OC. The OC does not generate data and is not a direct grantee or grantor for such 
purposes.  
OC membership. The OC will consist of up to ~35 scientists. Considerations for new OC 
members include expertise, geographical representation, and diversity. Additional members are 
added to the OC by majority vote of the OC. The OC will periodically seek input from the HCA 
community on the scientific scope of its members, performance, and potential new members. 
The current (founding) OC consists of 27 scientists from 10 countries and diverse areas of 
expertise (Table 2). 
Terms. All members will have five-year terms, which can be renewed once by a majority vote of 
the OC.  
Co-chairs. The OC is led by two co-chairs, who are members of the OC. The co-chairs have 
five-year terms, which can be renewed once by a majority vote of the OC.  
Executive Committee. The OC has an Executive Committee that is responsible for performing 
routine tasks between OC meetings, preparing meeting agendas, and providing guidance to the 
executive offices. The EC includes the two co-chairs and five additional OC members, with two-
year terms, which can be renewed once by a majority vote of the OC.  
Executive Offices. The HCA is coordinated by Executive Offices (EOs), which staff the OC in 
performance of its duties. The OC established four Eos, which are located in the U.K. (Sanger), 
U.S. (Broad Institute), European Union (Karolinska Institute), and Asia (RIKEN). The EOs’ 
responsibilities include meeting organization; community coordination; coordination of writing 
of community outputs (e.g., reviews, commentaries, white papers); coordination of interactions 
with companies; supporting interaction with funders; triage of press inquiries; triage of 
community inquiries; registry and tracking of projects; and registry and tracking of members. 
Each EO will also take the lead on some general duties, as well as regional activities. 
Quorum. A quorum for decision making by the OC will constitute (1) a majority of OC 
members at an in-person meeting that has been announced to the OC at least one month in 
advance, or (2) at least 75% of OC members responding by email to a proposed action that has 
been circulated to the OC. 
                                                        
1 The text is the formal governance of the HCA, as developed by its Organizing Committee, and ratified by it on 
September 19, 2017. 
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OC Member Affiliation 
Ido Amit Weizmann Institute of Science, Israel 
Gary Bader University of Toronto, Canada 
Peter Campbell Wellcome Trust Sanger Institute, U.K. 
Piero Carninci Riken, Japan 
Hans Clevers Hubrecht Institute, Netherlands 
Roland Eils German Cancer Research Center; University of Heidelberg, Germany 
Nir Hacohen Broad Institute, MGH, USA 
Arnold Kriegstein University of California, San Francisco, USA 
Eric Lander Broad Institute, USA 
Sten Linnarsson Karolinska Institutet, Sweden 
Partha Majumdar National Institute of Biomedical Genomics, India 
Miriam Merad Mount Sinai, USA 
Shalin Naik Walter + Eliza Hall Institute of Medical Research, Australia 
Garry Nolan Stanford University, USA 
Dana Pe’er Memorial Sloan Kettering Cancer Institute, USA 
Chris Ponting Edinburgh University, U.K. 
Steve Quake Stanford University / Chan Zuckerberg Biohub, USA 
Nikolaus Rajewsky Helmholtz Association, Germany 
Aviv Regev, Co-Chair Broad Institute, MIT, HHMI, USA 
Ehud Shapiro Weizmann Institute of Science, Israel 
Jay Shin Riken, Japan 
Michael Stratton Wellcome Trust Sanger Institute, U.K. 
Henk Stunnenberg Radboud University, Netherlands 
Sarah Teichmann, Co-Chair Wellcome Trust Sanger Institute, U.K. 
Alexander Van Oudenaarden Hubrecht Institute, Netherlands 
Jonathan Weissman  University of California, San Francisco, USA 
Barbara Wold California Institute of Technology, USA 
Table 2. HCA Organizing Committee members. Current co-chairs are noted. (EC members have not yet been 
chosen by the OC.) 
Working Groups 
The OC establishes Working Groups and mandates them to take on specific key areas. At the 
moment, these include the Analysis Working Group (AWG), the Meta Data Working Group 
(MDWG), the Common Coordinate Framework Working Group (CCFWG), the Standards and 
Technology Working Group (STWG), and the Ethics Working Group (EWG). Each Working 
Group has two co-chairs; one co-chair is a member of the OC and the other co-chair is external 
to the OC. The Working Group co-chairs together select the other members of the Working 
Group. Working Group members will have three–year terms, which can be renewed once by a 
majority vote of the OC. 
The OC governs the Data Coordination Platform (DCP), which includes making all policy 
decisions concerning the DCP; approving the overall plan for the DCP; and ensuring the plan’s 
successful execution by the major developers of the DCP. The OC will establish and appoint a 
DCP Governance Group (DCPGG), which will report to the OC, to oversee the 
implementation of these policies, by providing guidance and making decisions concerning 
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certain key topics, including definition of data manifest; official analysis pipelines; required 
metadata to reflect data collection standards; common coordinates framework; and any formal 
“release portal.” The DCPGG will be led by two OC members; will include at least one member 
from each of the AWG, MDWG, and CCFWG; and will include at least three additional experts 
from the community. 
The OC will convene, on a quarterly basis, a DCP Coordination Meeting — involving the 
DCPGG, the major developers of the DCP, and others as appropriate — to review progress and 
assist the OC in developing policy.  
HCA Meetings 
The HCA OC convenes and advertises meetings, workshops, and jamborees.  
HCA Members 
Any individual may become an HCA Member by registering at the HCA Member Registry and 
agreeing to abide by the principles of HCA, as stated in the HCA White Paper, especially 
including its ethical standards. HCA members are invited to attend HCA community-wide 
meetings and 
discussions; join the 
HCA Slack channel; 
be on mailing lists; 
and so on. 
In addition, an HCA 
member who is a 
participant in an HCA 
project (defined 
below) or a member 
of an OC-designated 
HCA group will be 
designated as an 
HCA Collaborating 
Member. Certain 







Any scientific project related to systematic biological characterization at single-cell resolution 
may become an HCA Project by registering in the HCA Project Registry. The registry will 
include a description of the project, its strategy, and its investigators. By registering a project, its 
investigators affirm their commitment to abide by HCA standards, including the Information 
Release Policy (below). Projects will fall into three categories: 
1. HCA Participating Projects. Any project (including those focused on data generation, 
experimental method development, or computational methods development) may be an HCA 
Participating Project, simply by registering.  
Figure 17. Organization of the Human Cell Atlas. 
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2. HCA Network Projects. An HCA Network Project is an HCA Participating Project that 
commits to liaise with other network participants. 
3. HCA Flagship Projects. An HCA Flagship Project is an HCA Network Project that is aimed 
a delivering a component of the HCA Draft Atlas Plan 1.0; adheres to the overall framework 
of Plan (e.g., being comprehensive, adhering to technology standards, engaging domain 
expertise, having available preliminary data, and having substantial impact); and involves 
funding of at least 20 M Euros over its duration. 
Information Release Policy  
All HCA Projects will commit to ensuring that data developed by or for the project will be (i) 
deposited in the DCP through regular data release, and (ii) made available in an open access 
manner to the maximal extent allowed by ethics (e.g., some metadata may be restricted). The 
DCP will tag the data to make it citable. Users will be free to use the data as they wish, apart 
from the obligation to cite the generators of the data and to not attempt to identify or contact 
individual participants contributing samples. The OC will work with journals to define 
opportunities for key data collection and analysis papers.  
In addition, all HCA Projects will commit to publicly releasing all experimental and 
computational methods used for data generation and/or analysis and source code for software 
developed by or for the project. 
FUNDERS’ FORUM  
The HCA works in close partnership with committed and visionary science funders across the 
globe. To provide funders with a forum for discussion without blurring boundaries with potential 
future grantees, the HCA has arranged for a Funders’ Forum. The forum’s goal is to create an 
organization for interested funders. It is reasonable to expect that at some point in the future, an 
investment in HCA will be required to join the forum, but we believe such restrictions are 
premature at this time. Ultimately, we expect the funders to define their roles and the forum 
independently. The HCA OC has set up and administers an email list to facilitate discussion 
among funders and introduces potential funders to this community. Critically, however, the HCA 
Executive Offices cannot access any of these emails. 
The Funders’ Forum consists only of funders, is distinct from the OC, and meets separately. 
Nevertheless, the forum coordinates with the HCA leadership and, ideally, meets with the 
leadership regularly.  
INTERACTIONS WITH OTHER CONSORTIA 
The HCA is one in a series of major consortium efforts going back to the Human Genome 
Project, and it builds on the scientific and organizational foundations laid by those previous 
consortia. We are committed to learn from past consortia and interact with active ones to gain 
inspiration and knowledge about the best ways to achieve success and to find new opportunities 
for collaboration.  
Several members of the OC have experience as members or advisors of other large consortia, 
including the International Cancer Genome Consortium (Bader, Campbell, Majumdar, Stratton), 
FANTOM (Carninci, Clevers, Shin), 1000 Genomes (Lander), ENCODE/ModENCODE (Wold, 
Pe’er), ImmGen (Merad and Regev), BLUEPRINT (Stunnenberg), and the Human Genome 
Project (Lander).  
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We have taken inspiration and used practical experiences from existing consortium projects in 
specific areas, such as the Data Coordination Platform, sample procurement and donor consent, 
and building networks of biological collaborators. For example, planning the Data Coordination 
Platform has benefitted from experiences in building the platform and portals for the Human 
Genome Project, the 1000 Genomes Project, the Cancer Genome Atlas, the International Cancer 
Genome Consortium , and the NCI Cloud Pilot, among others; procedures for tissue acquisition 
are based on the experience and pipelines of the GTEx project and ENCODE and the lessons 
learned in human genetics efforts; the experiences and participants of the Immgen consortium 
and the BRAIN Initiative have helped us shape and execute plans for the engagement of 
biological communities; and lessons from consortia spanning from the Human Genome Project 
to the Global Alliance for Genomics and Health (GA4GH) are helping shape legal and ethical 
considerations around data sharing.  
More generally, past experience has informed our commitment to technology development, 
intellectual flexibility, quality control, international collaboration, strong governance, data 
sharing, clear communication, high ethical standards, and the intention to work collaboratively 
with supportive funding organizations. Mechanisms developed to ensure multiple opportunities 
to join the project and to ensure transparency are key as well (Box 2).  
Finally, we have already identified several consortia that are complementary to HCA and where 
there is clear mutual benefit to coordination. For example, for the auxiliary profiles in the 
cellular branch, we hope to join forces with consortia like ENCODE, the 4D Nucleome or the 
Human Protein Atlas. Both 4D Nucleome and the Human Protein Atlas consortia have expressed 
similar enthusiasm for complementary partnership. We will also interface with organ- or disease-
specific programs, such as the Tumor Cell Atlas from the Cancer Moonshot and initiatives in the 
profiling of tissues such as kidney and brain. In particular, the HCA has put together a proposal 
to be a GA4GH driver project (through the HCA DCP and DCP GG) and is exploring 
opportunities to leverage and extend the HCA DCP in disease-specific projects (e.g., Kidney 
Precision Medicine Program). This gives us a wonderful opportunity to engage a wider 
community of scientists and expert communities and to integrate preexisting data into the 
construction of the atlas. 
PARTICIPATION AND REACH  
Establishing equity in the HCA. Throughout history, geographical atlases were largely 
developed to serve global power centers rather than the general good. Conversely, in an effort to 
maximize impact, the HCA should strive for equity. This means distributing power, ensuring 
comprehensive coverage of samples relevant to all of humanity, and empowering the global 
research community, while respecting local laws, mores, beliefs, and traditions.  
A fundamental question then becomes: how can the HCA best achieve these goals? As a start, it 
can learn from previous efforts that have faced similar challenges. For example, genome-wide 
association studies (GWAS) have been used to identify thousands of variants associated with 
hundreds of phenotypes, improving our biological understanding of a multitude of traits and 
diseases. Yet many GWAS have focused largely on individuals of European ancestry, raising 
questions about how generalizable their findings are. Notably, genetic diversity is only one set of 
factors we need to consider; experiential and environmental diversity could also have substantial 
effects on cells. Broadening ethnic and experiential representation in the HCA (and generally in 
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biomedical studies) must therefore be a priority to ensure that the biological insights gained will 
be broadly applicable to diverse human populations.  
One way to accomplish this is to sample from different locations. For example, the 1000 
Genomes Project and the Simons Genome Diversity Project used 140 different populations from 
diverse geographic settings as a proxy for genetic diversity. This revealed that human genetic 
diversity could be grouped into five major continental clusters — Sub-Saharan Africans, 
Oceanians, East Asians, Native Americans, and West Eurasians — with substantial sub-structure 
within each, suggesting that representative sampling may be sufficient to enable the generation 
of a relatively thorough draft atlas. 
When identifying appropriate samples and deciding how and where to profile them, the HCA 
should aim to foster equity in selection and community engagement (scientific and otherwise), 
yet strive to maintain uniformity and rigor. With somewhat similar goals in mind, the 
International Genome Sample Resource (IGSR) was established at the EMBL in 2015 to ensure 
the ongoing utility and relevance of the 1000 Genomes Project, while further extending it in 
existing populations and expanding it to new ones.  
To meet similar goals, the HCA’s design should be egalitarian and comprehensive on multiple 
levels.  
 Compositionally, it should include variety along axes of gender, age, ethnicity, environment, 
and cultural tradition, as well as, in some cases, disease or disease susceptibility. This would 
enable characterization of each factor that may affect the molecular profiles of cells and be 
representative of humanity.  
 Organizationally, it should be inclusive of all countries and researchers across educational 
backgrounds and stages of training. This will ensure continuity and comprehensive, informed 
coverage, and allow for careful consideration of potential regional barriers to success.  
 Educationally, it should strive to touch all sectors of society through a combination of 
training programs, workshops, conferences, outreach, and on-site dissemination initiatives.  
Compositional considerations. To provide the greatest utility to humanity, the HCA should 
itself be representative of it. Genders must be considered because sex impacts cells in both sex-
specific tissues and across the body. Diverse ethnicities must be profiled to understand how 
underlying genetic diversity informs the phenotypic heterogeneity of different cellular subsets. 
Multiple environments must be surveyed to understand how factors external to the body — such 
as temperature, altitude, pollution, allergens, and microorganisms — influence cells. A range of 
cultures must be sampled to understand how lifestyle factors, such as diet and nutrition, alter 
cellular phenotypes. Finally, the target tissues of globally prevalent diseases must be 
characterized to provide essential references for diagnosis and treatment. 
Given limited financial, technical, and human resources, how can the HCA ensure representative 
sampling? One path forward might be to profile a minimum of five populations from each of the 
broader geographic regions defined by the 1000 Genomes Project. However, such a top-down 
approach could undermine the overall aim of equity. A different strategy might be to empower 
distributed generation of the HCA, allowing regional partners, working with the HCA’s OC, to 
establish local priorities and performance goals. Together, they would determine the right 
technical and organizational controls — including the establishment of local centers of 
excellence to enable rapid on-site processing using standardized protocols, know-how, best 
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practices, and quality-control standards developed by the HCA — as well as engage local 
support structures (government, hospitals, philanthropy, etc.) to ease sample collection. Although 
such decentralization might make it more challenging to maintain the level of uniformity and 
rigor needed for HCA sample processing, it will ensure scientific equity, enhance standards, and 
empower scientists and communities globally. The HCA should establish the infrastructure 
(physical, experimental, and computational) and SWAT teams necessary to support such a 
distributed approach. Moreover, HCA scientists and engineers from the Technical Forum should 
work with field deployment in mind as they innovate, modify, and optimize techniques for 
diverse settings, expanding their reach in the scientific community. This would ultimately 
improve data quality, all while developing and leveraging local scientific talent, establishing 
essential resources, and promoting the universal relevance of the HCA. 
To make local profiling possible, all engaged communities must establish experimental 
infrastructure; develop controls that take into account the potential computational challenges of 
distributed sample collection (a topic of current focus for the AWG; Section 4); design and test 
methods for processing; and carry out hands-on training programs and workshops to educate 
engaged participants in preferred methods. To kick-start such an effort, and design pilots to 
inform how to link broad profiling to more targeted efforts, an initial planning meeting should be 
convened by the OC in the coming year, similar to those conducted for other aspects 
(technologies, computation, CCF. and model organisms). 
Organizational considerations. Equity should not only be evident in the samples analyzed by 
the HCA but also in the scientists carrying out the research. This means including, from the 
inception of the project, individuals from many countries, disciplines, educational backgrounds, 
and stages of training. These individuals must also represent the world’s countries, ethnicities, 
environments, and cultural traditions. The OC already has scientists from four continents — 
North America, Europe, Asia, and Australia — and the HCA community has scientists from all 
continents. We are working to better engage more scientists from Latin America and Africa. 
A key starting point for engagement — as has been the HCA approach for every community — 
is the first planning meeting. This would include participants across the communities that the 
HCA is meant to engage. To judiciously consider the local complexities associated with a global 
atlas, each geographical location should have representatives with backgrounds in science, law, 
government, business, and social sciences, and from diverse career stages. While broad inclusion 
could lead to a prohibitively large membership, a limited hierarchy could enable collective 
decision-making for several of the major outstanding questions, such as where and when to train 
those involved, how to perform sample collection, how to prioritize processing, where it should 
be performed, and more. Properly addressing these issues will require substantial outreach to 
educate, and be educated by, the global community on the ultimate needs and goals of the HCA. 
In the collection phase, the OC and its working groups will partner with each community to 
develop and deploy best practices in experimental design and protocols and in computational 
analysis, and to disseminate them through portals, educational workshops and SWAT teams. The 
DCP and related portals will be important for sharing data and helping facilitate global 
collaborations.   
Educational considerations. To establish equity, global buy-in to the HCA must be ensured. 
This will entail developing training programs, workshops, conferences, and outreach initiatives 
that captivate and inspire while also guiding overall thought processes. To facilitate global 
performance, training programs should empower local generation of high-quality data that can be 
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incorporated into the HCA, including in regions and situations where sample transport is not 
feasible for social, legal, or safety reasons. Similarly, to inspire relevant technological 
innovations across professions and stages — essential for global performance, especially in 
resource-poor settings — workshops will be convened to identify and tackle existing bottlenecks 
and difficulties. To keep a critical eye on progress, conferences to present progress should occur 
at locations around the globe and have financial aid available to ensure diverse participation. 
Finally, to build public trust and ease the substantial legal and ethical complications associated 
with equitable engagement and atlas composition, the HCA will need outreach initiatives that 
effectively educate the public using all available media. 
Disseminating and refining the wants and hopes of the HCA requires the formulation and 
effective sharing of materials to engender support across sectors. Hence, comprehensive 
educational plans should be established. These should involve creating globally accessible 
outreach materials that speak to people from all countries and backgrounds, perhaps by relying 
on the existing know-how of online education platforms. In parallel, the technologists and 
computational biologists involved in the HCA should help design training programs, workshops, 
jamborees, and conferences. Hosting responsibilities for these meetings should also rotate 
through the regional bodies to ensure equity, with additional centralized support. 
ETHICS, LEGAL, AND REGULATORY PRINCIPLES 
Ethics and regulatory principles. Rapid, international and open data sharing is a key tenet of 
the HCA. As with other large-scale community resources that promise broad utility, the atlas will 
require a data-sharing framework. Previous approaches include the Bermuda, Fort Lauderdale, 
and Toronto Statement Principles (2009)176 that ensure explicit, global cooperation between 
funding agencies, data producers, and data users. In these frameworks, data is rapidly made 
available and usable, proper incentives for data production are maintained, and the data’s 
generation and use respect and protect participants. As noted in the relevant section of the HCA 
Governance (Appendix I): “All HCA Projects will commit to ensuring that data developed by or 
for the Project will be (i) deposited in the DCP through regular data release, and (ii) made 
available in an open access manner to the maximal extent allowed by law and ethics (e.g., access 
to some metadata may be restricted). The DCP will tag the data to make it citable. Users will be 
free to use the data as they wish, apart from the obligation to cite the generators of the data and 
to not attempt to identify or contact individual participants who contributed samples. The OC 
will work with journals to define opportunities for key data collection and analysis papers.” 
A guide for achieving these goals can be found in the Framework for Responsible Sharing of 
Genomic and Health Related Data (http://genomicsandhealth.org/about-the-global-alliance/key-
documents/framework-responsible-sharing-genomic-and-health-related-data) established by the 
Global Alliance for Genomics and Health (GA4GH), an international coalition with a mission to 
promote data sharing and to improve human health. The framework emphasizes the importance 
of maximizing the availability and re-use of data so future patients can benefit from scientific 
progress, while minimizing risks to participant privacy and recognizing the contributions of 
researchers. 
Ideally, any and all data in the atlas will be immediately and publically accessible to the 
international community, with the only limit on use being the creativity of biologists, data 
scientists, and engaged members of the public. To achieve this, the HCA OC will negotiate 
varying regulatory constraints governing the collection, use, and international sharing of samples 
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and data, especially those that can be linked to identifiable individuals177. Tissue acquisition 
efforts are already focused on appropriately consented samples that maximize the availability of 
open-access data. Nevertheless, specific constraints can arise, both in the context of living 
research participants and in diverse jurisdictions. 
In cases when fully open consent cannot be achieved, steps will be taken to remove identifiers. 
Anonymization, however, is not straightforward for high-throughput molecular data, and it may 
be desirable to maintain a link with living research participants over time to collect more data 
(we do not generally anticipate returning results to research participants). A set of guidelines for 
deceased donors should be considered and can learn from experience learned from the GTEx 
project. Where necessary, sensitive samples or data will be sequestered with appropriate access-
controlled portions of the DCP, or locally (if required), while enabling open sharing of less 
sensitive data178. Where safeguards are needed, streamlined access processes will be in place to 
ensure qualified, trustworthy researchers can rapidly access data for legitimate research uses 
without jeopardizing data security179. 
In certain jurisdictions, researchers contributing to the atlas may need to seek either the 
permission of individuals for international sharing or an ethics waiver 
(https://genomicsandhealth.org/consent-policy-read-online). When privacy risks are negligible, 
researchers should ideally seek open consent from participants to enable unrestricted access and 
reuse by the international community. Where privacy risks are slight, researchers should instead 
seek broad consent — which is increasingly recognized in international statements and national 
regulatory frameworks — to future sharing and use, subject to ongoing and transparent 
governance mechanisms (https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-
EthicalGuidelines.pdf)180. Specific consent requirements limiting the domains of use may still 
pose a barrier to data sharing in some countries177. 
Because assembling the HCA will rely on emerging technologies such as scRNA-Seq and 
multiplex spatial approaches, unprecedented amounts and new varieties of molecular data about 
individuals — supported by metadata to clarify data quality and provenance — will need to be 
shared. It will be necessary to continue to assess privacy risks to ensure that data sharing will not 
expose participants to undue re-identification risks and harmful disclosure or misuse of sensitive 
health information. Security safeguards should be proportionate to the risk of data breach or 
misuse (https://genomicsandhealth.org/privacy-and-security-policy-read-online). Existing 
community monitoring and compliance infrastructure should be leveraged, and explicit 
responses prepared for intentional or malicious misuse (e.g., revocation of access or reporting to 
host institution) (https://genomicsandhealth.org/working-groups/our-work/accountability-policy). 
Communicating to research ethics committees and to participants the purposes, benefits, and 
risks of sharing these data will also be key. The approaches applied in many large-scale 
genomics projects show that solutions can be put in place to address each of these items. 
Just as different sample preparation techniques or analysis platforms undermine data 
interoperability, use of different ethical and legal tools can create confusing or contradictory 
thickets of access and use conditions, leading to a lack of “legal” interoperability 
(http://www.codata.org/uploads/Legal%20Interoperability%20Principles%20and%20Implement
ation%20Guidelines_Final2.pdf). Harmonizing consent, privacy, and security practices, access 
policies, and terms of use as much as possible across the HCA will help ensure that data sharing 
proceeds in an effective and responsible manner. 
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PUBLIC ENGAGEMENT 
Public engagement throughout the course of the research will be essential to achieve the goals of 
the HCA. The research will better thrive with public support and involvement, and patients and 
the public should be engaged in all aspects of the HCA in a sustained manner. Thus, the HCA 
community must empower an ongoing dialogue between researchers, funders, patients, and the 
public. 
Because the HCA will be built over several years it will require a public engagement strategy 
that evolves with the project, taking stakeholders and future beneficiaries on a journey of 
discovery and debate as the research progresses. As a global collaboration, the HCA will also 
require public engagement activities that are designed to cater to diverse audiences and are 
sensitive to cultural differences (for example, science popularization approaches that focus on 
debate are more common in the U.S. and U.K. than in other countries likely to be involved in the 
project). Importantly, the public engagement strategy will target a wide range of constituents, 
including generally interested members of the public, citizen-scientists, schoolchildren, and 
possible research participants.  
Public engagement activities will take a wide range of forms and methods — from traditional 
didactic formats to immersive citizen-science approaches contributing to the research itself. In 
addition to traditional outreach strategies (such as press campaigns) and digital resources, such as 
the HCA website (http://www.humancellatlas.org) and YouTube channel 
(https://www.youtube.com/channel/UCK7wBjw53JdpLYBCvzHosWA) and streaming of HCA 
meetings), or yourgenome (http://www.yourgenome.org), ideas might include:  
 involving the public in the research through citizen-science initiatives — for example, 
working with partners such as Institute for Research in Schools (U.K.) 
(http://www.researchinschools.org);  
 using the open access, open source data platform and its ancillary portals to “gamify” 
analysis tasks (e.g., image segmentation and interpretation) or to “crowd-source” 
software solutions through open challenges;  
 generating a data portal for the general public to facilitate exploration, including with 
emerging Virtual Reality applications; 
 featuring the HCA at festivals, such as the Cambridge Science Festival in the U.K. 
(http://www.sciencefestival.cam.ac.uk) and the Cambridge Science Festival in the USA 
(http://www.cambridgesciencefestival.org), and in exhibition and event programs in 
partner localities. 
 establishing artist residencies and similar partnerships with members of the creative 
industries; and  
 developing science expos and projects to engage high school students with the HCA, 
especially in data analysis. 
For any project of the magnitude and ambition of the HCA, the general public must be 
considered a target stakeholder community. An important aspect is making the fundamental 
principles and motivations of the project as accessible as possible, both via major media outlets 
and through social media. The name of the HCA itself should be helpful: The term atlas creates 
an instant image of the scale and objectives of the project; in the way that a reader can look with 
detail beyond continents and countries into individual regions and towns, the HCA will enable 
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scientists to visualize and characterize individual cell types within different organs and tissues of 
the body. A portal to HCA data for the general public that uses a “Google Maps” approach to 
free exploration would help forge this connection. 
That said, the science and approaches of the HCA are complex and sometimes may evoke 
emotive responses, so describing it and its impact clearly in a way that is compelling to 
nonscientists will be an important challenge. To succeed at this, the project’s researchers will 
need to be comfortable engaging with the public. An important part of the HCA strategy should, 
therefore, be to support and empower researchers to build confidence and communication skills.  
Of course, there will be many other, more specific target audiences for HCA engagement efforts. 
These include:  
 Patient advocacy groups. Although the HCA will be made up of basic research, the data 
will ultimately translate into new ways of diagnosing and treating disease. For that 
reason, we must ensure that the findings are communicated to these groups correctly, 
without hype, and that public expectations are appropriately managed. Ongoing dialogue 
and discussion through a suite of public engagement activities will enable us to gauge 
potential areas of concern or misconception.  
 Teachers and students. Groundbreaking research from the HCA will take our 
understanding of cell biology to a new level. It will also present an opportunity to 
implement new approaches to teaching the basic concepts of cell biology and shaping 
curricula to reflect this, from K–12 to well beyond. Teachers can be further engaged to 
communicate to others about HCA. 
 Potential research participants and donors. The engagement team should be involved in 
developing strategies for how to sympathetically and effectively approach dialogue with 
potential tissue donors and their families, whose fully informed consent will be essential 
for key components of the HCA. Working with patient advocacy groups, such 
relationships can leverage new approaches for direct-to-patient interactions, especially in 
specific diseases, as is increasingly occurring in cancer (https://www.mbcproject.org/) 





The HCA will require financial support from many partners. Worldwide, this will involve 
collaborations with governmental agencies; partnerships with philanthropic foundations, 
organizations, and individuals; and collaborations with technology and pharmaceutical 
companies that can contribute equipment, expertise, or financial resources in support of HCA 
data collection, analysis, storage, and distribution (Box 3). 
 
Funding partners 
The HCA will be internationally supported by science funders across government agencies, 
foundations, philanthropies, and the pharmaceutical, biotechnology, and technology industry. 
Government support. National science funding agencies in countries where HCA researchers 
work have funding mechanisms that can be accessed to support various stages of the HCA effort. 
Box 3. Opportunities to fund the HCA. 
Each of the four pillars of the Human Cell Atlas, and its overall organizational and training 
activities, requires financial support to meet its respective goals in areas such as: 
 data generation in each organ, system, and tissue, including support of a full flagship 
project for each tissue; 
 tissue acquisition pipelines from healthy research participants, organ donors, and 
postmortem;development of the Data Coordination Platform, from developing, 
revising, and maintaining the software through supporting data portals, data storage, 
and computational resources; 
 technology development, including invention of new techniques, rigorous 
comparison, and benchmarking; 
 technology dissemination and training, from necessary infrastructure to training on 
site by experienced SWAT teams of scientists (such support will be particularly 
critical for tissue handling and for spatial methods);  
 computational methods development, from invention of new methods through their 
comparison and benchmarking across labs and in jamborees;  
 computational methods dissemination and training, both through development of 
hardened and scaled software and portals and by hands-on and online training; 
 development and testing of the Common Coordinates Framework;  
 scientific planning and organization, including planning workshops and jamborees to 
develop and test aspects of the atlas, tracking progress across our many research sites 
and projects, and connecting and onboarding members of the community; 
 convening HCA meetings, to bring together, educate, update, inspire, and elicit 
expertise from the HCA community, and to draft and refine designs and plans; and 
 engaging the broader scientific community, the public, and the media. 
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In the U.S., for example, these include, among others, the NIH Common Fund, the NIH BRAIN 
Initiative, the National Cancer Institute, including the Cancer Moonshot, and institutes related to 
individual organs (e.g., the National Institute of Allergy and Infectious Diseases for the immune 
system and the National Institute of Diabetes and Digestive and Kidney Diseases for the kidney). 
Importantly, early grants have already been awarded by the NIH through pre-existing 
mechanisms for research in several tissues, in both human (e.g., colon) and mouse (e.g., through 
the BRAIN initiative); additional applications are pending. The NIH HubMAP program and the 
NCI Cancer Moonshot (through the Tumor Cell Atlas Network program) are important and 
engaged partners in the HCA. Other national and international agencies also have mechanisms to 
support research leading to the construction of the HCA, and several have expressed interest. 
These include the European Union through its H2020 funding mechanism and the German 
Federal Ministry of Education and Research, as well as the Japanese, Australian, and Indian 
governments.  
Philanthropy. The HCA has benefitted from generous support of a number of philanthropic 
foundations that support science. The planning process — especially the scientific meetings and 
workshops that kick-started HCA — has been funded by both individual philanthropists and by 
foundations including (in chronological order) by an anonymous donor (U.S.), the Wellcome 
Trust (U.K.), the Chan Zuckerberg Initiative (U.S.), the Kavli Foundation (U.S.), and the 
Helmsley Charitable Trust (U.S.). The initial development of the DCP is funded by the Chan 
Zuckerberg Initiative, which has recently funded 38 grants for technical method development 
(https://chanzuckerberg.com/human-cell-atlas/collaborators) and another RFA has closed for 
computational method development and has supported the first computational jamboree.  
Members of the OC and other members of the HCA Consortium continue to engage with 
additional foundations and medical research institutes with the goal of developing partnerships. 
As HCA grows, we will emphasize the importance of disease foundations as partners in both 
charting relevant organs and tissues and expanding the scope of HCA in disease areas. 
Partnering with technology and pharmaceutical companies. The HCA provides a unique 
opportunity for tech companies: they can make important contributions to the collection of data 
through gifts of equipment or materials, but they can also benefit from the widespread adoption, 
standardization, rapid technology development, and new software tools built to use these 
companies’ techniques. For example, the creation of the atlas helps establish and broaden the use 
of single-cell genomics techniques. And the technology and software we develop under the 
auspices of the HCA will have wider application to technology companies as it is adopted by 
more and more researchers around the world. While we strive to negotiate terms for use of 
technologies including early access programs and reduce costs, we remain open to all 
technologies. Given the HCA’s principles of equity, transparency, openness. and nimbleness, we 
can make no exclusive commitments and promises to commercial partners. 
In addition, pharmaceutical companies can benefit tremendously from the data produced which 
will likely shed light on new actionable targets for medical diagnostics and therapeutics. For 
example, information from the atlas could lay the groundwork for new diagnostic approaches, 
help determine inadvertent toxicities, and help identify new disease mechanisms. In this context, 
a precompetitive consortium of pharmaceutical companies could support some of the HCA 




SECTION 8. APPENDICES 
APPENDIX I: GOVERNANCE 
Organizing Committee 
The HCA is steered and governed by an Organizing Committee (OC), which is the decision-
making body of the HCA.  
OC responsibilities. The responsibilities of the OC include convening the community through 
regular meetings, workshops and jamborees; coordinating and authoring key documents; 
defining scientific values and ethical principles; defining and upholding processes including 
quality-control standards and analytic standards; governing the Data Coordination Platform 
(DCP) and Common Coordinate Framework (CCF); coordinating HCA work products; 
communicating on behalf of HCA; representing and negotiating on behalf of the HCA with other 
entities and organizations; and polling the HCA community at regular intervals for input on 
issues, including performance of the OC. The OC does not generate data and is not a direct 
grantee or grantor for such purposes.  
OC membership. The OC will consist of up to ~35 scientists. Considerations for new OC 
members include expertise, geographical representation, and diversity. Additional members are 
added to the OC by majority vote of the OC. The OC will periodically seek input from the HCA 
community on the scientific scope of its members, performance, and potential new members. 
The current (founding) OC consists of 27 scientists from 10 countries and diverse areas of 
expertise (Table 2). 
Terms. All members will have five-year terms, which can be renewed once by a majority vote of 
the OC.  
Co-chairs. The OC is led by two co-chairs, who are members of the OC. The co-chairs have 
five-year terms, which can be renewed once by a majority vote of the OC.  
Executive Committee. The OC has an Executive Committee that is responsible for performing 
routine tasks between OC meetings, preparing meeting agendas, and providing guidance to the 
executive offices. The EC includes the two co-chairs and five additional OC members, with two-
year terms, which can be renewed once by a majority vote of the OC.  
Executive Offices. The HCA is coordinated by Executive Offices (EOs), which staff the OC in 
performance of its duties. The OC established four Eos, which are located in the U.K. (Sanger), 
U.S. (Broad Institute), European Union (Karolinska Institute), and Asia (RIKEN). The EOs’ 
responsibilities include meeting organization; community coordination; coordination of writing 
of community outputs (e.g., reviews, commentaries, white papers); coordination of interactions 
with companies; supporting interaction with funders; triage of press inquiries; triage of 
community inquiries; registry and tracking of projects; and registry and tracking of members. 
Each EO will also take the lead on some general duties, as well as regional activities. 
Quorum. A quorum for decision making by the OC will constitute (1) a majority of OC 
members at an in-person meeting that has been announced to the OC at least one month in 
advance, or (2) at least 75% of OC members responding by email to a proposed action that has 
been circulated to the OC. 
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OC Member Affiliation 
Ido Amit Weizmann Institute of Science, Israel 
Gary Bader University of Toronto, Canada 
Peter Campbell Wellcome Trust Sanger Institute, U.K. 
Piero Carninci Riken, Japan 
Hans Clevers Hubrecht Institute, Netherlands 
Roland Eils German Cancer Research Center; University of Heidelberg, Germany 
Nir Hacohen Broad Institute, MGH, USA 
Arnold Kriegstein University of California, San Francisco, USA 
Eric Lander Broad Institute, USA 
Sten Linnarsson Karolinska Institutet, Sweden 
Partha Majumdar National Institute of Biomedical Genomics, India 
Miriam Merad Mount Sinai, USA 
Shalin Naik Walter + Eliza Hall Institute of Medical Research, Australia 
Garry Nolan Stanford University, USA 
Dana Pe'er Memorial Sloan Kettering Cancer Institute, USA 
Chris Ponting Edinburgh University, U.K. 
Steve Quake Stanford University / Chan Zuckerberg Biohub, USA 
Nikolaus Rajewsky Helmholtz Association, Germany 
Aviv Regev, Co-Chair Broad Institute, MIT, HHMI, USA 
Ehud Shapiro Weizmann Institute of Science, Israel 
Jay Shin Riken, Japan 
Michael Stratton Wellcome Trust Sanger Institute, U.K. 
Henk Stunnenberg Radboud University, Netherlands 
Sarah Teichmann, Co-Chair Wellcome Trust Sanger Institute, U.K. 
Alexander Van Oudenaarden Hubrecht Institute, Netherlands 
Jonathan Weissman  University of California, San Francisco, USA 
Barbara Wold California Institute of Technology, USA 
Table 2. HCA Organizing Committee members. Current co-chairs are noted. (EC members have not yet been 
chosen by the OC). 
Working Groups 
The OC establishes Working Groups and mandates them to take on specific key areas. At the 
moment, these include the Analysis Working Group (AWG), the Meta Data Working Group 
(MDWG), the Common Coordinate Framework Working Group (CCFWG), the Standards and 
Technology Working Group (STWG), and the Ethics Working Group (EWG). Each Working 
Group has two co-chairs; one co-chair is a member of the OC and the other co-chair is external 
to the OC. The Working Group co-chairs together select the other members of the Working 
Group. Working Group members will have three-year terms, which can be renewed once by a 
majority vote of the OC. 
Data Coordination Platform  
The OC governs the Data Coordination Platform (DCP), which includes making all policy 
decisions concerning the DCP, approving the overall plan for the DCP, and ensuring the plan’s 
successful execution by the major developers of the DCP. The OC will establish and appoint a 
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DCP Governance Group (DCPGG), which will report to the OC, to oversee the 
implementation of these policies, by providing guidance and making decisions concerning 
certain key topics, including definition of data manifest; official analysis pipelines; required 
metadata to reflect data collection standards; common coordinates framework; and any formal 
“release portal.” The DCPGG will be led by two OC members; will include at least one member 
from each of the AWG, MDWG, and CCFWG; and will include at least three additional experts 
from the community. 
The OC will convene, on a quarterly basis, a DCP Coordination Meeting — involving the 
DCPGG, the major developers of the DCP, and others as appropriate — to review progress and 
assist the OC in developing policy.  
HCA Meetings 
The HCA OC convenes and advertises meetings, workshops, and jamborees.  
HCA Members 
Any individual may become an HCA Member by registering at the HCA Member Registry and 
agreeing to abide by the principles of HCA, as stated in the HCA White Paper, especially 
including its ethical standards. HCA members are invited to attend HCA community-wide 
meetings and discussions; join the HCA Slack channel; be on mailing lists; and so on. 
In addition, an HCA member who is a participant in an HCA project (defined below), or a 
member of an OC-designated HCA group will be designated as an HCA Collaborating Member. 
Certain types of scientific meetings, opportunities, and activities will specifically engage HCA 
Collaborating Members. 
HCA Projects 
Any scientific project related to systematic biological characterization at single-cell resolution 
may become an HCA Project by registering in the HCA Project Registry. The registry will 
include a description of the project, its strategy, and its investigators. By registering a project, its 
investigators affirm their commitment to abide by HCA standards, including the Information 
Release Policy (below). Projects will fall into three categories. 
 HCA Participating Projects. Any project (including those focused on data generation, 
experimental method development, or computational methods development) may be an 
HCA Participating Project, simply by registering.  
 HCA Network Projects. An HCA Network Project is an HCA Participating Project that 
commits to liaise with other network participants. 
 HCA Flagship Project. An HCA Flagship Project is an HCA Network Project that is 
aimed a delivering a component of the HCA Draft Atlas Plan 1.0; adheres to the overall 
framework of Plan (e.g., being comprehensive, adhering to technology standards, 
engaging domain expertise, having available preliminary data, and having substantial 
impact); and involves funding of at least 20M Euros over its duration. 
Information Release Policy  
All HCA Projects will commit to ensuring that data developed by or for the project will be 
deposited in the DCP through regular data release and made available in an open access manner 
to the maximal extent allowed by ethics (e.g., some metadata may be restricted). The DCP will 
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tag the data to make it citable. Users will be free to use the data as they wish, apart from the 
obligation to cite the generators of the data and to not attempt to identify or contact individual 
participants who contribute samples. The OC will work with journals to define opportunities for 
key data collection and analysis papers.  
In addition, all HCA Projects will commit to publicly releasing all experimental and 
computational methods used for data generation and/or analysis and source code for software 
developed by or for the project. 
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APPENDIX II: HCA DATA COORDINATION PLATFORM OVERVIEW 
Last modified 3/27/2017, current as of 3/27/2017 
This document is attributed to all attendees of the meetings on Feburary 9th and 22nd, 2017, held 
jointly by Broad, EBI/Sanger UCSC, and the Chan Zuckerberg Initiative (CZI). It evolved from 
an initial proposal from EBI/Sanger and Broad, through the two meetings at CZI, and several 
follow up discussions. 
Overview diagram  
 
Preface 
This document describes a dataflow architecture, and a set of principles, for coordinating data 
across the international Human Cell Atlas project. 
The four key components, described in detail below, are the ingestion service [1], the 
synchronized data store [2], the secondary analysis pipelines [3], and the tertiary portals [4]. The 
overall data flow sequence is ingestion of raw data and metadata into the ingestion service, 
depositing into the data store, processing via the secondary analysis pipeline, ingestion of 
derived analysis results through the ingestion service, depositing those derived results into the 
data store, and then access from portals via the data store consumer API.  
Key principles informing design 
 Simple, open, and direct access to data. 
 Modular components interact via standards and protocols rather than monolithic systems, 
which encourages good separation of concerns. 
 Maximal opportunity for downstream innovation in how the data is analyzed and used. 
 Extensible system encouraging a diversity of layered third-party components (e.g., pipelines, 
data replicas, portals, etc.). 
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 MIT or similar open source license for any code powering key project components. 
 Apache-style governance for any software components requiring community agreement. 
 Governance around three key areas of the project: the data ingestion system (for defining 
data and metadata standards), the synchronized data store (for development and operation), 
and the official secondary analysis pipelines (for validating and maintaining core analysis 
pipelines). 
Table of contents 
[1] Data ingestion 
[2] Synchronized data store 
[3] Secondary analysis pipelines 
[4] Tertiary portals 
[5] Quality checking 
[6] Training 
[7] Governance 
[1] Data ingestion 
The HCA Ingestion Service [1] is the single point of entry for all HCA data, including both raw 
data and metadata for projects, experiments, and samples, as well as a subset of approved derived 
analyses and quality metrics that result from running vetted analysis pipelines (see [3]). The 
ingestion service will both ingest data and perform basic quality assurance (see also [5]). 
Multiple data brokers will act as alternative user-facing entry points, providing any domain- or 
lab-specific handling or formatting — e.g., data from image-based transcriptomics may require 
different handling than single-cell RNA sequencing — and delivering data and metadata to the 
single Ingest API. A primary broker (dark purple) will be “branded” as HCA, but additional 
brokers will be developed and potentially branded as HCA over time, as determined by the 
ingestion governance (see [7]). 
Design principles 
 Standards will be defined for data and metadata for different aspects, including samples, 
experiments, and analyses, and will evolve with technological and biological understanding. 
 Standards and validation processes will be defined and developed transparently, e.g., in open 
Github repositories like the GA4GH file formats group (https://github.com/samtools/hts-
specs).  
 Biomedical ontology terms will be used when possible, and HCA scientists will consult to 
help extend the ontologies where needed. 
 The metadata validation ruleset will be exposed as an API to enable submitters to debug and 
validate before submission. The validation will eventually be published in containerized form 
to empower data brokers — in coordination with data producers and the ingestion service — 
to prevalidate submissions prior to upload. 
 Forms of acceptable derived data from the secondary analysis pipelines will be determined 
by its governance group (see [3] and [7]). 
 Users should get rapid feedback on the basic validity of their submissions. 
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 Users will be able to submit data in a manner that is most compatible with their workflows 
and level of expertise (e.g., Web UIs, spreadsheet templates, or bulk upload via APIs). 
 Finalizing a data submission is an optionally interactive process, in which the submitter 
declares responsibility for accuracy and can review the results and metadata summary. 
 For all data modalities, it will be possible to preregister sample metadata or any other study 
metadata before experimental data is collected, and updating preregistered metadata will be 
supported through versioning (see [3]).  
 To obtain best network performance and availability, submitters should be able to upload 
bulk data either to their geographically proximal cloud provider, or directly to the ingestion 
service. 
Functional components 
The Data Brokers are user-facing sites or services for data upload that handle lab-specific or 
data-type specific formatting (e.g., a setting in which spatial information about cell locations 
within tissue is available). Brokers should consider only complete data sets, i.e., not samples 
isolated from a project. Brokers may be staffed by “data wranglers” and other support staff who 
can liaise with and establish relationships with labs providing data, ideally co-located with 
submitters for rapid iteration. This additional human interface, coupled to engineering, will allow 
a broker to adapt to the needs of different labs, and to communicate data requirements back to 
the core group running the ingestion service. 
The Ingest API provides submission and validation functionality and will underlie all HCA 
broker operations and ingestion of data, metadata, and derived analyses. Validation will be 
applied at the metadata and file format level only, and check for data duplication across brokers, 
but will not involve quality control or data quality checks that require subsequent analysis (e.g., 
alignment). Users will be tracked upon account creation and at each data submission or data 
update, and users should be able to track their existing submissions. 
The Ingest CDN is an upload acceleration network, operated using an independent replica of a 
subset of the synchronized data store [2] infrastructure, designed to allow data producers to 
upload data to their most performant, geographically proximal endpoint. From that endpoint, the 
Ingest CDN forwards data to the single ingestion point for subsequent processing. From the 
submitter’s point of view, the Ingest CDN is write only, with the same authentication semantics 
as the Ingest API itself. 
An email help desk will be available to support HCA submitters with follow-up phone 
conversations or in-person meetings where appropriate. Those providing help must understand 
the requirements, train users to structure information appropriately, and interact with domain 
experts to ensure standards are appropriate. Help desk activities should use a shared 
infrastructure (e.g., a ticketing system) to present a unified service for submitters and ensure 
responses are synchronized across brokers. 
[2] Synchronized data store 
The HCA Data Store [2] is a multisite replicated storage system containing all raw data and 
metadata and certain forms of derived data, materialized and stored as flat files. Its goals are to 
ensure simple and direct data access for downstream consumers, to notify users of repository 
changes, and to synchronize data across multiple sites.  
Design principles 
 95 
 Data deposited in the data store will flow from the HCA ingestion service [1], which is solely 
responsible for data and metadata schemas, naming, accessioning, and validation. 
 All access between the ingestion service and the data store is via well-defined APIs, ensuring 
modularity and separation of concerns. 
 The data store will manage data replication across official HCA object stores. There will be 
at least three public cloud stores, and additional public or on-premise stores may be added 
over time. 
 At the lowest level, all data and metadata will be stored as a set of identical objects, invariant 
across cloud stores, and synchronization across cloud providers will thus depend on 
synchronization of this set of objects. 
 A common object layer across clouds will provide homogeneity and aid portability of 
analysis and access between different clouds, and allow cloud-independent data indexes to be 
built that link to each of the data copies on each cloud.  
 The public reference atlas will not require authenticated access, but access control and 
authentication may be required for some subsets of data. 
 It must be possible for any third party to add its own external pipeline or portal (as a 
consumer), to add a data replica, and to receive timely updates about changes to the data 
store. 
 Data change notification and replication must be rapid (e.g., significantly less than a day). 
 Tracking of data access via analytics will help determine data usage patterns to minimize 
costs (e.g., which data needs to be highly available or placed in cold storage). 
Functional components 
The Producer API is primarily responsible for receiving data directly from the authenticated 
ingestion service [1]. In addition, it will communicate with internal systems to trigger object 
synchronization across the replicas, and drive change notification Webhooks. All data and 
metadata will be explicitly versioned; the data store is effectively append-only, except in 
emergency circumstances. Updates to data will generally require new submissions, and updates 
to metadata will manifest as a series of files or explicit file versions. 
The Consumer API provides read-only access to data, via cloud-native APIs. Access is subject 
to authentication and access control for subsets of data where required. The Consumer API also 
provides Webhook change notification (e.g., GitHub-style), allowing downstream computation 
to be triggered and ensuring that all secondary and tertiary analysis tools can be reliably and 
rapidly updated as changes occur. 
The Object synchronization system and the Pub/Sub bus and replication logs systems are 
private subsystems that provide synchronization and change notification infrastructure across 
distributed object stores, and they communicate with both consumer and producer APIs. 
The Object stores are the multiple S3-like object stores on public and/or private clouds. 
[3] Secondary analysis pipelines 
The HCA Secondary Analysis Pipelines are defined as analyses with results that may, subject to 
approval, be deposited back into the data store, in contrast to the tertiary analysis portals (see 
[4]). We consider it critical to have robust pipelines that run continuously on new data because 
most data types for the HCA will require some processing to support the majority of downstream 
use cases (e.g., alignment and demultiplexing for single-cell RNA sequencing, detection and 
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segmentation for image-based transcriptomics). The analysis governance group (see [7]) will 
determine which analysis pipelines should be “approved” to deposit results back into the data 
store and which ones should additionally be designated as “official” for continuous deployment. 
Design principles 
 Encourage a diversity of analysis approaches, while ensuring that only vetted pipelines can 
deposit data back into the system and that one or more of those vetted pipelines are run 
continuously on all data from project onset.  
 Any approved pipelines must be open source and under a MIT or similar license. 
 Any approved pipelines must be packaged to ensure convenient reproducibility (e.g., via 
containerization and workflow description languages). 
 It must be possible to run any approved pipeline against local data in local test environments. 
 In support of the HCA, there will be continued development of two workflow standards 
(Workflow Description Language and Common Workflow Language) and two engines for 
running these workflows (FireCloud and Toil); both will be usable for analyzing HCA data 
across the three major cloud providers (AWS, GCE, Azure). 
 Test and example datasets should be provided for core tasks and can be used by the 
governance group for the development of benchmarks and objective assessments of 
pipelines. 
 Pipelines that need to aggregate multiple data sets, as opposed to running on individual 
samples, will run as close to continuous as possible, though delays may be inevitable; these 
analyses can reference appropriate metadata to ensure they only run on complete data sets. 
Functional components 
An extensible pipelining service for use by the HCA consortium. This service will have the 
ability for users to easily string together tools into pipelines and deploy them at scale and in a 
cost-effective manner across multiple computational backends. It should be container-based to 
support portability and ease-of-use by the community. 
A methods repository for storing and sharing pipelines within the HCA community. 
Approved analysis pipelines that consume raw data from the data store’s consumer API and 
generate derived results (e.g., gene cell tables or quality-control metrics) to be deposited back 
into the ingestion service, running either once or multiple times depending on resources. 
At least one official HCA analysis pipeline per data type [dark green], where data type could 
be, for example, single-cell RNA sequencing or image-based transcriptomics. These pipelines 
should reflect current best practices as determined by the analysis governance group (see [7]). 
They will be run continuously on all data of that type and be maintained by the HCA consortium. 
If multiple official pipelines are available for a single data type, they must provide information 
about their utility, features, and comparisons to other pipelines. 
[4] Tertiary portals 
The HCA Tertiary Portals support a wide range of downstream user-facing analyses, 
visualizations, and forms of access for working with HCA data. We imagine a diversity of portal 
types to bloom, targeting different levels of users, including Web-based interfaces, analysis 
results, custom APIs for performing rich and structured queries, and other novel interfaces. 
Design principles 
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 A rich ecosystem of portals covering a wide variety of use cases should be supported. 
 Coordination on similar efforts should be encouraged within the community, where 
appropriate. 
 Multiple portals can become branded with an “HCA” badge by following certain guidelines. 
Functional components 
At least one developer-oriented portal providing a platform (e.g. FireCloud or Toil) in which 
developers can bring containerized environments to perform analyses on the data 
At least one user-oriented portal providing interactive interfaces to the data; for example: 
 Quantifying the expression of a given gene (e.g., marker genes specified by user) across cell 
types, shown in several popular modalities (e.g., low-d plots, heatmaps, violin plots); 
 Showing clustering of individual cells from an experiment based on expression profiles; 
 Painting cell clusters (ordinations) by metadata (technical and experimental) to identify batch 
effects and visualize biological groupings (depending on the type of metadata); 
 Visualizing gene signatures by several modalities, including heatmaps and dot plots of 
average expression by cell group; and 
 Cross-correlating gene expression with epigenetic markers. 
Multiple query-oriented portals with APIs targeting custom access patterns, for example: 
 Querying all gene expression tables generated with a particular analysis; 
 Querying all cells for those that match the expression pattern of a target cell and return the 
metadata for the matching cells; and 
 Querying all raw data for a specific tissue type, ranked based on a custom combination of 
quality-control metrics. 
 
[5] Quality checking 
Below is a framework for ensuring the quality of Human Cell Atlas data, including the types of 
quality checks that will be performed throughout the lifecycle of HCA data, how these quality 
checks are coupled to the flow of HCA data through the architecture, and how this framework 
will evolve over time as data grows and pipelines harden. 
Tiers of quality checking 
Quality assurance (QA) is focused on the structural soundness of the data, with greater 
emphasis on checking consistency of metadata than the experimental quality of the data itself. 
Key elements include checking that a file is not empty at point of ingest, that data and metadata 
formats are correct, that syntax is well formed (e.g., correct UUIDs), and that there is intra-
sample consistency (e.g., if one cell has many files, all must be present). In general, failing this 
tier should result in rejection of data submission, unless there is an immediate and obvious fix, 
and passing this tier results in data ingestion (although it may be later blacklisted if it fails 
subsequent checks). 
Quality control (QC) is focused on the experimental quality of the data itself. Defining these 
metrics will be governed by the analysis governance [7] of HCA, who will also determine the 
approved pipelines for secondary analyses [3]. In the example of single-cell RNA sequencing, 
checks will include mapping quality, potential contamination, and quality of cells. In 
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collaboration with the analysis governance, criteria will be determined for a single sample, or 
entire batch, to pass this step, causing it to be whitelisted (official HCA data) or blacklisted (data 
has been withdrawn). These metrics will be made available as tables computed during secondary 
analyses by the official pipelines. 
Inspection is focused on exceptional circumstances where a sample fails either QA or QC and 
the cause is not immediately obvious. In such situations, a human analyst must inspect the data to 
determine the cause of failure. The emphasis at this stage is ensuring that the human analyst has 
the data sets and analytical tools needed for rapid debugging.  Data visualization will be key, and 
example steps, likely developed as part of the tertiary portals [4], and, in the example of single-
cell RNA sequencing, might include plots focusing on potential technical batch effects or 
comparing mapping quality of cells within a study. Following this step, a sample or set of 
samples will either be repaired or not, resulting in whitelisting or blacklisting, and provenance of 
all changes will be stored. 
Relationship to data flow 
Quality assurance will primarily happen during ingestion [1] and be coupled to the date of 
submission receipt. Formats will evolve during the project, so it must be possible to repeat 
backward-compatible checks on old data. Data that pass this step will become part of the primary 
HCA data set and deposited into the data store [2]. 
Quality control results and metrics will be performed as part of the secondary analysis pipelines 
[3] that run on top of the data from the data store. Although in principle these analyses can run 
against any of the replicated cloud stores, in practice it will be most efficient if the continuously 
running pipelines run against one cloud store and distribute results. 
Evolution of quality checks 
Quality assurance during the first year will focus on format, compression, essential metadata, 
file integrity, and consistency with metadata ontologies. After the first year, checks can begin to 
incorporate the correct number and composition of files per sample. 
Quality control during the first year will be closely coupled to ongoing developments in 
analysis approaches, and the focus will be maximizing experimentation and diversity of 
techniques. This rapid prototyping could benefit from running quality checks in a single cloud 
compute environment, alongside ad-hoc external deployments on other clouds. After the first 
year, emphasis can shift to standardizing, scaling, and optimizing the cost of continuously 
running analyses, and deployment strategies can tailor to this need.  
[6] Training 
All components of the system will require training. The project will therefore have dedicated 
coordination of training activities. Training needs are broken down by project components but 
will ideally conform to common templates to provide an integrated user experience. 
Components 
 A training entry point will provide links to training materials and documentation. 
 Training for use of the Ingest API will be needed for external users and brokers; example 
data files should form part of the materials as well as documentation of the API. 
 Training for the secondary analysis portals will include webinars for analysis methods and 
hackathons to encourage analysis development and teach existing tools to new members. 
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 Training for developers of the tertiary portals will ensure that they understand how data 
updates occur and how to use the Webhook notifications from the data store’s Consumer 
API. 
[7] Governance 
An oversight group with representatives from international funding bodies and the HCA 
consortium will ensure that all data storage and access protocols satisfy all relevant regulatory, 
legal, and ethical guidelines.  
In addition, we imagine three broad areas of governance — ingestion, data management, and 
analysis — falling under the umbrella of the HCA consortium. 
Ingestion 
 Define standards around data and metadata formats. 
 Ensure that standard definitions are developed transparently and are publicly available. 
 Ensure that all quality assurance checks can be performed locally prior to data upload. 
 Ensure harmonization and coordination of data broker activity and user-facing support. 
Data management 
 Define cost tiers for data storage based on usage. 
 Define file organization, naming practices, and versioning within the data store. 
 Define any foreign key indexing. 
 Define protocols for handling authenticated data. 
Analysis 
 Responsible for shepherding pipeline development and determining approved project 
pipelines (which are allowed to deposit results back into the data store) and official pipelines 
(which, in addition, run continuously on all new data). 
 Ensure that any approved analysis pipeline can be reproduced and deployed in multiple cloud 
environments, as well as run locally (e.g., via containerization). 
 Decisions on approved and official pipelines should be handled via Apache-style voting. 
 There should be one subgroup for each broad data type (e.g., single cell RNA sequencing, 
image-based transcriptomics), all operating under an analysis governance umbrella. 
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